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Abstract 
Currently, both congenital abnormalities and developmental problems of the bladder in children, 
and other dysfunctions in adults, require reconstructive surgery. Such correction involves 
transplant action of native tissues (such as gastrointestinal segments, or mucosa), homologous 
tissues from a donor, heterologous tissues or substances, or artificial materials to act as a 
replacement for normal bladder tissue. However, such surgery does not entirely restore the 
function, as the replacement tissue is either rejected due to immune system, fibrosis, contraction 
or causes metabolic complications due to a mismatch in different functional parameters, such as 
gastrointestinal segment for absorbance versus bladder for excretion. Tissue engineering is 
emerging as a significant alternative potential treatment for bladder dysfunction. To achieve this 
goal, we have explored fibrin gels as a natural material based scaffold to seed infiltrating smooth 
muscle cells to mimic the ontogeny of the bladder tissue. 
Our interest in developing fibrin-based biomaterial technology is based on fibrin’s central role in 
tissue binding and in the initiation of tissue repair and defence. It is well known that fibrinogen/ 
fibrin binds to platelets as well as to different cells, growth factors, and extracellular matrix 
proteins, which is critical for the wound repair process. 
Insulin-like growth factor I (IGF1) is well known as a key regulator in carbohydrate metabolism 
and growth. It can promote smooth muscle cell growth. In this thesis it was also chosen due to 
its simple active form, namely a single chain of low molecular weight, 10kDa. A novel 
engineered insulin-like growth factor I (IGF1) - factor XIIIa substrate fusion protein was chosen 
as the bioactive macromolecule to be released from the scaffold in order to control cellular 
growth and differentiation. Therefore, we can achieve close to the natural biomechanical 
environment in the regenerated tissue. 
In this work, two generations of fibrin matrices for tissue engineering were developed. The first 
part of the work was devoted to preventing rapid diffusion of the growth factor from the matrix 
and to controlling its release. IGF1 was modified by inserting a factor XIIIa substrate sequence 
(denoted TG) based on the 2-plasmin inhibitor to cross-link into the fibrin gel during 
coagulation. This is so that the variant IGF1 will bind to the fibrin gel itself and will be released 
upon matrix degradation. In order to produce this recombinant protein TG-IGF1, IGF1 GST tag 
plasmid DNA was transformed into BL21 competent cells. After protein production, the 
recombinant TG-IGF1 protein was purified by GST affinity chromatography. The purified TG-
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IGF1 was confirmed via SDS-PAGE and western blot with an anti-hIGF1 antibody. The 
sequence was confirmed using MALDI-TOF mass spectrometry. 
The biological activity of TG-IGF1 was validated in vitro by receptor tyrosine phosphorylation and 
metabolic assay (MTT assay) with fibroblast 3T3 cells. The cell proliferation profile was similar 
for both TG-IGF1 and native recombinant IGF1. Although we were able to obtain relatively pure 
TG-IGF1 protein, the purification protocol may still require some development due to loss of 
protein via aggregation during protein production. 
Using a three-dimension in vitro model, neonatal human bladder smooth muscle cells were 
seeded in the fibrin gel only, in the fibrin gel either with TG-IGF1 or native recombinant IGF1 as 
a control. The morphology of the seeded cells was analysed using ultra-structural transmission 
electron microscopy after three days. Secretory vesicles had not been found in the cells without 
IGF1. The cells with the TG-IGF1 displayed larger and more numerous secretory vesicles than 
those with native recombinant IGF1, presumably due to the rapid diffusional loss of the native 
recombinant IGF1 from the gel.  
The bladder smooth muscle cell in the fibrin gel responses to either TG-IGF1 or native 
recombinant IGF1 at the genomic level were analyzed by qRT-PCR for extracellular matrix and 
adhesion molecules after 24 hours incubation. The cells in the fibrin gel only were used as 
control. We did not observe a difference in gene expression between the two groups. 
The bioactivity of TG-IGF1 was also investigated in vivo utilizing a rat bladder model. A wound 
was induced via resection on the rat bladder. Either the TG-IGF1 or native recombinant IGF1 
containing fibrin gel was then applied to the wound site, with a second control group receiving 
only the fibrin gel alone. Three classic histological stainings were done using Hematoxylin & 
Erythrosine (HE), Masson’s Trichrome (TM) and Prussian Blue (PB). It was found that TG-IGF1 
greatly enhanced rat bladder muscle layer regeneration compared to native recombinant IGF1 
and the control group of fibrin gel according to the histology staining and quantitative analysis of 
the ratio of detrusor muscle regenerated / normal detrusor muscle (0.27±0.10 for TG-IGF1 and 
0.23±0.10 for native recombinant IGF1).  
The second part of the work was devoted to making a new generation of fibrin matrices. 
Fibrinogen (Fgn), a soluble plasma protein found in all vertebrates, is a covalent dimer 
composed of pairs of three polypeptide chains called A-, B- and -chains. Fibrinogen A chain 
can be truncated to B-and -chains while maintaining the capacity to be assembled into a 
secreted, detectable fibrinogen. It is feasible to produce recombinant chimeric fibrinogen in cell 
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culture, which can then be used to incorporate growth factors into fibrin matrices as a fusion 
protein with fibrinogen at the genetic level. In this way, fibrin based natural material hydrogels 
can be formed which can bind and release signalling biomacromolecules for directed cellular 
growth and tissue regeneration. 
In order to produce this new fibrinogen recombinant protein, a novel stable cell line of Chinese 
Hamster Ovary cells, CHOfgn-hIGF1, needed to be developed. This was accomplished via 
transfection of an FGA-hIGF1 plasmid DNA into CHOcells. After protein production, the 
recombinant chimeric fibrinogen variant hIGF1 fusion protein was purified by affinity 
chromatography. The successful production of these cell lines and the resultant variant IGF1 
was confirmed via ELISA with fibrinogen and hIGF1 antibodies, and also by fluorescence 
activated cell sorting (FACS). Due to protein polymerisation in the column during purification, the 
protein purification step still requires additional development. Although the targeted fusion 
protein was successfully produced, overall protein yield was so low as to prevent further 
exploration. 
By harnessing the powerful technique of protein engineering and using the fibrinogen/fibrin 
hydrogels developed in our lab, we were able to demonstrate a new type of multifunctional gel 
capable of regenerating smooth muscle type tissue with the aim to repair bladder function. Here 
we were able to demonstrate the production of the variant IGF1 factor XIIIa substrate fusion 
protein, its biological activity in vitro, and its application in an in vivo rat model. 
Key words: Tissue engineering, biomaterials, fibrin gel, IGF1, SMC, smooth muscle cells, 
bladder, fibrinogen, muscle, fibrin matrices, CHO cells, regenerative medicine 
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Résumé 
Actuellement, les anomalies congénitales et les problèmes développementaux de la vessie chez 
les enfants, ainsi que d'autres dysfonctionnements chez les adultes exigent la chirurgie 
reconstructive comme traitement. Celle-ci implique l’implantation de tissus de l’hôte (tels que 
segments gastro-intestinaux, ou mucus), de tissus homologues d'un donateur, de tissus ou 
substances hétérologues, ou des matériaux artificiels pour reconstituer le tissu normal de la 
vessie. Cette chirurgie ne reconstitue toutefois pas entièrement la fonction, car le tissu de 
remplacement est rejeté par le système immunitaire, fibrose, contraction ou cause des 
complications métaboliques dues à une disparité dans différents paramètres fonctionnels, tels 
que des segments digestifs pour l'absorbance contre la vessie pour l'excrétion. L’ingénierie 
tissulaire est devenue un traitement potentiel alternatif significatif pour le dysfonctionnement de 
la vessie. Afin atteindre ce but, nous avons utilisé des gels de fibrine, une matrice naturelle, 
ensemencée de cellules musculaires lisses (SMCs) à imiter une ontogénèse du tissu urologique. 
Notre intérêt pour développer une technologie des biomatériaux à base de fibrine est basé sur le 
rôle central de la fibrine dans l’adhésion, le déclenchement de la réparation et de la défense du 
tissu. La liaison entre fibrinogène/fibrine et des protéines, plaquettes d’hémostasies aussi bien 
qu’avec divers cellules, facteurs de croissance, et protéines de la matrice extracellulaire (ECM) 
est indispensable pendant le processus de réparation de blessure.  
Le facteur de croissance insulinomimétique (IGF1) est bien connu en tant que régulateur 
principal dans le métabolisme des hydrates de carbone et la croissance. Il peut favoriser la 
croissance de cellules musclaires lisses. Dans cette thèse, il a été choisi également pour sa 
forme active simple, une chaîne unique, et son faible poids moléculaire, 10kDa. Une nouvelle 
protéine recombinante de fusion IGF1 facteur XIIIa a été choisie en tant que macromolécule 
bioactive à être libérées de la matrice pour contrôler la croissance et la différentiation cellulaire. 
Ainsi, nous pouvons obtenir un environnement biomécanique presque naturel dans le tissue 
réparé. 
Dans ce travail, deux générations de matrices fibrines pour ingénierie tissulaire sont planifiées. 
La première partie du travail est dédiée à empêcher la diffusion rapide du facteur de croissance 
de la matrice et contrôler sa libération retardée. L’IGF1 a été modifié en insérant une séquence 
TG du substrat de facteur XIIIa en base de l’inhibiteur 2-plasmine pour réticuler dans le gel de 
fibrine pendant la coagulation. C’est la raison pour laquelle le variant IGF1 est adhéré au gel de 
fibrine et libéré pendant la dégradation. Pour produire la protéine recombinante TG-IGF1, un 
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plasmide ADN d’IGF1 GST tagué a été transformé dans des cellules compétentes BL21. Après 
la production de la protéine, la protéine recombinante TG-IGF1 a été purifiée par 
chromatographie d'affinité GST. La pureté de TG-IGF1 a été vérifiée par SDS-PAGE et WB 
avec l’anticorps hIGF1. La séquence a été confirmée par spectrométrie de masse de MALDI-
TOF.  
Les activités biologiques de TG-IGF1 ont été validées in vitro par phosphorylation du récepteur 
et par essai MTT avec des cellules 3T3. Le profil de prolifération des cellules était semblable 
pour le TG-IGF1 et le naturel IGF1 recombinant. Bien que nous avons pu obtenir la protéine TG-
IGF1 assez pure, le protocole de purification nécessiterait des développements supplémentaires 
dû à la protéine perdue via agrégation pendant la production de celle-ci.  
Dans le modèle 3D, des SMCs humaines néonatales de vessie ont été ensemencées dans le 
gel de fibrine, dans le gel de fibrine incorporé respectivement avec TG-IGF1 et naturel IGF1 
recombinant. La morphologie des cellules ensemencées a été analysée en utilisant la 
microscopie électronique à transmission (TEM) après 3 jours d’inoculation. Les vésicules 
sécrétrices n’ont pas été trouvées dans les cellules sans IGF1. Les cellules avec TG-IGF1 
montraient de plus grandes et plus nombreuses vésicules sécrétrices que celles avec le naturel 
IGF1 recombinant. Ceci est dû à la diffusion de ce dernier du gel.  
Les SMCs de vessie répondant respectivement au TG-IGF1 et au naturel IGF1 recombinant au 
niveau du gène ont été analysées par qRT-PCR dans le domaine des molécules d'adhérence et 
ECM après 24 heures d'inoculation. Les cellules dans le gel de fibrine étaient utilisées comme le 
contrôle. Aucune différence pour l'expression de gène pour ces cellules n’a été observée dans 
les deux cas.  
La bio-activité de TG-IGF1 a également été étudiée in vivo dans le modèle de la vessie du rat. 
L'incision a été faite sous le microscope sur la vessie du rat. Soit TG-IGF1 soit le naturel IGF1 
recombinant a été appliqué sur l’incision, avec le groupe de contrôle recevant que le gel de 
fibrine. Trois techniques classiques de coloration histologique ont été utilisées, Hématoxyline & 
érosine (HE), Masson’s Trichrome (TM) et Blue Prusse (PB). Nou avons constaté que le TG-
IGF1 a considérablement accéléré la régénération de la couche musculaire de vessie du rat, en 
comparant avec le naturel IGF1 recombinant et le groupe de contrôle d’après les colorations 
histologiques et l‘analysis quantitative du rapport de muscle détrusor régénéré / muscle détrusor 
normal (0.27±0.10 pour le TG-IGF1 et 0.23±0.10 pour le naturel IGF1). 
La deuxième partie de ce travail a été dédié à la fabrication d’une nouvelle génération de 
matrices de fibrine. Le fibrinogène (FGN), une protéine soluble de plasma présente dans tous 
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les vertébrés, est un dimère covalent composé de paires de trois chaînes de polypeptide, 
appelées A-, B- and -chaînes. La chaîne du fibrinogène A peut être tronquée au B- and -
chaînes en gardant la capacité d'être réuni en fibrinogène sécrété et discernable. Il est faisable 
de produire le recombinant fibrinogène chimérique, qui dirige l'incorporation, au niveau 
génétique, du GF dans des matrices de fibrine. Dans ce cas, les hydrogels de matériel naturel 
basé sur la fibrine peuvent être faits en adhérant et libérant des bio-macromolécules signales 
pour diriger la croissance cellulaire et la régénération du tissu. 
Pour produire cette nouvelle protéine fibrinogène recombinante, une nouvelle ligne cellulaire 
stable de cellules ovaires d'hamster chinois CHOfgn-hIGF1 a dû être développée. Elle a été faite 
par un plasmide ADN du FGA-hIGF1 transfecté dans les CHO cellules. Après la production de 
la protéine, la protéine chimérique recombinante de fusion hIGF1 a été purifiée par la 
chromatographie d'affinité. La production avec succès de ces nouvelles lignes cellulaires stables 
et de IGF1 variante résultante a été confirmée par dosage d'immunosorption liée à une enzyme 
(ELISA) avec l'anticorps du fibrinogène et du hIGF1 et par le tri des celles activées par la 
fluorescence (FACS). En raison de la polymérisation de protéine dans la colonne pendant la 
purification, l’étape de purification exige toujours un développement supplémentaire. Bien que la 
protéine ait été produite avec succès, le très bas rendement global était empêché le davantage 
de son exploration. 
En utilisant la technique puissante de l’ingénierie de protéine et en employant les hydrogels de 
fibrinogène/fibrine développés dans notre laboratoire, j’ai pu démontrer un nouveau type de gel 
multifonctionnel capable de régénérer le tissu de type musculaire lisse avec le but de 
reconstruire la fonction de la vessie. Nou avons pu démontrer la production de la protéine de 
fusion variante IGF1facteur XIIIa, son activité biologique in vitro et son application in vivo dans 
un modèle de rat. 
Mots clés: Ingénierie tissulaire, biomatériaux, gel de fibrine, IGF1, SMC, cellule musculaire lisse, 
vessie, fibrinogène, muscle, matrices de fibrine, CHO cellules, médecine régénérative 
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Abbreviations 
ALS   Acid-labile subunit  
bFGF    Basic fibroblast growth factor 
BAM   Bladder acellular matrix  
BSA    Bovine serum albumin 
COL16A1  Collagen, type XVI, alpha 1 
DNAse I  Deoxyribonuclease I  
dNTPs.  Nucleotides  
ELISA   Enzyme-linked immunosorbent assay  
EPC   Endothelial progenitor cells 
EtOH   Ethanol 
FBS   Fetal bovine serum 
FOXO   Forkhead box O  
GH   Growth hormone 
GnRH   Gonadotropin-releasing hormone  
GSK-3  Glycogen synthase kinase 3 beta  
GST   Glutathione S-transferase  
HBSS   Hanks Balanced Salt Solution 
H&E   Hematoxylin and eosin (erythrosine), 
His tag  Polyhistidine-tag  
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HH   Hypogonadotropic hypogonadisms  
IGF1   Insulin-like growth factor 1 
IGFBPs  IGF binding proteins  
IGFD   IGF1 deficiency  
IPTG   Isopropyl β-D-1-thiogalactopyranoside  
IRS1   Insulin receptor substrate 1  
ITGA4   Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 
ITGAV   Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
KAL1    Kallmann syndrome 1 sequence 
KS   Kallmann’s syndrome  
LAMA3  Laminin, alpha 3 
LBA   Luria-Bertani ampicillin  
MDCs   Skeletal muscle-derived cells  
ml   Milliliter  
MMP15  Matrix metallopeptidase 15 (membrane-inserted) 
MMPs   Matrix metalloproteinases  
MT   Masson's Trichrome 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Thiazolyl 
Blue Tetrazolium Bromide) 
NaF    Sodium fluoride  
OB   Olfactory bulbs  
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PB   Prussian blue 
PBS   Phosphate buffered saline  
PCR   Polymerase chain reaction  
PDK1   Phosphoinositide-dependent kinase-1 
PFA   Paraformaldehyde 
PI3K   Phosphoinositide 3 kinase  
PIP3   Phosphatidylinositol (3,4,5)-trisphosphate  
PGA    Polyglycolic acid  
PLA   Polylactic acid  
PLGA   Poly(lactic-co-glycolic acid) 
PMSF   Phenylmethylsulphonyl fluoride  
PS   Penicillin streptomyocin  
qRT-PCR   Quantitative real-time PCR  
RT   Room temperature  
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SFM   Serum-free media  
SIS   Small intestine submucosa  
SMCs   Smooth muscle cells 
SPP1    Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-
lymphocyte activation 1) 
THBS1  Thrombospondin 1  
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TBS   Tris-Buffered Saline  
TBST   Tris-Buffered Saline Tween-20 FBS     
TEM   Transmission electron microscope 
TGF-  Transforming growth factor alpha  
TGF-   Transforming growth factor beta  
THBS1  Thrombospondin 1 
TIMP3   TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) 
TPO   Thrombopoietin  
UC   Urothelial cells 
VEGF   Vascular endothelial growth factor 
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Chapter I Introduction and Background 
Medical motivation for our research 
Insulin-like growth factor 1 (IGF1) is both a hormone and a tissue growth factor. It is normally 
produced throughout our life, and it plays some role in nearly every cell in the body. Since IGF1 
was discovered in 1957, it has remained a top research topic in biology. Recently, IGF1 has 
been discovered to be an important factor or mediator for child growth, antineoplasic activity and 
treatment, cartilage and bone growth, skeletal muscle regeneration, and peripheral neurons 
apoptosis protection 1-9. In August 2005, the FDA approved Tercica’s IGF1 drug, Increlex, for 
severe primary IGF1 deficiency (IGFD), which is injected twice per day at a concentration of 
10mg/ml. In December 2005, Insmed’s Iplex, IGF1 with IGFBP3 complex, was also approved by 
the FDA for IGFD, which is injected only once per day 4. There is still extensive work to be done 
before more IGF1 related drugs are approved by the FDA.  
Biopharmaceutical companies have expressed more interest in IGF1 since 1987 when the IGF1 
receptor was found to have relationship with human breast and colon cancer 2. Several 
companies have developed therapeutic monoclonal antibodies against IGF1 to target IGF1 
receptors for the treatment of different diseases (Table 1) 2, 4, such as type 1 diabetes, type 2 
diabetes, amyotrophic lateral sclerosis, and growth deficiency. One project for type 1 and 2 
diabetes which was in a phase 3 clinical trial was withdrawn by Genentech due to severe side 
effects. Cephalon also withdrew a project for amyotrophic lateral sclerosis in 20012, 10. 
IGF1 concentration in the circulation is normally quite low, at 10-1000ng/ml 90. Long-term IGF1 
related drug use will disturb the IGF1 signalling pathway in the body and may result in severe 
irreversible side effects. The economic cost is also high, requiring large quantities of 
recombinant protein once or twice daily. So, development of an IGF1 protein formulation could 
be one solution to this problem. Controlled release of IGF1 could be another opportunity to avoid 
the effect of sudden spikes in IGF1 caused by large dose. The goal is to use IGF1 drugs safely 
and effectively by decreasing the quantity and frequency of IGF1 during the treatment.  
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Table 1. Several therapeutic monoclonal antibodies against IGF1 developed by divers’ 
biopharmaceutical companies to target IGF1 receptors are undergoing clinical trial 2, 4. 
Company Product Development stage Indication 
CP-751,871 (fully human IgG2 mAb 
against IGF-1R extracellular domain) 
Phase 3 Non–small-cell 
lung cancer 
Pfizer (New York) CP-751,871 with Taxol (paclitaxel) and 
carboplatin 
Phase 2 Non–small-cell 
lung cancer and Ewing’s 
sarcoma 
IMC-A12 (fully human IgG1 mAb against 
IGF-1R extracellular domain) 
Phase 2 Head-and-neck 
cancer 
ImClone (New York) IMC-A12 in combination with gemcitabine 
and Tarceva (erlotinib; targets 
EGFR tyrosine kinase domain) 
Phase 1-2 Advanced pancreatic 
cancer 
 
Genmab (Copenhagen)/ 
Roche (Basel) 
R1507 (fully human mAb targeting 
IGF-1R extracellular domain) 
Phase 2 Recurrent or refractory 
sarcoma 
Roche/Sarcoma Alliance for 
Research through Collaboration 
(Ann Arbor, Michigan) 
R1507 Phase 2 Solid tumors, 
including 
sarcoma 
Merck (Whitehouse Station, 
New Jersey)/Pierre Fabre 
(Paris) 
MK-0646 (humanized IgG1 antibody targeting 
IGF-1R extracellular domain) 
Phase 2 Metastatic 
colon cancer 
Amgen (Thousand Oaks, 
California)/Takeda Bio (Tokyo) 
 
AMG 479 (fully human mAb targeting 
IGF-1R extracellular domain) combined 
with anti-EGFR mAb panitumumab or 
gemcitabine 
Phase 2 Advanced solid 
tumors 
 
AVE-1642 (humanized IgG1K  mAb targeting 
IGF-1R extracellular domain) with 
Velcade (bortezomib) 
Phase 1 Multiple 
myeloma 
 
Sanofi-Aventisa (Paris) 
AVE-1642 with Taxotere (docetaxel) Phase 1 Solid tumors 
mAb, monoclonal antibody; EGFR, epidermal growth factor receptor. 
aUnder license from ImmunoGen (Waltham, MA). 
  
 
21 
Insulin-like growth factor 1 (IGF1) 
Growth factors are a class of proteins that can stimulate cellular growth, proliferation, 
differentiation and maturation 11, 12. They act as signalling molecules between cells to regulate 
cellular effects. Several examples are thrombopoietin (TPO), insulin-like growth factor (IGF), 
transforming growth factor alpha (TGF-) and transforming growth factor beta (TGF-), etc.  
The insulin-like growth factors (IGFs) are single-chain polypeptides. They are well known as key 
regulators of energy metabolism and cellular growth for normal fetal and postnatal life. IGFs act 
as cell survivor factors because they simulate cell proliferation and inhibit apoptosis. The IGF 
system is composed of two ligands (IGF1 and IGF2), two receptors (IGF1R and IGF2R), six 
high-affinity IGF binding proteins (IGFBPs), a glycoprotein called the acid-labile subunit (ALS) 
and IGFBPs proteases. IGFBPs proteases allow IGFs to be released continuously from the 
inactive IGFs-IGFBPs conjugates 13. 
IGF1/GH axis 
Normally, the IGF/growth hormone axis (IGF/GH) refers specially to IGF1, because IGF2 
expression is independent of GH activity. This axis (Fig. 1) plays a role in aging. 
Growth hormone (GH) is a single polypeptide chain of 191 amino acids with 2 intramolecular 
disulfide bridges. It is produced and stored in secretory vesicles in the pituitary gland. GH is 
regulated by hypothalamic factors (GH releasing hormone (GHRH) and somatostatin (SMS)), 
ghrelin and the IGF1 negative feedback.  
IGF1 is also called somatomedin C and is produced throughout life. Nearly every cell in the body 
is affected by IGF1. In the fetus, the supply of nutrition is the main regulator of IGF1 expression. 
In postnatal growth, GH is the essential regulator. Most circulating IGF1 is secreted by the liver 
as an endocrine hormone via stimulation by pituitary growth hormone (GH) 14. It is also 
expressed by many target tissues as an autocrine or paracrine cytokine due to a number of 
regulatory influences, including stimulation by GH level and inhibition by malnutrition, GH 
insensitivity, GH receptors absent, or GH signalling pathway downstream failure 14.  
IGF1 is one of the most critical factors in the growth of children. It is the principal mediator for 
bone growth in the body. A deficiency in IGF1 (IGFD) causes abnormal growth. Severe primary 
IGFD refers to those children having normal or high GH levels, height lower than 3 standard 
deviation (<3SD) and IGF1 level in the blood <3SD. To catch up with the average height of their 
friends, these children can be treated with IGF1 4. 
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Fig 1. Relationships within the IGF1-GH system 91. 
Regulated by hypothalamic factors, growth hormone (GH) 
is synthesized in pituitary. Endocrine IGF1 is secreted 
primarily by the liver when GH binds to its GH receptor. Or 
autocrine/paracrine IGF1 is generated by target tissue 
when GH binds to its IGF1 receptor. Then IGF1 binds to 
both IGF-binding proteins (IGFBP) and acid-labile subunit 
(ALS) in the circulation to extend its half-life. 
 
Fig 2. Primary amino acid sequence of human IGF1 
structure 15. It is a small polypeptide growth factor that 
consists of 70 amino acids in a single chain with three 
intramolecular disulfide bridges. 
The structure of IGF 
Structurally, IGF1 is very similar to IGF2. IGF1 is a single chain basic polypeptide of 70 amino 
acids with three intramolecular disulfide bridges 16. Its molecular weight is 7649 Dalton (Fig. 2). 
IGF2 is a single chain neutral polypeptide of 67 amino acids. The two proteins have different 
biological activities 13.  
IGF1 plays one important role in promotion of cell proliferation for maximal growth and inhibition 
of cell death (apoptosis). In contrast, IGF2 is one of the primary growth factors for early 
development. In this sense, it has a more specific function compared to IGF1.  
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IGF receptors 
Because IGFs’ molecular structure is similar to insulin, IGFs can also bind to the insulin receptor, 
but with much lower affinity than insulin. Both the insulin receptor and IGF1 receptor are tyrosine 
kinase receptors. The bioactivity of IGF1 is mediated by binding to IGF receptors present on 
many cell types 14. The IGF1 receptor has a high degree of homology to the insulin receptor, 
while the IGF2 receptor is identical to the cation independent mannose 6-phosphate receptor 17. 
IGF2 can bind to both IGF1 and IGF2 receptors. The IGF2 receptor lacks a signal transduction 
capacity. So, the IGF2 receptor acts as a sink for IGF2 in order to decrease the chance of IGF2 
binding to the IGF1 receptor. So, the IGF2 receptor was discovered to display tumour 
suppressor activity 1, 18.  
The IGF1 receptor is a hetero-tetrameric transmembrane glycoprotein with two subunits 1. Each 
subunit consists of one -chain containing an extracellular ligand binding domain and one -
chain containing an intracellular tyrosine kinase domain. The IGF1 receptor plays an important 
role in cancer 2. Neoplastic cell lines and many human cancers express the IGF1 receptor. That 
is the reason why many cancer cell lines respond to physiological concentrations of IGFs.  
IGF binding proteins (IGFBPs) 
The interaction between IGF proteins and IGF receptors is regulated by IGFBPs 19. Despite a 
similar molecular structure between IGFs and insulin, insulin can directly access its receptor, 
while IGFs are modulated by IGFBPs 1. The main functions of IGFBPs are to transport the IGFs 
to the target tissues or cells, modulate the IGF bioactivity, limit the access of IGFs to IGF1 
receptors and to extend IGFs half-life in the circulation.  
There are six homologous multifunctional proteins in the IGFBPs gene family, named IGFBP1 to 
IGFBP6. Their precursor forms have secretory signal peptides from 20 to 39 amino acids. Their 
mature proteins have between 216 and 289 amino acids and are all extracellular 18, 20. Both the 
N-terminus and C-terminus of IGFBPs are rich in cysteine, containing an IGF binding domain 
(Fig. 3 and Table 2). The RGD integrin-binding and cell binding sites are also at the C-terminus. 
The central domain of IGFBPs contains the posttranslational modification, glycosylation, 
proteolytic cleavage sites and phosphorylation domains 18, 20, 21.  
IGFBPs also display various biological activities, which are both dependent and independent of 
their interactions with IGFs. It is known that they modulate cell functions and play a role in 
apoptosis for example. 
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The IGFBPs have the potential to stimulate or inhibit IGF1 action in IGF-dependent manner 19, 20, 
22. On the one hand, IGFBPs can enhance IGFs action by prolonging IGF half-life, increasing the 
IGFs concentration level around the IGFs receptor and cell exposure. On the other hand, 
IGFBPs can inhibit the IGF action via sequestration of the IGF from the receptor (Fig. 4).  
 
Fig 3. IGFBPs structure. The family of six high 
affinity IGFBPs share common domain 
architecture: mid-region, highly conserved N- and 
C-domains. N- and C-domains are important for 
high affinity IGF1 binding to modulate the 
bioavailability and hence the action of IGF1 20. 
However each of the IGFBPs has unique 
sequences that underlie differentiating 
biochemical and functional properties, such as 
nuclear localization and RGD integrin binding. The 
central domains are sites of posttranslational 
modification, such as glycosylation, 
phosphorylation and IGFBP proteolysis. 
Domain Function IGFBP 
IGF binding IGFBP1, IGFBP2, IGFBP3, 
IGFBP5  
Insulin binding IGFBP3 
Inhibition of insulin receptor 
autophosphorylation 
IGFBP3  
Amino terminal 
Inhibition of mitogenesis IGFBP3 
Heparin bindinga IGFBP2, IGFBP3, IGFBP5 
ALS bindinga IGFBP5 Central 
Cell binding IGFBP3 
IGF binding IGFBP1, IGFBP2, IGFBP3, 
IGFBP5 
Nuclear localization signalb IGFBP3, IGFBP5 
Heparin-bindingb IGFBP3, IGFBP5 
ALS bindingb IGFBP3, IGFBP5 
Cell bindingb IGFBP3, IGFBP5 
Carboxyl 
terminal 
Integrin binding IGFBP1 
Table 2. IGFBPs different functional domains. The N- and C-
domains of IGFBPs both contain IGF binding site, which is 
important for the half-life of IGF 20. At the C-terminus, there 
are also heparin binding, ALS binding, nuclear localization 
and RGD integrin-binding domains. The inhibitor domains are 
at the N-terminus. The central domains are highly variable 
containing sites for posttranslational modification. 
When IGFBPs can not bind IGFs, they still have impact on the action of IGFs without activation 
or inhibition of type I IGF receptor in an IGF-independent manner 19, 20, 22. IGFBP1 displays an 
effect on cell motility and adhesion through binding 51 integrin, such as healing stimulation in 
a dermal wound model. IGFBP3 can inhibit cancer cell growth and induce their apoptosis 
through a putative IGFBP3 receptor. IGFBP3 can also stimulate TGF signalling via the smad 
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pathway. IGFBP5 displays normal osteoblast mitogenesis stimulation through a putative IGFBP5 
receptor (Fig. 5). Both IGFBP3 and IGFBP5 possess nuclear localisation sequence via importin 
. But the mechanism of these activities is still unclear. 
Fig 4. IGF-dependent IGFBPs action 20. IGFBPs 
limite IGF bioavailability and decrease its activity by 
blocking its binding to IGF-receptor. The 
dissociation of the IGFBPs-IGF complex in the 
plasma of the target tissue enables IGF to interact 
with IGF-receptor on the cell membrane. 
Fig 5. IGF-independent IGFBPs action 20. IGFBPs can 
activate cell-surface receptors directly to stimulate cellular 
events in the absence of IGFs. For example, IGFBP1 can 
act on cell growth and adhesion through binding 51 
integrin. IGFBP3 can inhibite cellular actions through 
interactions with putative IGFBP3 receptor or some other 
receptors. 
IGF1 actions in skeletal muscle  
IGF1 can act either as a hormone or as a local growth factor 6. It is essential for normal growth 
and development. It is a key regulator of skeletal muscle development. It enhances the ability for 
muscle to grow and undergoes repair throughout life 23. It is one unique mitogenic growth factor 
that can stimulate both proliferation and differentiation of myoblasts in culture 24. IGF1 is also 
known to function as survival factor to protect skeletal muscle cells from apoptosis 17. 
IGF1 can stimulate myoblast proliferation with the presence of mitogenic competence factor 25. It 
is one important mediator of anabolic pathways in skeletal muscle cells. The effect of IGF1 on 
muscle protein metabolism is associated with the stimulation of muscle protein synthesis and the 
suppression of proteolysis 26.  
IGF1 controls the myogenesis in all skeletal muscle cells 27. The family of myogenesis genes 
MyoD, myogenin, myf-5, and MRF4 is only expressed in skeletal muscle cells, not even in 
cardiac or smooth muscle cells 28, 29. These genes functioned in similar ways are transcription 
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factors essential for the specification and determination of the muscle cell lineage. They can 
transform other cell types to the myogenic lineage. This muscle regulatory factor gene family is 
associated with teminal myogenic differentiation, which is crucial for normal skeletal muscle 
development. During myogenesis, myoblasts can be fused to form postmitotic myotubes, where 
the transcription factors MyoD and myf-5 plays a crucial role for the initial determination of the 
myogenic lineage 27. Expression of MyoD is then downregulated shortly before myogenin 30. The 
gene myf-5 is essential for the initial elevation of myogenin expression, which is then 
autocatalytic 17. The expression of myogenin and MRF4 is activated during myoblast 
differentiation. Myogenin mRNA can be actively induced and elevated in treated cells. MRF4 is 
expressed only in the late phase of differentiation 29. 
Proliferation and differentiation are two opposing processes. It is found that IGF1 does not 
stimulate differentiation while it is stimulating proliferation 31. There is one short separation time 
between two effects, which presented one perfect period for the repair of damaged tissue 6. The 
cultured muscle cells exhibited a biphasic concentration dependent response to IGF1 treatment. 
At first cell proliferation was stimulated during which expression of myogenic factors is inhibited 
and then the myogenic differentiation was enhanced during which proliferative signals are down-
regulated. During the stimulation of muscle cell differentiation by IGF1, the process was 
significant at relatively low IGF1 concentration. But at higher concentration (>100ng/ml IGF1), 
the process of differentiation was slowly, even stpped at very high IGF1 concentration 17.  
Disuse or denervation causes rapid atrophy. During atrophy, skeletal muscles exhibit a common 
set of biochemical and transcriptional changes, such as breakdown of myofibrillar proteins. 
Because 60-70% of the total cell protein is myofibrillar proteins in adult muscle, proteolysis will 
have important effect on muscle size and functional capacity 32. Muscle atrophy results mainly 
from a general activation of the ubiquitin-proteasome pathway. FoxO family transcription factors 
play a critical role in this loss of cell protein 33. When activated, FoxO3 causes expression of the 
atrophy-related ubiquitin ligaes atrogin-1 and MuRF1 and profound loss of muscle mass. IGF1 is 
one important cytokine which maintains skeletal muscle mass. It can stimulate muscle protein 
synthesis and hypertrophy via the phosphatidylinositol 3-kinase (PI3K)-Akt pathway. Activation 
of this pathway can reduce muscle atrophy. Atrogin-1 is a regulated downstream target of PI3K. 
IGF1 can block protein degradation, which is associated with decreased expression of two 
muscle-specific ubiquitin ligases, atrogin-1 and MuRF1 32. IGF1 can rapidly reduce atrogin-1 
expression by blocking mRNA synthesis, while MuRF1 mRNA is just decreased slowly.  
Contractile activity is necessary for postnatal muscle growth and for the maintenance of skeletal 
muscle mass in adults. Increased work can cause fiber hypertrophy. IGF1 mediates skeletal 
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muscle hypertrophy to activate of protein synthesis through PI3K-Akt pathway 34. The key 
elements of this pathway are activation of PI3K, Akt and mTOR 35.  
IGF1 actions and signalling in skeletal muscle regeneration after injury 
Muscle deficiency or injury can result in a significant loss of function, which will have an impact 
on the quality of life. IGF1 is a central regulator of muscle regeneration 6. IGF1 increases muscle 
mass and strength in two main ways. First, IGF1 acts directly on the muscle fibers to increase 
protein synthesis and muscle mass. Secondly, it can drive activated satellite cells to fuse to 
existing muscle fibers in order to repair damaged regions of the fibers and to promote muscle 
growth. It is the reason that IGF1 is a potential candidate for a therapeutic agent, both in aging 
and muscle disease 23. 
Muscle regeneration following injury is a coordinate process in which multiple factors are 
activated to maintain and preserve muscle structure and function on injured stimuli. There are 
four phases involved, degeneration, inflammation, regeneration, and fibrosis 36. Injury results in 
the rapid necosis of myofibers and the activation of inflammation, which is to remove necrotic 
materials and to secrete several cytokines and growth factors for activation of satellite cells 5, 36. 
IGF1 can down-regulate proinflammatory cytokines, such as tumor necrosis factor- and 
interleukin-1, and modulate the expression of CC chemokines involved in the recruitment of 
monocytes and macrophages 5. IGF1 can also act as a survival factor by prolonging the 
regenerative potential of skeletal musle through increases in satellite cell activity 6.  
IGF1 initiates cellular action by directly binding to the IGF1 receptor  subunit on the cell surface 
and subsequent phosphorylation of the IGF1 receptor  unit (Fig. 6) 16. The phosphorylated 
receptor recruits and phosphorylates the insulin receptor substrate 1 (IRS1), which activates 
phosphoinositide 3 kinase (PI3K). PI3K transfers a phosphate group to the membrane bound 
phosphatidylinositol (3,4)-bisphosphate (PIP2) to generate phosphatidylinositol (3,4,5)-
trisphosphate (PIP3). PIP3 serves as a nucleation site for Akt1 and phosphoinositide-dependent 
kinase-1 (PDK1) 37, 38. PDK1 phosphorylates and activates Akt1, which in turn transfers 
phosphate groups to several substrates, mammalian target of rapamycin (mTOR), glycogen 
synthase kinase 3 beta (GSK-3) and forkhead box O (FoxO). The combined effects of PIP3, 
Akt1 and PDK1 are important for cell migration, growth and survival 39-41.  
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Fig 6. Mechanisms for IGF1-induced muscle growth promotion through PI3K/Akt pathway 18, 38, 
41, 42. IGF1 binds to IGF1 receptor resulting in receptor autophosphorylation, followed by tyrosine 
phosphorylation of several cellular substrates, such as insulin receptor substrate 1 (IRS1). 
Association of IRS-1 with phosphoinositide 3 kinase (PI3K) results in activation of Akt kinase. 
Akt can in turn activate mammalian target of rapamycin (mTOR) and inhibite both glycogen 
synthase kinase 3 beta (GSK-3) and forkhead box O (FoxO). The combined effects result in 
increasing protein synthesis and reducing protein degradation. Activation of the pathway is 
indicated with green arrows. Inhibition of the pathway is indicated with red arrows. 
Akt1-mediated phosphylation and inhibition of GSK-3 activates the eukaryotic translation factor 
eIF-2B and increase protein synthesis. With the help of the protein Raptor, the phosphorylated 
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mTOR then phosphorylates and inhibits 4EBP1. mTOR also promotes protein synthesis also by 
activating ribosomal p70S6K 42. At same time, down stream of the Akt mediated FoxO 
phosphorylation signalling pathway results in decreasing protein degradation.  
So, the signalling cascades induced by IGF1 lead to increased muscle protein production and 
regenerate the muscle layer after injury and tissue damage. 
IGF1 actions in smooth muscle  
IGF1 regulates the growth of smooth muscle cells (SMCs) of the vascular wall, bladder, 
myometrium, and gastrointestinal and respiratory tracts. This enables SMCs to have adaptive 
responses to injury, hormonal, or mechanical stimulation 43. It is reported that smooth muscle 
hypertrophy secondary to partial urethral ligation is associated with increased IGF1 biosynthesis 
in the bladder wall 44. The transgenic mice selectively overexpressing IGF1 in SMCs exhibited 
overexpression of IGF1 in all smooth muscle-rich tissues (i.e. bladder, stomach, intestine, 
uterus, and aorta), where the growth factor promotes a striking degree of hyperplasia without 
affecting plasma IGF1 levels or total body weight 45.  
The ligand occupancy of v3 integrin is required for IGF1 stimulated SMCs proliferation and 
migration and DNA synthesis. The v3 integrin occupancy is also important for the activation of 
IGF1 receptor dependent downstream signaling events, such as activation of PI3K and MAPK 
pathways. So, this integrin receptor has a significant role in regulating IGF1 recptor signalling 46. 
Vascular SMCs are the principal source of collagen and extracellular matrix, which maintain the 
tensile strength of atherosclerotic plaques. Apoptosis of vascular SMCs decreases the synthesis 
of collagen and extracellular matrix, and induces features of plaque instability 47. Rupturing of 
plaques can result in thrombotic complications. Oxidative stress is increasingly implicated in the 
development of atherosclerosis 48. It can induce vascular SMCs apotosis in cel culture 
conditions. IGF1 receptor dependent signalling is a critical regulator for smooth muscle cell 
survival. Increased expression of the IGF1 receptor can rescue plaque vascular SMCs from 
oxidative stress-induced apoptosis 49. A major downstream effector of IGF1 receptor signalling is 
the serine/threonine kinase Akt. Akt-dependent phosphorylation and subsequent inactivation of 
its downstream targets FoxO3a or GSK3 is important for vascular SMCs survival 50.  
We will use IGF1 for bladder smooth muscle layer regeneration. 
30 
Biomaterials as delivery devices for growth factors 
The field of biomaterials research is a specialization within biomedical engineering that 
integrates engineering fundamentals in materials science with the principles of cell biology, 
chemistry and physiology to aid in the design and development of novel medical devices 51. 
Using biomaterials is an increasing utilized approach for wound healing and tissue regeneration. 
Biomaterials can serve as temporary scaffolds for tissue growth. They can direct cellular 
interactions, and also can provide bioactive signalling, such as in the delivery of growth factors 
52.  
Biomaterials are already widely applied in biomedicine, such as in drug delivery systems, 
surgical implants, artificial organs, wound healing, and vaccines 53, 54. Due to their wide 
application in clinical use, there are some design and production criteria, such as 
biocompatibility, sterility, favourable processing conditions, and stability in response to biological 
conditions. Biomaterials for tissue repair should display favourable biodegradation and 
bioresorption, with limited inflammation and toxicity to avoid long-term complications. 
Generally, three classes of biomaterials have been used in tissue engineering: natural protein 
and polysaccharide based biomaterials (e.g., collagen and alginate), inorganic biomaterials 
(e.g., metals, ceramics and glasses for artificial hips in orthopaedic research) and synthetic 
polymers (e.g., polyglycolic acid (PGA), polylactic acid (PLA), and poly(lactic-co-glycolic acid) 
(PLGA)) 55-58. These materials have been investigated using two- or three- dimensional models 
in vitro to mimic the multicellular ECM in order to guide morphogenesis in tissue repair 59, 60. 
In this thesis, one of these natural biomaterials, fibrin, was applied for bladder muscle layer 
regeneration. Natural biomaterials have the potential advantage of biological recognition, but 
also present some complexities associated with purification, immunogenicity and pathogen 
transmission. However, these limitations can be overcome using recombinant protein expression 
technologies 60. 
Fibrinogen structure 
Fibrinogen (also called coagulation factor I) is synthesised in the liver by hepatocytes and 
megakaryocytes. It is a rod-shaped dimeric glycoprotein (molecular weight, 340kDa) that 
circulates in the plasma (the pale yellow, protein-containing liquid part of blood in which the 
blood cells and platelets are suspended) at a concentration of 2 to 4 mg/ml with a normal half-
life of 3 to 5 days. Each monomer is composed of three different polypeptides; the A (610 
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amino acids, 67kDa), the B (461 amino acids, 55kDa) and the  (411 amino acids, 47.5kDa) 
chains 61. These three polypeptides are linked to one another through 13 pairs of disulfide bonds 
to form the fibrinogen monomer. The two monomers are then bridged together to form a 
symmetric dimer through three additional disulfide bonds located near the N-terminus, which 
enables the monomers to face each other, such that the N-terminus of the six chains colocalize 
near the center of the rod (Fig. 7). The amino-terminal region of the molecule (located in the 
middle of the rod) provides the thrombin-binding site and the polymerizing domains. The 
carboxy-terminal regions contain the principle cross-linking sites for factor XIIIa, the platelet-
binding sites, and the fibronectin-binding domains. Two of the three chains, B and , have 
single N-linked carbohydrate clusters which are first added to the different chains during the 
translation/translocation event 62.  
 
 
 
 
 
Fig 7. Schematic model of fibrinogen. T denotes the thrombin cleavage sites in central, or “E”, 
domain located on the A and B chains. The two disulfide clusters in the E domain and one 
each in the end, or “D”, domains are referenced by “-S-S- cluster”. The location of the 
carbohydrates on the - and B- subunits is noted by “CHO”. The tightly wound supercoiled -
helical regions are shown as coiled coils under the arrows. The C-terminal region of the B and  
chains form “random coils”. In this region of the  chain reside the Gln-Lys cross-linking sites 
catalyzed by activator factor XIIIa 62. 
Fibrin tissue engineering 
Fibrin is made from fibrinogen polymerisation. It is a specialized ECM protein network involved in 
blood clotting. Fibrinogen is transformed to fibrin by the coagulation enzyme thrombin (factor 
IIa). Thrombin catalyzes the hydrolysis of Arginyl-Glycine bonds. It binds to the N-terminal region 
of fibrinogen and initiates two steps of proteolysis to remove two acidic peptides. First is a rapid 
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removal of fibrinopeptide A (A chain, aa 1 to 16), followed by a slower hydrolysis of 
fibrinopeptide B (B chain, amino acid from 1 to 14) 62. The release of these peptides activates 
the fibrinogen molecule, which is thus designated the fibrin monomer. The molecular weights of 
fibrinogen and the fibrin monomer are identical. The only difference is that fibrinogen is more 
electronegative. The newly exposed amino termini ("knobs") are the principle contact sites 
during polymerization. In human fibrinogen, the A chain "knob" begins with the sequence Gly-
Pro-Arg (G-P-R) while the B chain starts with sequence Gly-His-Arg (G-H-R) 62-64. 
 
Fig 8. Schematic diagram of fibrin polymerisation and crosslinking 65. 
Thrombin cleavages fibrinopeptides A and B from the N-terminal 
ends of the fibrinogen A and B chains, respectively. Then the 
assembly of fibrin begins with non-covalent interactions between E 
and D domains, followed by C-terminal ends of the A chains 
interact with other A domains to form a gel consisting of long 
polymers. Factor XIIIa catalyzes the covalent crosslinks between C-
terminal sites in the  chains and then A chains, which results in 
fibrin polymer web. 
 
 
 
 
 
 
Fig 9. Scanning electron microscope (SEM) 
image of fibrous structure of fibrinogen 
scaffold with scale bar of 1 micrometer. 
Image was offered by Professor Thomas 
Barker. 
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The first step of polymerization is the adherence of adjacent fibrinogen molecules in a half-
overlapped fashion brought about following the removal of the charged clusters of the 
fibrinopeptides. Activation of the A N-terminus leads to lateral aggregation of polymers by the 
association of the “knobs” with binding pockets, called “holes”, located at the C-terminal portions 
of both the B and  chains. The mature fibrin product when A knobs are involved, are called 
fibrin I, and when A- as well as B-knobs are engaged, it is called fibrin II 66. A second stage of 
fibrin polymer stabilization occurs, induced by the enzyme factor XIIIa, when the formation of 
isopeptide bonds between lysyl and glutaminyl residues located at the C-terminus of the -
chains that have aligned end to end (Fig. 8) 62. Finally, the same coagulation enzyme factor 
XIIIa, forming - crosslinking, introduces numerous covalent crosslinks between adjacent A-
chains. 
The resulting fibrin web (Fig. 9) is capable of capturing platelets and red blood cells, effectively 
sealing a wound and stemming plasma (fluid) loss. Fibrin gels can be applied in tissue 
engineering by incorporating cells, adsorbing bioactive proteins or covalently bound peptides. 
These modifications can increase cell adhesion, or induce specific cell signalling pathways 53, 59. 
Fibrin gels are sensitive to degradation by proteolytic enzymes activated by cells trapped inside. 
All cells that migrate activate plasminogen to plasmin and matrix metalloproteinase precursors to 
active matrix metalloproteinases. These active enzymes normally allow the cells to penetrate the 
extracellular matrix to degrade the fibrin gel in the nano- and micro-domain close to the cell 
surface. In this way, the cells can tunnel through the fibrin gel, which leads to a slow degradation 
and bioresorption of the biomaterials. At same time, these enzymes also liberate bound 
bioactive proteins or peptides from matrix 52. This system has been used now for some time as a 
tissue adhesive/bioglue as well as a delivery system for growth factors and cells.  
We will use the fibrinogen/fibrin polymer system as a means to deliver a growth factor 
(IGF1) and cells infiltrating (bladder smooth muscle cells) for bladder muscle layer 
reconstruction. 
Bladder tissue engineering 
Tissue engineering 
Organ shortage and suboptimal prosthetic or biological materials for repair or replacement of 
diseased or destroyed human organs and tissues are the main motivation for increasing 
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research in the field of tissue engineering 67. As one of the major disciplines in regenerative 
medicine, tissue engineering follows the principles of cell transplantation, materials science, and 
engineering toward the development of biologic substitutes that can restore and maintain normal 
function. Tissue engineering strategies generally fall into two categories: use of acellular 
matrices, where matrices are used alone and depend on the body’s natural ability to regenerate 
for proper orientation and direction of new tissue growth, and use of matrices with cells 68.  
Acellular tissue matrices are usually prepared by removing cellular components from tissues via 
mechanical and chemical manipulation to produce collagen-rich matrices. These matrices tend 
to slowly degrade upon implantation and are generally replaced by the ECM proteins that are 
secreted by the ingrowing cells 68-72.  
When cells are used for tissue engineering, a small piece of donor tissue is dissociated in vitro 
into individual cells. These cells are either implanted directly into the host or are expanded in 
culture, attached to a support matrix, and then reimplanted into the host after expansion (Fig. 1). 
The source of donor tissue can be xenogeneic (different species, such as bovine), allogeneic 
(same species, different individual), or autologous (same individual). Ideally, both structural and 
functional tissue replacements will occur with minimal complications. The most preferred cells to 
use are autologous, where a biopsy of tissue is obtained from the host, the cells are dissociated 
and expanded in culture, and the expanded cells are implanted back into the host. The use of 
autologous cells avoids rejection, and thus the deleterious side effects of immunosuppressive 
medication use can be avoided 67, 72. 
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Fig 10. Concept of tissue engineering 67. Cells can be taken from a biopsy of patient’s body or 
differentiated from stem cells, and cultured until there is a sufficient quantity. Then the cells are 
seeded on a polymeric scaffold material where they grow in vitro in a bioreactor or incubator. 
The regrown tissue can be implanted in the area of defect in patient’s body. 
For cell-based tissue engineering, expanded cells are seeded into a scaffold prepared with the 
appropriate biomaterial. In tissue engineering, biomaterials attempt to mimic the biologic and 
mechanical function of the native ECM found in tissues in the body by serving as an artificial 
scaffold. As a result, the ideal biomaterial should be biocompatible in that it is biodegradable and 
bioresorbable to support the replacement of normal tissue without inflammation. Furthermore, 
biomaterials provide a three-dimensional space for the cells to form into new tissues, and also 
can allow for the delivery of cells and appropriate biomolecules (e.g., cell adhesion peptides, 
growth factors), to desired sites in the body 68, 73, 74.  
The formed hydrogel should provide a microenvironment in which the appropriate regulation of 
cell behavior (e.g., adhesion, proliferation, migration, and differentiation) can occur so that the 
desired tissue can form. These interactions can include cell-adhesion ligands 75 and with soluble 
growth factors such as IGF1. Because the majority of mammalian cell types are anchorage 
dependent and will die if no cell-adhesion substrate is available, hydrogels also can act as cell-
adhesion substrates. The formed hydrogels can also provide mechanical support against in vivo 
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forces such that the predefined three-dimensional structure is maintained during tissue 
development 68.  
In this way, hydrogels formed from biomaterials can provide for cellular growth and 
differentiation for a wide variety of cell types as well as a matrix whose elastic and viscous 
modulus can be well controlled. Tissue regeneration or replacement can be tailored for that 
specific medical application. 
Bladder wall 
The urinary tract consists of the organs, tubes, and muscles that work together to make, move, 
store, and release urine, the liquid waste of the human body. The upper urinary tract includes 
the kidneys, which filter wastes and extra fluid from the blood, and the ureters, which carry urine 
from the kidneys to the bladder. There is a valve in the ureters that provides for a one-way flow, 
prohibiting reflux of urine from the bladder to the kidneys. The lower urinary tract includes the 
bladder, a balloon-shaped muscle that stores urine, and the urethra, a tube that carries urine 
from the bladder to the outside of the body during urination. The sphincter is a circular muscle 
that wraps around the bladder where it connects to urethra. Its purpose is to keep the 
connection closed so that urine does not leak out of the bladder (Fig. 11). 
 
Fig 11. The urinary tract structure. The system 
includes two kidneys, two ureters, one bladder, 
two sphincter muscles, and one urethra. 
 
Fig 12. Bladder wall anatomy. It is composed of four 
principal layers, mucosa, submucosa, detrusor muscle and 
serosa 76 
A B 
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The urinary bladder is unique and the most distensible organ in the body. It has a more or less 
spherical shape and is located at the end of both ureters, down in the abdomen, behind the 
pubic bone.  
The bladder is capable, under normal circumstances, of storing 400-500 ml of urine at low 
pressure, and then to expel this completely, several times a day. When empty, it is no larger 
than a tennis ball. It is an autonomic organ under voluntary control. Contrary to what many 
people think, it is not the action of the abdominal wall muscles that empties the bladder, but the 
bladder contains its own smooth muscles.  
Bladder compliance is determined by the structural properties of the extracellular matrix (ECM) 
and cells that make up the bladder wall. The bladder wall has a serous coat (serosa) over its 
upper surface. The serosa is a reflection of the peritoneum which covers only the superior 
surface and the upper part of the lateral surfaces. It is fibrous connective tissue. The other layers 
of the bladder wall are the fascial, muscular, submucosal, and mucosal coats.  
The fascial coat (adventitia) is a layer of connective tissue between serosa and muscular coat.  
The muscular coat (detrusor muscle) is composed of smooth muscle. The smooth muscle fibers 
are interwoven in all directions and collectively these are called the detrusor muscle. Contraction 
of this muscle expels urine from the bladder (Fig. 12) 77. Detrusor smooth muscle cells are very 
elastic. During filling of the urinary bladder, the smooth muscle cells elongate and rearrange in 
the wall over a very large length interval. During expulsion, force generation and shortening are 
initiated comparatively fast, synchronized, and occur over a large length range 77. 
The submucosal coat (lamina propria) is composed of connective tissue with elastic fibers and 
supports the muscular coat. This layer contains blood vessels, nerves, and in some regions, 
glands.  
The mucosal coat (mucosa or urothelium) is a transitional epithelium, composed of epithelial 
layer and basal lamina. It is the inner lining of the urinary bladder. When the bladder is empty, 
the mucosa has numerous folds called rugae. The rugae and transitional epithelium allow the 
bladder to expand as it fills. It contains no blood or lymphatic vessels and lines the bladder, 
ureters, and urethra. The basal lamina includes proteoglycans separating the epithelial layer 
from the lamina propria. It contains a sheet of extracellular material serving as a filtration barrier 
and supporting structure for the mucosal layer 76. 
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Bladder tissue engineering 
Table 3 Recent studies on experimental bladder reconstruction 79 
Methodology        Authors    Year 
Animal derived matrix only  
Small intestine submucosa (SIS)    Kropp et al.   1995 
Bladder acellular matrix (BAM)    Sutherland et al.  1996 
Collagen scaffold      Hattori et al.   2006 
Scaffold + autologous cell transplantation (tissue engineering) 
Polymer scaffold + UC + SMC    Oberpenning et al.   1999 
BAM/Collagen + UC      Moriya et al..   2003 
Acellular bowel + UC + SMC + EPC   Schultheiss et al.   2005 
Polymer scaffold + UC + SMC (clinical trial)  Atala et al.   2006 
Scaffold + growth factor loading 
Bladder acellular matrix + bFGF    Kanematsu et al.  2003 
Bladder acellular matrix + VEGF    Youssif et al.   2005 
Composite cystoplasty 
Demucosalized gastric segment + UC sheet  Shiroyanagi et al.  2004 
Demucosalized uterus/colon + UC    Fraser et al.   2004 
Demucosalized colon + UC spray    Hafez et al.    2006 
Reconstructive surgery is required for diseased and injured bladder. Currently, classical 
reconstruction is performed with native or homologous nonurologic tissues, such as small 
intestine (ileum), stomach, or mucosa. These techniques are called intestinal cystoplasty, 
gastrocystoplasty, ureterocystoplasty, vesicomyomectomy (autoaugmentation), seromuscular 
augmentation etc 31,78. Due to complication after reconstruction and shortage of donors, bladder 
tissue engineering is emerging as a potential alternative to current treatment. Bladder tissue 
engineering is one part of regenerative medicine. It involves material science, engineering, cell 
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culture to develop biological substitutes for maintaining and reconstructing the normal function of 
bladder. 
Bladder tissue engineering was begun in 1917 by Neuhof 79. During the last decades, it is 
developing more and more fast. The main problem is to avoid covering a wound with a scar of 
fibrosis tissue. Three main classes of biomaterials are used as scaffold for bladder tissue 
engineering: naturally derived materials, acellular tissue matrices and synthetic polymer (Table 
3). Acellular tissue matrices, such as bladder acellular matrix (BAM) and small intestine 
submucosa (SIS), are collagen-rich matrices and can be remodelled by ingrowing or 
transplanted cells. It contains cell adhesion sequences, such as RGD, which can attract many 
types of cells 79.  
Synthetic polymers, such as polyglycolic acid (PGA) and poly(lactic-co-glycolic acid) (PLGA) 80, 
can be produced on a large scale. Their degradation rate and strength can be controlled. The 
growth factors can be loaded and cells can be seeded in the polymers. Urinary bladders in 
canines [55,80 and humans 81 were made successfully using PGA/PLGA with autologous 
urothelial cells (UCs) and smooth muscle cells (SMCs).  
The detrusor muscle in the bladder wall has a role predominant in bladder physiological function. 
It relaxes during bladder filling. It contracts during bladder voiding. A lot of causes can cause 
detrusor muscle failure, such as nerve damage, bladder stones, Parkinson’s disease, prostate 
and stress. The malfunction of detrusor muscle results in bladder diseases, such as urinary 
incontinence and cystitis. So, the bladder muscle layer regeneration is an important topic in 
bladder tissue engineering. Researches were using acellular tissue matrices with mesenchymal 
cells, collagen and skeletal muscle-derived cells (MDCs). But actually no effective method is 
available to treat impaired detrusor dysfunction. 
We will use bladder tissue engineering methods for bladder muscle layer reconstruction. 
Scope and survey of this thesis 
The bladder has two important functions, specifically filling and emptying of urine. These 
functions provide a significant mechanical challenge to the muscle component in the bladder 
wall where elasticity and compliance is required to accommodate the gross changes in volume 
77. From the time the fetus develops the bladder is exposed to a variety of possible deformities 
and injuries which may lead to bladder tissue damage or loss, requiring eventual bladder repair 
or replacement. Currently, gastrointestinal segments are commonly used for bladder 
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replacement or repair. However, gastrointestinal tissues are designed to absorb solutes, 
whereas bladder tissues are designed for the excretion of solutes 82-86. Due to multiple 
complications encountered with the use of gastrointestinal segments and a severe shortage of 
donor tissues, alternative materials and tissues for bladder replacement or repair are being 
sought.  
Over the last few decades the use of several bladder-wall substitutes has been attempted with 
both synthetic and natural biodegradable materials. They have usually failed due to either 
mechanical, structural, functional, or biocompatibility problems 84, 85, 87-89. Tissue engineering 
using selective cell transplantation and matrices for tissue regeneration may provide for a means 
of creating functional new bladder segments.  
IGF1 is used to supplement child growth and in short-term post-operational trauma in clinical 
trials. Due to severe side effects, an IGF1 formulation is being developed for long-term use. The 
IGF1 signalling pathway also plays an important role in maintaining skeletal muscle 5 and 
smooth muscle 43. The goal of this thesis is to develop a fusion protein of IGF1 with a substrate 
for factor XIIIa, to allow binding to a fibrin matrix for bladder muscle layer regeneration. A second 
approach to the same end tried and reported first was to explore truncation mutants of 
fibrinogen, into which truncation site IGF1 would be grafted as a fusion protein. Thus two 
methods by which to incorporate IGF1 in bond form within fibrin matrices were evaluated. 
Using the current fibrin gel platform technology developed in the lab, the IGF1 was modified by 
inserting one peptide TG, the first eight amino acids of 2 plasmin inhibitor, at the N-terminal. 
The recombinant truncated TG-IGF1 was produced by E. Coli cells and purified by FPLC. The 
purified TG-IGF1 was characterized by SDS-PAGE and by western blot using anti-human IGF1 
antibody. Then the bioactivity of TG-IGF1 was analyzed in vitro in 2-dimensional and in 3-
dimensional models. In 2-dimensional model, 3T3 cells were used for cell metabolic assay (MTT 
assay) and IGF1 receptor phosphorylation assay. In 3-dimensional model, the fibrin gels were 
incorporated with neonatal bladder smooth muscle cells (SMCs). The quantitative real-time PCR 
(qRT-PCR) was used for genes expression about adhesion and extracellular matrix proteins by 
SMCs in fibrin gels. The morphology of SMCs in fibrin gels was characterized by the 
transmission electron microscopy (TEM). The bioactivity of TG-IGF1 was done also in vivo, 
where rat bladder model was used for muscle layer regeneration.  
One new fibrin gel platform was tried to generate in this thesis by producing fusion fibrinogen 
IGF1 protein using mammalian CHO cells. The best growth and production media for CHO cells 
were screened among 23 commercial media by cell viability and cell number counting. For the 
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quantity and quality of recombinant protein produced, CHO cells were in the suspension and 
serum-free media culture. Then IGF1 protein was inserted at the C-terminal of truncated 
fibrinogen -chain in genetic level by cloning technology. The generated stable new CHO cell 
lines were characterized by ELISA using fibrinogen and human IGF1 antibodies. The fusion 
fibrinogen IGF1 protein was then produced by new CHO cell lines and purified by affinity 
chromatography. The purified fusion protein was analyzed by SDS-PAGE and western blot using 
fibrinogen antibody. The clot assay was done for the bioactivity of fusion protein. 
In this thesis, we will address the hypothesis that the delivery of an IGF1 fusion protein in 
a fibrin matrix will result in bladder muscle layer regeneration by promoting bladder 
smooth muscle cell infiltrating growth and differentiation. 
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Chapter II High-level recombinant fibrinogen protein 
production in suspension cultured mammalian cells 
Summary 
Mammalian cell culture is a widely used technique to produce many therapeutic recombinant 
proteins. To get relatively high quantities of protein, Chinese Hamster Ovary (CHO) cells are 
usually modified and grown in bioreactors. Due to the wide application of fibrin matrices in tissue 
engineering, recombinant fibrinogen was also tried to be obtained from CHO cells in serum free 
and suspension culture. However, expressed recombinant fibrinogen can be polymerized easily 
in cell culture due to proteases and trace of calcium ions present in the growth media. To resolve 
this problem, doxycycline-regulated pTet-on gene expression system was used. Because the 
fibrinogen expression is tightly controlled by the presence of doxycycline in the cell medium, this 
offers one new way to express a special gene from mammalian cells in culture. In this work, 
ProCHO5 cell medium was found to be the optimal growth and production medium among 23 
media tested with CHO cells (containing fibrinogen B and -chains) and CHOfgn cells 
(containing fibrinogen A-, B and -chains). CHO cells were grown successfully in 
suspension and serum free culture. And some CHO cells were transfected with fibrinogen A 
chain cDNA using pTet-on system to obtain CHOfgn cell line. Due to five vectors in CHOfgn cells 
(two vectors for pTet-on system and three vectors for fibrinogen A-, B and -chains 
respectively) and importance of conformational change in gene level in pTet-on system for 
fibrinogen on/off expression, up to date no stable CHOfgn cell line with pTet-on system was 
obtained. 
Introduction 
The primary role of fibrin is to provide for hemostasis and as a provisional structural scaffold for 
invading cells and an immuno-modulator of innate immune cells that will eventually repair the 
damaged tissue. Currently, the fibrin used in tissue engineering is derived from human plasma. It 
carries the risk (albeit small) of transmission of infectious agents and precipitating immunological 
reactions 1. The development of recombinant sources of human fibrinogen could provide a 
reliable, predictable and chemically defined source of purified human fibrinogen that contains 
few additional components. Cultivated mammalian cells (such as CHO) have become the 
predominant system for the production of recombinant proteins for clinical applications because 
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of their capacity for proper protein folding, assembly and post-translational modification 2. Due to 
the utility of fibrin, including use as a scaffold for tissue engineering constructs, and the risk of 
transmission of infectious agents, several systems for the production of the recombinant 
fibrinogen protein have been attempted, including anchorage-dependent CHO cell culture 
systems used in other laboratories 3-5. However, the limitation in cell growth area in two-
dimensional culture systems significantly limits large-scale cell culture. To overcome the 
limitation of cell growth area and to develop a system capable of producing industrially relevant 
quantities of recombinant soluble, bioactive fibrinogen, recombinant Chinese Hamster Ovary 
cells will be adapted to suspension culture in this aim. Even if it were to prove too difficult to 
recombinantly produce human fibrinogen at an acceptably low cost (the protein is used in 
matrices at concentrations > a few mg/ml), it may be possible to produce variant fibrinogen 
claims (such as IGF1 fusions) to be doped into fibrin produced from human plasma. 
Fibrinogen is a dimeric glycoprotein. Each monomer is composed of three polypeptides, A, B 
and 6. CHOfgn cells refer to Chinese hamster ovary (CHO) cells expressing recombinant human 
fibrinogen, that is, these cells are capable of producing each of the three individual chains of 
fibrinogen and secrete the fully-assembled, bioactive protein. CHO cells refer to CHO cells 
containing human cDNAs encoding fibrinogen B- and -chains under the control of a 
constitutively-active promoter. These genetically-engineered CHO cells were obtained from Prof. 
ST Lord at University of North Carolina at Chapel Hill 5, 7-9. They were anchorage-dependent and 
cultured in Dulbecco’s modified Eagle media (DMEM)/F12 media (Invitrogen, UK) supplemented 
with 10% fetal bovine serum (FBS, Invitrogen, UK), 100U/ml penicillin (Invitrogen, UK), 100g/ml 
streptomycin (Invitrogen, UK) and 0.4mg/ml G418 (Promega, USA). Both cell lines were grown 
at 37°C in 5% CO2.  
Although calcium plays an important role in fibrinogen polymerisation 10, trace amounts of 
calcium in the cell medium are required for the growth of CHO cells in culture. This is because 
calcium regulates cell proliferation, growth and apoptosis by Ras-MAPK pathway 11, 12. So, it is a 
bad idea to neutralize calcium in cell medium as it is required to keep CHO cells in culture. To 
overcome this problem, fibrinogen expressed by CHO cells can be regulated by the doxycycline 
Tet-on gene expression system 13. The “Tet-on” system contains two vectors, regulatory and 
response plasmids (Fig. 13).  
The regulatory plasmid contains the regulatory protein, based on a reverse Tet repressor (rTetR) 
13, 14, which was created by four amino acid changes in TetR. The 37kDa protein is a fusion of 
amino acids 1-207 of rTetR and the C-terminal 127amino acids of the Herpes simple virus VP16 
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activation domain. Addition of the VP16 domain converts the rTetR from a transcriptional 
repressor to a transcriptional activator, and the resulting hybrid protein is called the reverse 
tetracycline-controlled transactivator (rtTA). The pTet-on regulator plasmid contains a neomycin-
resistance gene. 
The response plasmid expresses the gene of interest under the control of the tetracycline-
response element (TRE) 14. The pTRE2 plasmid consists of seven direct repeats of a 42-bp 
sequence containing the tetO, located just upstream of the minimal CMV promoter (PminCMV). 
PminCMV lacks the strong enhancer elements normally associated with the CMV immediate early 
promoter. Because these enhancer elements are missing, there is extremely low background 
expression of the gene of interest from the TRE in the absence of binding by the rTetR domain 
of rtTA. The pTRE2pur response plasmid contains puromycin-resistance gene. In the Tet-on 
system, rtTA binds to the TRE and activates transcription in the presence of doxycycline 15.  
 
Fig 13. The Tet-on gene expression system. The system contains two vectors, regulatory and 
response plasmids. The regulatory plasmid contains the regulatory protein, based on a reverse 
Tet repressor (rTetR). The response plasmid expresses the gene of interest under the control of 
the tetracycline-response element (TRE). rtTA binds to the TRE and activates transcription in the 
presence of doxycycline. 
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In addition, the supplementation of cell culture media with serum components of animal origin is 
commonly used to provide cells necessary nutrition, shear protection, growth factors and 
cytokines for optimal growth 16, 17. Because of its undefined composition, risk of contaminations, 
complication of desired protein purification and relatively expensive cost, rCHO will also be 
adapted to grow in serum free conditions. 
Finally, the medium development is of utmost importance and has to be done on an individual 
basis, for each process and cell line. Commercial media for cell culture is now available with a 
variety of additives for cell growth. Optimal conditions for cell growth and fibrinogen production 
must be determined if recombinant wild-type fibrinogen and recombinant fibrinogen fusion 
proteins are to be produced in sufficient quantity and activity. 
Materials and methods 
Plasmid construction 
Plasmid DNA was amplified in the E.coli strain E10 and extracted using a plasmid Maxi Kit 
(QIAGEN GmbH, Germany). Purified plasmid was resuspended in sterile water and checked by 
gel electrophoresis and OD readings at 260 and 280 nm. Only the preparation of the highest 
purity (R260/280>1.8) was used for transfection. 
pTRE2pur-FgnA full vector 
The Tet-on system used in this thesis is composed of pTRE2 response vector (Clontech, USA) 
and pTet-on regulator vector (Clontech, USA). The 1935 nucleotides fibrinogen A full length 
gene was PCR-amplified from p584 A plasmid (provided by Prof. Dr. Susan Lord) and purified 
by Genomed JETquick PCR product purification spin kit (Brunschwig, Basel, Switzerland). The 
Forward primer was 5’- CGGGATCCCGATGTTTTCCATGAGGATCGT-3’, in which a restriction 
enzyme BamHI sequence GGATCC (solid underline) was inserted before the FGN A start 
codon ATG. The reverse primer was 5’- GAATTGCGGCCGCCCATTTAACTTAGTCTA-3’, in 
which another restriction enzyme NotI sequence GCGGCCGC (solid underline) was 
incorporated after the stop codon TAG. Then purified PCR product was digested with restriction 
enzymes BamHI and NotI. The band was purified from agarose gel by Genomed JetQuick gel 
extraction spin kit (Brunschwig, Basel, Switzerland). The purified digested band was inserted 
into pTRE2pur plasmid to get pTRE2pur-FgnAa full vector. After ligation at 16°C, ligation 
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products were transformed into chemical competent E.coli subcloning Efficiency® DH5TM cells. 
Colonies were grown on LB agar ampicillin plates and screened by restriction digest analyses.  
pMYKpuro-FgnA full vector 
Due to the availability of 23 commercial media which was required to be screened, a large 
quantity of fibrinogen A plasmid DNA was needed for transfection. Polymerase chain reaction 
(PCR) is a commonly used method to amplify the quantity of cDNA. Native A chain cDNA, in a 
shuttle vector, served as the template for the PCR reactions that used taq polymerase and 
reaction conditions recommended by the manufacturer. The Forward primer was 5’-
ATATAGATATCTTAGAAAAGATGTTTTCCATGA-3’, in which a restriction enzyme (EcoRV) 
sequence GATATC was inserted before the FGN A start codon ATG. The reverse primer was 
5’-GAATTGCGGCCGCCCATTTAACTTAGTCTA-3’, in which another restriction enzyme (NotI) 
sequence CGCCGGCG was incorporated after the stop codon ATC.  
The PCR products and PMYKpuro vector (Provided by F. Wurm) were digested with the 
appropriate restriction enzymes (EcoRV and NotI) and ligated at 16°C. Ligation products were 
transformed by electroporation into competent E.coli E10 cells. Colonies were grown on LB agar 
ampicillin plates and screened by restriction digest analyses.  
Cell culture and transfection 
Cell culture 
For the cell culture, CHO cells were seeded in a bioreactor at a cell concentration of 3x105 
cells/ml in serum free ProCHO4 medium (Cambrex, Belgium) supplemented with 100U/ml 
penicillin (Invitrogen, UK), 100g/ml streptomycin (Invitrogen, UK), 0.2mM sodium hypoxanthine 
(Invitrogen, UK), 0.032mM thymidine (Invitrogen, UK) and 4mM L-Glutamine (Invitrogen, UK). 
The bioreactor was incubated in an incubator minitron (Infors HT, Switzerland) with a shaking 
speed 130rpm at 37°C in 5% CO2. 
Transfection by lipofectamine 2000 reagent 
The transfection of Tet-on system into CHO cells was achieved in two steps. CHO cells were 
seeded in one 6-well plate at a density of 2x105 cells/ml per well in 2ml medium without antibiotic 
G418. The transfection was carried out the following day in serum-free medium with 
lipofectamine 2000 (Invitrogen, UK) according to manufacturer’s protocol. For each well, 4 g of 
pTet-on plasmid DNA in 125 l of OPTI-MEM®I Reduced Serum Medium without serum 
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(Invitrogen, UK) was transfected using 10 l of Lipofectamine 2000 Reagent. So the ratio of 
lipofectamine to plasmid is 5:2. 20 hours later, the cells were trypsinized, washed and seeded in 
one new 6-well plate, 2ml medium per well without antibiotics G418. The second transfection 
was carried out two days later using pTRE2pur-FgnAa full plasmid DNA. The process was exact 
same as the first transfection. Finally, 24 hours later after the second transfection, the CHOfgn 
pTet-on cells were selected in puromycin and neomycin containing medium, 20g/ml puromycin 
(Brunschwig, Basel, Switzerland) and 0.4mg/ml G418, in 96-well plates. 
Transfection by PEI reagent 
CHO cells were seeded in fresh serum free ProCHO4 medium at 5x105 cells/ml and transfected 
one day later. Transient transfection with polyethylenimine (PEI) was carried out in serum free 
conditions. Linear 25kDa PEI (Polysciences, Eppenheim, Germany) was prepared in water at a 
final concentration of 1mg/ml, pH 7.0, and sterilized by filtration. 
The optimal PEI: DNA ratio used for this transient transfection was analysed from 1:1 to 1:14. 
The PEI (Polyscineces, Germany)/DNA complexes were prepared in 150 mM NaCl, using a total 
of 2.5g DNA /ml of cell culture. In all experiments, 2% EGFP (0.05g) was mixed with 2.45g 
plasmid DNA. Cells were resuspended in serum free RPMI medium at a density of 2x106 
cells/ml. After 4 hours post-transfection the culture was aliquot in 50 ml tubes (5ml per tube). 
These tubes were centrifuged at 800rpm for 10 minutes and the supernatant was removed. CHO 
cells were resuspended by adding 10 ml 23 different media.  
Characterization 
Cell number, viability and aggregate number were determined using a Cedex HiRex cell analysis 
system (Innovatis AG, Germany).  
The transfection efficiency was assessed using green fluorescent protein (pEGFP-N1 plasmid) 
by both green fluorescence microscope and FACS (CyAnTM ADP from Dakocytomation, 
Denmark). 
Expressed recombinant fibrinogen by CHOfgn pTet-on cell line was analyzed by a sandwich 
ELISA using antibody against fibrinogen. The ELISA assay of the conditioned media was carried 
out in triplicate as described previously 7, 18. This assay can just detect bioactivity of recombinant 
fibrinogen which has all three polypeptide chains fully-assembled. Briefly, 96-well assay plates 
(Milian) were bound with IgG fraction goat anti-human fibrinogen capture antibody (MP 
Biomedicals, USA) with dilution 1:1000 at room temperature for 1 hour. After washing three 
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times in PBST (0.05% Tween-20 in PBS, pH 7.4), the plates were blocked with 1% bovine 
serum albumin (BSA) (Sigma, Switzerland) in PBS for 30 minutes at room temperature. Then 
the conditioned medium of cultured CHO cells and/or CHOfgn cells was collected after 24 hours 
and incubated in plates at room temperature for 2 hours. The fibrinogen standard was diluted 
serially to obtain several solutions of different concentration for standard curve. The solvent was 
served as zero standard (0ng/ml). The standard samples were also incubated in same plates as 
conditioned media. The plates were detected by goat anti-human fibrinogen peroxidise-
conjugated detection antibody (MP Biomedicals, USA) using TMB peroxide substrate. Colour 
was developed and plates were measured at 450nm. 
Optimal growth and production medium for CHO cells 
Table 4 Medium used for screening experiment 
Medium Supplier URL 
BD CHO medium BD, USA http://www.bd.com/ 
ExCell 325 PF CHO CHO SFM JRH Biosciences, USA JRH Biosciences, Inc. 
ExCell CD-CHO CHO SFM JRH Biosciences, USA JRH Biosciences, Inc. 
CD CHO medium Invitrogen, Switzerland http://www.invitrogen.com/ 
HyQCDM4CHO HyClone, USA http://www.hyclone.com/ 
ProCHO4 Cambrex, Belgium http://www.cambrex.com/ 
ProCHO5 Cambrex, Belgium http://www.cambrex.com/ 
ProMediaSelect K#1 Cambrex, Belgium http://www.cambrex.com/ 
 Cambrex, Belgium http://www.cambrex.com/ 
 Cambrex, Belgium http://www.cambrex.com/ 
ProMediaSelect K#16 Cambrex, Belgium http://www.cambrex.com/ 
Since i) the components of each commercial serum free medium vary, ii) the response to 
medium differs from one recombinant cell line to another, and iii) medium has a big impact on 
cell growth and protein production, screening the medium is a necessary procedure to find the 
optimal growth and production medium for the cell line. 
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Experiments were performed in triplicate in 50 ml bioreactor tubes (Fig. 14) containing 10ml of 
serum free media (SFM). Different commercial SFM for CHO cells were chosen (Table 4). Since 
CHOfgn cells were not able to be adapted to grow in suspension in serum free ProCHO4 medium, 
transient transfection of CHOcells with fibrinogen A cDNA were used as a screening medium. 
 
 
 
 
 
 
 
 
 
Fig 14. TubeSpin consisted of 50-ml ventilated centrifuge tubes for small-scale experiments in 
suspension culture. These 50ml sterile tubes have five openings and one gas-porous filter on 
the cap to regulate gas transfer. They are small bioreactors, used for large-scale parallel tests, 
optimization experiments and small-scale suspension culture. 
Results and discussion 
Growth of CHO cells in serum free culture 
CHOfgn and CHO cells were grown at first in T flasks with 5% FBS and 0.4mg/ml G418 in 
DMEM/F12 media at 37°C under a humidified atmosphere of 5% CO2. G418 (Promega, USA) is 
a neomycin antibiotic analogue, called geneticine. The use of G418 in culture media provides 
selective pressure for cells stably expressing a neomycin resistance gene. CHO cells acquired 
from Dr Lord have been co-transfected with the cDNAs of fibrinogen and a neomycin resistance 
gene. Therefore, the genome of the cell population can be controlled.  
57 
After 3 successive passages, CHOfgn and CHO cells were weaned from 5% to 2% FBS. The 
cells were left to grow in T flasks until the cells reach 80-90% of the flask confluence. Then cells 
were transferred into sterile square bottles or 50ml bioreactor tubes with 2% FBS and 0.4mg/ml 
G418 in ProCHO4 media (Cambrex, Belgium), a media designed for suspension culture. The 
square bottles or 50ml bioreactor tubes were placed in an incubator under an atmosphere of 5% 
CO2 with a relative humidity of 85% and shaken at 120-180rpm. The culture media was changed 
twice per week. During each passage, a new square bottle or a new bioreactor was used and 
the cell number was counted using a hemocytometer. The inoculum cell concentration was 
always adjusted to 3x105cells/ml. If the cell concentration was higher, serum free ProCHO4 
media with G418 would be added to maintain 3x105cells/ml. If cell concentration was lower, the 
cell culture would be centrifuged at 800 rpm for 5 minutes and about 90% supernatant would be 
removed, then the fresh media added to maintain 3x105cells/ml. When the serum in the medium 
was infinitely diluted, it is assumed to be zero, or serum free. Once the cells were adapted to 
grow in suspension in serum free ProCHO4 media, the cell culture was centrifuged at 800 rpm 
for 5 minutes at each passage and the supernatant was all removed and replaced by the fresh 
SFM media for cell expansion. 
CHO cells were able to be adapted to grow in suspension in serum free ProCHO4 media. As 
shown in Fig. 15 and16, CHO cells displayed a regular proliferation curve with high viability 
(more than 85%) in ProCHO4 medium supplemented with ProHT (hypoxanthine, thymidine) and 
4mM L-glutamine for repeated-batch culture in square bottle. When CHO cells were cultivated in 
suspension, the unadapted cells either failed to grow or formed large aggregates with 
intercellular adhension. The viability of cells in the large aggregates was often rather low.  
CHOfgn cells were adapted to grow in serum free DMEM/F12 media supplemented with 15mM 
HEPES and 4mM L-glutamine (Fig. 17), but CHOfgn cells never adapted to growth in suspension. 
Under the microscope, large aggregates were observed. During one assay, it was found that if 
the culture medium was changed each day, CHOfgn cells could grow in suspension. It is known 
that fibrinogen is secreted from CHOfgn cells and fibrin network formation requires Ca++ as a 
catalyser 10. So, there are maybe some traces of Ca++ in the medium which favour cell 
attachment to fibrin matrix. At same time, the calcium ion plays an important role in the cell 
cycle, and influences cell proliferation and growth 11. So, using Ca2+ binding reagent as anti-
coagulant, such as EGTA, EDTA and dextran sulphate, would influence cell viability in the cell 
culture, which resulted in decreasing fibrinogen production by CHO cells. In this case, the 
doxycycline-regulatable Tet-on system was a good solution. CHO cells would not express the 
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fibrinogen protein when doxycycline was absent from the cell medium. So, the CHOfgn-pTet on 
cells would have no problem to grow in the serum free suspension cell culture. When the cell 
concentration was high enough for fibrinogen production, doxycycline would be added in the cell 
medium and the fibrinogen could be harvested in this way. 
For the Tet-on system, the full pTRE2pur-fgnA plasmid was obtained successfully by cloning. 
The PCR amplification product of the full length fibrinogen A was analyzed on a 1% w/v 
agarose gel (Fig. 18) using GeneRulerTM 1kb DNA ladder (Fermentas, Germany) as standards. 
The result showed one visible band at about 2000bp, which corresponded to the size of full 
length fibrinogen ADNA. Then full length fibrinogen ADNA was inserted into response 
plasmid pTRE2pur using restriction enzymes. Several random clones of pTRE2pur-fgnA full 
were selected from an ampicillin LB plate and analyzed by digestion using restriction enzymes, 
BamHI and NotI (Fig. 19). On a 1% w/v agarose gel, two bands around 2kb and 5kb were visible 
for clones #10 and 13, which corresponded to the size of full length fibrinogen ADNA and 
response plasmid pTRE2pur. So, these two clones were sent to Microsynth Company for DNA 
sequence analysis. The analyse results confirmed that the clones #10 and 13 had the correct 
DNA sequences. 
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Fig 15. Viability curve of the repeated-batch culture of 
suspension CHOcells in ProCHO4 medium. 
Suspension CHO cells showed the adaptation to the 
new serum concentration in ProCHO4 medium by 
displaying a regular proliferation curve with high 
viability (more than 85%) for more than 30 days. 
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Fig 16. Growth curve of the repeated-batch culture of 
suspension CHO cells in ProCHO4 medium. 
Suspension CHO cells showed the adaptation to the 
new serum concentration in ProCHO4 medium by 
displaying a regular proliferation curve with cell 
concentration constantly up to more 1 million cells/ml 
from 3x105 cells/ml after growth for 3 days. 
Good growth pattern
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Fig 17. The repeated-batch culture of adherent CHOfgn cells in DMEM/F12 medium. Adherent 
CHOfgn cells showed the adaptation to the new serum concentration by displaying a regular 
growth confluence after several cell passages 
 
 
 
 
Fig 18. PCR fragment of 
fibrinogen A full DNA about 
2kbp showed on a 1% w/v 
agarose gel (lane 2). The 
DNA size marker is a 
commercial GeneRulerTM 1kb 
ladder (lane 1)  
 
Fig 19. pTRE2pur-FgnAa full plasmid 
screening on a 1% w/v agarose gel. 
Restriction digest showing a similar 
fragment cut about 5kbp from plasmid 
vector and a fragment about 2kb from 
fibrinogen A full DNA insert (clones 10 
and 13). Lane 1: commercial 
GeneRulerTM 1kb DNA ladder.  
 
Fig 20. CHOfgn-pTet on cell line 
screening by fibrinogen ELISA. 
Samples in triplicate. The standard 
fibrinogen solutions were in first 
column, 2ng/ml (up) and 1ng/ml 
(down), and also in second column, 
0.5ng/ml (up) and 0ng/ml (down), 
The same cell line was in 2 different 
cell medium, with 2ug/ml 
doxycycline (down, fibrinogen 
expression on) and without 2ug/ml 
doxycycline (up, fibrinogen 
expression off). 2 cell lines were 
analyzed, 10(2) and 11(1). The cell 
line 11(1) seems good. 
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The Tet-on system was transfected into CHO cells in two steps using the lipofectamine 2000 
reagents. After selection of cells in puromycin and neomycin containing media, two clones of 
CHOfgn-pTet on cell lines were selected. The cell medium was collected after 24 hours 
inoculation before and after 2g/ml doxycycline (Sigma, Switzerland) was added. It should have 
no fibrinogen expression before adding doxycycline. According to a fibrinogen ELISA assay (Fig. 
20), the color detection of the clone 11(1) was good. But three months later, the cells were dead 
due to the selection medium. This indicates that the plasmid failed to insert into the cell genome 
and was rejected by the cells. More clones were analyzed in the subsequent experiments.  
There are two reasons that CHOfgn pTet-on cell line was difficult to produce. First, because pTet-
on plasmid contains a neomycin resistance gene and CHO cells are also neomycin resistant, 
the stable CHO pTet-on cell line was not obtained, which is very important for Tet-on system 
application according to manufacturer’s protocol. Instead, transient CHO pTet-on cell line was 
transfected immediately by the pTRE2pur-FgnA full plasmid, which was selected out by 
puromycin. That is the reason why it is difficult to obtain the CHOfgn pTet-on cell line. Secondly, 
during culture in selection medium, the CHOfgn pTet-on cell line may lose one or two plasmids of 
Tet-on system, which is expressed as cell death, fibrinogen expression leaking during 
doxycycline absence, and no fibrinogen expression during doxycycline presence. This is what 
was observed. One good clone was obtained according to color detection using the fibrinogen 
ELISA. But the cells were dead during culture in the selection medium. So, more cell clones 
would be chosen and analyzed in additional experiments.  
Optimal growth and production medium for CHO cells 
CHO cells were transfected with different PEI: DNA mass ratios (from 1 to 14) to determine the 
optimal charge ratio. During all transfection experiements, 2% mass of pEGFP-N1 (green 
fluorescent protein plasmid) was added into the other plasmid DNA. Two days post-transfection, 
transfected cells were analysed by FACS to check the transfection efficiency (Fig. 21) and cell 
viability was checked using a haemocytometer (Fig. 22). Results indicated that the transfection 
efficiency increased with higher charge ratios, but cell viability decreased dramatically. A charge 
ratio 5 (equivalent to mass ratio 2) was chosen for future CHO cell transfection based on the 
combined transfection efficiency and cell viability. 
Transient transfected CHO cells were used to screen 23 commercially available medium for 10 
days. Fluorescence microscopy on day 3 (Fig. 23) demonstrated the successful transfection and 
this was confirmed using FACS (Fig. 24) indicating that 41% of the cells were successfully 
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transfected. ELISA protein analysis indicates us that transfected CHO cells were capable of 
producing fibrinogen in several medium, such as CD CHO, ProCHO5 and ProMedia Select k#10 
(Fig. 25). Finally the cell growth curve (Fig. 26) indicated that cells passed the lag phase of 1 or 
2 days during adaptation to the new medium. Following adaptation they grew more than 4 days 
in the same medium without exchange and maintained viability higher than 70% (Fig. 27). From 
the summary (Table 4), it was shown that several medium, such as Excell 325 PF, 
HyQCDM4CHO, ProMedia Select k#9 and ProMedia Select k#16, are good for cell growth. The 
cell concentration in these medium reached more than 3 million/ml on day 4 in the culture with a 
viability higher than 85%. However, ELISA data illustrated that these media were not good for 
fibrinogen production. 
 
Fig 21. FACS Analysis of PEI transfection to 
CHO cells using EGFP with eight different 
DNA:PEI ratios. The first peak represents the 
population of cells non-transfected. The second 
peak represents the population of cells 
transfected. Note that the population of cells 
transfected increased with DNA:PEI ratio. 
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Fig 22. Cell viability of CHO cells transfected using PEI 
reagent with eight different DNA: PEI ratios. Note that cell 
viability decreased with DNA:PEI ratio. 
DNA : PEI ratio [-] 
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Fig 23. Imaging of CHO cells (3 days post-transfection) transfected using PEI reagent with DNA: PEI 
ratio 1:2. a) bright field (left) and b) Green fluorescence (right) under a fluorescence microscope, with 
scale bar 100 micrometers. It is evident that CHO cells showing green fluorescence were 
successfully transfected.  
 
 
Fig 24. FACS analysis of CHO cells (3 days post-
transfection) transfected using PEI reagent with 
DNA: PEI ratio 1:2. Note that about 41.5% cells 
were successfully transfected 
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Fig 25. Fibrinogen ELISA analysis of CHO cells (2 days 
post-transfection) transfected using PEI reagent with DNA: 
PEI ratio 1:2. Note that fibrinogen expressed by 
transfected CHO cells was higher in three cell medium, 
CD CHO, ProCHO5 and ProMedia Select k#10 
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Fig 26: Growth curve of batch transfected CHO cells 
culture in selected 11 commercial media for 10 days. 
Note that cells were adapted to the new medium very 
quickly, about 2 days, with nice cell growth pattern 
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Fig 27. Cell viability curve of batch transfected CHO 
cells culture in selected 11 commercial media for 10 
days. Note that cells were adapted to the new medium 
very quickly, with high cell viability (>70%) 
For batch culture, cells always proceed through four growth phases: lag phase, exponential 
growth phase, stationary phase and death phase (Fig. 28).  
Lag phase: When first added to a medium, cells often have to adapt to the new medium which is 
different from that in which they have been growing. Adjusting to the new conditions takes time 
and during this period of gene expression and enzyme synthesis, no increase in cell number is 
observed causing a “lag” in the cell growth. 
Exponential growth phase: Cells begin to divide and fairly quickly reach a maximal rate of 
division for the conditions present in the culture.  
Stationary phase: Cell number in the culture reaches a maximum. Due to the depletion of a 
nutrients and/or accumulation of waste products, a small number of cells dying is equal to the 
number of slow growing cells 
Death phase: Growing cell rate drops below death rate. The population slowly decreases over 
time at a rate that is normally much slower than the exponential growth phase 19. 
 
Good growth pattern
Good viability
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Fig 28. Typical batch cell culture growth curve 19. It consists of 4 phases, lag phase, exponential 
phase, stationary phase and death (declining) phase. 
The length of time spent in each phase and the growth rate during exponential phase is 
dependent upon the species and medium conditions. Cell growth rate  was calculated using 
Nt=N0*exp(t) with Nt number of viable cells present at time t and N0 initial number of viable cells. 
As shown in Fig. 29 and Table 4, cell growth rates differed in different medium. Cells grew faster 
in Excell 325 PF CHO, HyQCDM4CHO, ProMedia Select k#5, k#8, k#9, k#10 and k#16 medium. 
And cell growth rate was slightly higher in ProMedia Select k#10 and Excell 325 PF.  
As shown in Table 5 and Fig. 25, CD CHO, ProCHO5 and ProMedia Select k#10 were the best 
production media. But they were not good growth media for the CHO cell line. The best growth 
medium among these three medium was ProCHO5 where the cell concentration reached 3 
million/ml. The worst was the CD CHO medium where cell growth rate was nearly 0 and cell 
concentration was less than 1 million/ml in 4 days.  
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Fig 29. Growth rate curve of batch transfected CHO cells culture in 23 commercial media for 10 
days. Note that cell medium had definitively effects on cell growth rate and that cells grew faster 
in Excell 325 PF CHO, HyQCDM4CHO, ProMedia Select k#5, k#8, k#9, k#10 and k#16 medium 
Low aggregate rate is another criterion for selection cell growth and production medium. 
Comparing cell aggregation rate in those medium at day 4 (Fig. 30) and at day 5 (Fig. 31), it was 
shown that cells were more easily aggregated in ProMedia Select k#6 and ProCHO4 with an 
aggregate rate higher than 50% compared to k#16 and CD CHO medium with an aggregate rate 
of 20%.  
It is shown that fibrinogen A chain can be transfected to CHO cells to produce secreted, 
detectable fibrinogen. Cell concentration can reach 6 million cells per ml 10 days after transient 
transfection and cell viability is still higher than 50%. For the optimal growth and production 
medium for CHOfgn cells, Excell 325 PF CHO, HyQCDM4CHO, ProMedia Select k#9 and k#16 
are shown to be the best growth medium for our CHO cells. ELISA results show us that CD 
CHO, ProCHO5 and ProMedia Select k#10 are the best production medium. The growth rate 
tells us that Excell 325 PF CHO and ProMedia Select k#10 are the best. Finally cell aggregate 
rate shows us that ProCHO4 and ProMedia Select k#6 are not ideal. Based on the available 
data, ProCHO5 was determined to be the optimal production and growth medium for CHO and 
CHOfgn cells (Table 5). Alternatively we may grow our CHO cells in Excell 325 PF CHO medium 
to the desired cell number then transfer to ProCHO5 or ProMedia Select k#10 medium for 
fibrinogen production. This screening result provides us an optimal means for the future 
production of recombinant chimeric fibrinogen. 
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Fig 30. Aggregate rate curve of batch transfected CHO cells culture in selected 14 commercial 
media at day 4. Note that cell medium had definitively effects on cell aggregate rate and that 
cells aggregated easily in ProMedia Select k#6, k#10 and ProCHO4  
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Fig 31. Aggregate rate curve of batch transfected CHO cells culture in selected 14 commercial 
media at day 5. Note that cell medium had definitively effects on cell aggregate rate and that 
cells aggregated easily in HyQCDM4CHO, ProMedia Select k#6 and ProCHO4 
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Table 5 Summary of optimal growth and production medium for CHOfgn and CHO cells 
Medium 
Fgn conc 
[ng/ml] 
Total cell 
number d4 
[106] 
Viability d4 
[%] 
Growth 
rate [day-1] 
Aggregate 
rate d4 [%] 
Excell 325 PF 0.70±0.02 3.29±0.36 86.16±2.07 0.434 27.10±1.48
CD CHO 1.19±0.10 0.88±0.16 19.90±6.47 0.000 22.83±9.41 
HyQCDM4CHO 0.69±0.03 3.32±0.10 90.65±0.88 0.293 32.33±1.46
ProCHO4 0 1.95±0.12 93.46±0.17 0.209 50.07±4.50
ProCHO5 1.33±0.09 2.75±0.23 92.45±3.46 0.288 38.33±5.16
ProMedia k#5 0 3.08±0.05 95.15±0.35 0.314 42.13±0.59
ProMedia k#6 0 2.86±0.09 94.85±0.17 0.300 51.47±2.51
ProMedia k#8 0.70±0.06 3.18±0.01 88.51±2.41 0.307 31.37±4.98
ProMedia k#9 0.11±0.02 3.62±0.32 91.15±0.50 0.331 32.17±2.89
ProMedia k#10 1.36±0.01 1.62±0.10 88.55±0.72 0.370 48.07±3.51
ProMedia k#12 0.33±0.05 2.57±0.09 82.33±1.22 0.127 28.33±2.78
ProMedia k#16 0.19±0.03 3.72±0.39 86.35±0.86 0.365 27.43±4.22
d4: at day 4 
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Conclusion 
Due to the wide application of fibrin matrices in tissue engineering, recombinant fibrinogen 
produced by CHO cells is a new way to obtain this bioactive protein. Furthermore since natural 
fibrin purified from blood could cause problems, such as purification and contamination, 
recombinant fibrinogen could overcome these short comings and is developing well in the 
laboratory. To produce relatively high quantities, CHO cells are grown in suspension using 
serum free culture conditions. In this chapter, CHO cells are shown to adapt to grow in serum 
free medium in suspension which is difficult for CHOfgn cells. Due to trace calcium in the cell 
medium, fibrinogen expressed by CHOfgn cells were polymerized to form cell aggregates. In this 
way, all CHO cells were trapped in the matrix and precipitated to the bottom of the spin bottle. 
For CHOfgn cells in suspension culture, the problem of calcium should be resolved. Since 
calcium plays an important role in cell growth, the Tet-on system was used to resolve the 
expressed fibrinogen polymerisation problem by regulating the fibrinogen expression. The Tet-
on system was composed of one response plasmid, pTRE2pur, and one regulator plasmid. One 
good clone of CHOfgn pTet-on cell line was obtained according to a fibrinogen ELISA assay. 
However the cells were dead during culture in the selection medium due to plasmid rejections by 
CHO cells. So, additional development is required to get CHOfgn cells in suspension culture, 
such as screening more cell clones by ELISA.  
During screening for optimal growth and production medium for CHO cells, ProCHO5 was 
chosen for several reasons, such as cell viability, cell growth rate, cell number and the low cell 
aggregation rate. For CHO cells in serum free suspension culture, optimal medium ProCHO5 
plays one key role for cell viability. In future studies, ProCHO5 was used as standard cell 
medium for CHO cells in suspension culture.  
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Chapter III Development of a 3rd generation fibrin delivery 
system: recombinant fibrinogen IGF1 fusion protein 
Summary 
The development of fibrin-based biomaterials is based on fibrin’s central role in tissue binding 
and in the initiation of tissue repair and defence. The binding of Fgn/fibrin to hemostasis proteins 
and platelets as well as to different cells, growth factors, and extracellular matrix proteins is 
indispensable during the wound repair process. Technologies have been developed with some 
success for the incorporation of growth factors into fibrin, ranging from simple admixing to 
covalent incorporation using the coagulation transglutaminase factor XIIIa. Here we explore a 
novel platform technology where the growth factor is incorporated into Fgn’s A-chain at the 
genetic level. We have chosen this region since evidence suggests that the C-terminus of Fgn’s 
A-chain is not required for bioassembly or polymerization.  
Here we produced truncation and fusion variants of the fibrinogen A chain, denoted FGA5aa, in 
which the C-terminus of the fibrinogen A chain was truncated to 5 amino acid residues of the 
second disulfide cluster; FGA5aa-IGF1, in which the truncation was fused with IGF1, and 
FGA5aa-MMP-IGF1, in which an MMP substrate was inserted between the two fusion domains. 
In this work, the cell lines CHOFGA5aa-IGF1 and CHOFGA5aa-MMP-IGF1 were made and protein variants 
of fibrinogen expressed. Fibrinogen was detectable by fibrinogen antibody using an ELISA 
assay. From the ELISA results, it was discovered that CHOFGA5aa-MMP-IGF1 cell line was more 
immune-reactive than the CHOFGA5aa-IGF1 cell line due to the stoichiometric concentration ratio of 
fibrinogen to IGF1. The ratio expected was 0.5 because fibrinogen structure contains 2 A-
polypeptide chains. According to experimental result, this ratio was 15.8:1 for the CHOFGA5aa-MMP-
IGF1 cell line and 152.8 for the CHOFGA5aa-IGF1 cell line. So, it was guessed that the structure of 
FGA5aa-MMP-IGF1 was more flexible than FGA5aa-IGF1 due to linker matrix metalloproteinase 
MMP substrate site. The fusion fibrinogen protein produced by the cell lines was collected and 
purified by saturated ammonium sulphate and by fibrinogen binding peptide AAGPRP or 
fibrinogen antibody IF-1 affinity chromatography consecutively. The release profile and 
functional significance of this novel fibrin-delivery system will be addressed in the future. 
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Introduction 
The use of fibrin instead of other materials is based on its central role in the initiation of tissue 
repair. The three-dimensional fibrin network can induce cell proliferation and migration 1. As 
invading cells migrate into the fibrin matrix they produce and activate another enzyme, plasmin, 
at the leading edge of the cell. This enzyme degrades the fibrin polymer in a highly regulated 
manner and leaves the polymer intact where cells have not yet invaded, and where structural 
support is still required 2. These activities of this system make fibrin an attractive material for 
medical applications. The interested in fibrin was sparked In 1998 when the FDA approved the 
fibrin polymer to be commercially used for tissue hemostasis, called Tisseel VH kit (Baxter AG). 
To enhance wound healing and regeneration, several bioactive proteins have been successfully 
incorporated into the fibrin matrices as developmental signals, such as adhesion factors and 
growth factors 3-5.  
In our laboratory, we have developed a fibrin platform to delivery bioactive proteins in a 
controlled manner, which resulted in a more effective wound healing process. Up to date, this 
platform has two generations (Fig. 32). The first generation was used to incorporate the heparin-
affinity bioactive proteins, heparin and a heparin-binding peptide into fibrin matrices during 
polymerization. This peptide was composed of a factor XIIIa substrate from the 2-plasmin 
inhibitor at N-terminus and one heparin-binding site based on the antithrombin III (ATIII) at the 
C-terminus. This peptide, which was covalently cross-linked into the fibrin matrix, was used to 
immobilize heparin electrostatically in fibrin. Then the immobilized heparin was used to bind 
electrostatically the heparin-affinity bioactive proteins 3. This system provided for an indirect but 
strong affinity between heparin-affinity bioactive proteins and the fibrin. The second generation 
was to covalently bind a mutant form of a bioactive protein into the fibrin matrices 5. This mutant 
protein contained a factor XIIIa substrate sequence NQEQVSPL from the 2-plasmin inhibitor 
(2PI1-8) at the N-terminus, which would attach to fibrin during coagulation through the action of 
factor XIIIa. In this chapter, the third generation of the fibrin platform was explored, a genetic 
modification of fibrinogen A polypeptide chain itself. 
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Fig 32. Two generations of the fibrin platform in our lab. The first generation (left) incorporated 
peptides, heparin and heparin-affinity growth factor in fibrin matrices. The second generation 
(right) was to create a mutant form of growth factor X, named 2PI1-8-X 5 
It has been found that -chains and B-chains were relatively constant in size among most 
species of 30 mammalian fibrins surveyed, but the carboxyl domains of the A-chains varied 
considerably. These domains (C) contained a series of repeated sequences, which resulted in 
the flexible nature of the region. This region was easily trimmed away by proteolysis and was 
often referred to as ‘‘free-swimming appendages’’6. As described by R. Doolittle, chicken 
fibrinogen A-chain lacked these C repeats and the A C-terminus was neither required for 
fibrinogen bioassembly nor did it participate in the formation of fibrin polymer 7, 8. Engineered 
truncations of the fibrinogen A chain could create about 40 kDa of space available for the 
fusion of other bioactive proteins respecting the fact that the disulfide bridges at the C-terminus 
of the coiled-coils were absolutely essential for fibrinogen stability (Fig. 33).  
 
 
 
 
Fig 33. Diagram of the third generation of fibrin platform. The carboxyl terminal region of the 
fibrinogen A chain (ΔA) can be replaced by bioactive protein chosen 8. 
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One preliminary screening experiment by fibrinogen ELISA was manipulated to determine how 
many amino acids of A C-terminus from the second S-S ring were sufficient for proper 
fibrinogen assembly while its native bioactivity remained. This ELISA assay can just detect 
bioactivity of truncated fibrinogen which has all three polypeptide chains fully-assembled. 
 
 
 
 
 
 
Fig 34. Fibrinogen ELISA assay for detection of truncated fibrinogen expressed by CHO cells. 
Here pMYC vector was a negative control, no fibrinogen expression detectable. It was clear that 
fibrinogen antibody could not detect mutant fibrinogen expressed by CHO cells because of 
just B-and -chains, lack of fibrinogen A chain. Note that fibrinogen expressed by all truncated 
fibrinogen species CHO cells could be detectable by fibrinogen antibody. FGA5 represented 5 
amino acids of A C-terminus from the second disulfide cluster. 
FGA10 represented 10 amino acids of A C-terminus from the second disulfide cluster. 
FGA20 represented 20 amino acids of A C-terminus from the second disulfide cluster. 
FGA30 represented 30 amino acids of A C-terminus from the second disulfide cluster. 
FGAfull represented full length of fibrinogen A chain. 
According to fibrinogen ELISA results (Fig. 34), fibrinogen expression of all truncated fibrinogen 
species (A189, 194, and 199) could be detectable by the fibrinogen antibody. This confirmed 
that the C-terminus of fibrinogen A-chain could be cut as short as only 5 amino-acids from the 
second disulfide cluster (FGA5aa). It provided at least 40kDa of free space in FGA5aa for 
therapeutic DNA insertion. This discovery showed us a means for the direct incorporation, at the 
genetic level, of protein therapeutics such as growth factors into fibrin matrices without additional 
enzymes. This technology should extend the residence time of growth factors in the matrix for 
enhanced tissue regeneration. Among growth factors, IGF1 was suggested as one example of a 
bioactive protein that could be incorporated into fibrinogen A chain due to its single chain and 
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small mass weight of 10kD. So, a new protein engineering system was proposed in this chapter: 
genetic fusion of IGF1 to the fibrinogen Aα polypeptide chain C-terminus. The advantage of this 
new generation was a high level of control of the release profile of the desired bioactive protein 
and that the incorporation of the bioactive protein into the fibrin matrices was independent of 
coagulation.  
Materials and methods 
Materials 
The mammalian expression vector pMYKpuro was provided by Dr. Lucia Baldi, EPFL. Plasmid 
p584 Acontaining cDNA for the Achain of human fibrinogen, was provided by Prof. Dr. 
Susan Lord, the University of North Carolina at Chapel Hill. Plasmid pCR2.1-hIGF1, containing 
cDNA of hIGF1, was provided by Prof. Aebischer, EPFL. CHO cells, expressing both Band  
chains of human fibrinogen, were provided by Prof. Dr. Susan Lord, the University of North 
Carolina at Chapel Hill. All enzymes used were purchased from New England Biolabs. Unless 
otherwise specified, all cell culture reagents were supplied by Invitrogen, UK.  
Construction of expression vector 
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Fig 35. Truncated FGA5aa DNA generation. Fibrinogen A full length cDNA is showed above. 
One fragment of DNA is taken from the start codon ATG to 5 amino acids after the second S-S 
ring. Then EcoRI restriction enzyme is added before ATP start codon and NotI restriction 
enzyme is added after the 5th amino acid DNA sequence by PCR using two primers coding 
EcoRI and NotI restriction enzyme sequence separately.  
The cDNA encoding fibrinogen A chain 1-567 nucleotides was cloned into an expression vector 
pMYKpuro using a 5’ primer containing the EcoRI restriction site and a 3’ primer containing the 
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NotI restriction site (Fig. 35). Then a restriction enzyme XbaI sequence TCTAGA was added 
closely after the 3’-terminus of fibrinogen A chain by PCR as a unique fusion cloning site. This 
vector was called pMYKpuro FGA5aafus.  
Human IGF1 cDNA was obtained from the plasmid pCR2.1-hIGF1 by PCR with both termini 
containing the XbaI restriction sites. The Forward primer was 5’- 
GCTCTAGAGGAAAAATCAGCAGTCTTCC -3’. The reverse primer was 5’- GCTCTAGACTACA 
TCCTGTAGTT CTTGT-3’. The restriction enzyme XbaI sequence was solid underlined in both 
primers. The IGF1 PCR product was inserted downstream and immediately adjacent to and in 
frame with truncated fibrinogen A chain at the XbaI site of the vector pMYKpuro FGA5aafus. 
The resulted vector was called pMYKpuro FGA5aaIGF1. 
Construction of the vector for the mutant human IGF1 was obtained by adding one MMPs 
sensitive sequence, which corresponded to the 8 amino acids GPQG↑IWGQ 9 with cleavage site 
indicated ↑ and double underlined in the forward primer. This primer was 5’-
GCTCTAGAGGACCTCAGGGTATTTGGGGACAAGGAAAAATCAGCAGTCTTCC-3’. The 
added MMP sensitive sequence was to allow for the cleavage of human IGF1 from fibrinogen 
Achain by several MMP enzymes. The resulted vector was called pMYKpuro 
FGA5aaMMPIGF1. 
DNA transfection and cell cuture 
CHO cells were growing in Dulbecco’s modified Eagle media (DMEM)/F12 media 
supplemented with 10% Fetal Bovine Serum (FBS), 100U/ml penicillin, 100g/ml streptomycin 
and 0.4mg/ml G418 (Promega, USA) at 37°C in 5% CO2. These cells were used as the host for 
all transfections.  
The Plasmids DNA sequences were analyzed by Microsynth. The plasmid DNA was amplified in 
the E.coli strain E10 and extracted using a plasmid Maxi Kit (QIAGEN GmbH, Germany). The 
purified plasmid was resuspended in sterile water and checked by gel electrophoresis and by 
OD readings at 260 and 280 nm. Only the preparation of the highest purity (R260/280>1.8) was 
used for transfection.  
CHO cells for stable transfection were seeded in one 6-well plate at a density of 2x105 cells/ml 
per well in 2ml medium without antibiotic G418. The transfection was carried out the following 
day in serum-free medium with lipofectamine 2000 reagent according to manufacturer’s protocol. 
For each well, 4 g of plasmid DNA in 125 l of OPTI-MEM®I Reduced Serum Medium without 
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serum was transfected using 10 l of Lipofectamine 2000 Reagent. Thus the ratio of 
lipofectamine to plasmid is 5:2 (Fig. 36). Cells were incubated with precipitated DNA for 24 
hours. The medium was removed. After washing in PBS, the cells were trypsinized. After cell 
counting using the Trypan blue exclusion method, the cells were distributed to 96-well plates, 
1cell per well. Three days later, the cells were selected in puromycin and neomycin containing 
medium, 20g/ml puromycin (Brunschwig, Basel, Switzerland) and 0.4mg/ml G418. The cell 
medium was changed twice per week.  
 
Fig 36. DNA transfection process by Lipofectamine 
2000 reagent. It is one fast and efficient transfection 
method. In brief, diluted DNA and Lipofectamine 2000 
reagent were mixed and incubated at room temperature 
for 20 minutes. And then the complexe was added to 
cells in growth medium for 24h up to 48h. 
 
Fig 37. Large-scale cell growth in 10-layer cell 
factory Nunclon™Δ. The surface equals to 36xT-
175 flasks. Thus it is one space saving cell culture 
device, easy change of medium, single-use and 
sterile. It is excellent for large-scale recombinant 
protein production from mammalian cells. 
Individual colonies were picked from 96-well plates and tested for fibrinogen antibody detection. 
Positive cell lines were kept. The cell lines which expressed the highest quantity of truncated 
fibrinogen were grown to confluence and stored in a liquid nitrogen container. Large-scale cell 
growth was performed in a 10-layer cell factory Nunclon™Δ (Milian, USA) in serum free 
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DMEM/F12 supplemented with 1% PS, 10U/ml Aprotinin (Roche, Basel, Switzerland) and 
1mg/100ml ITS for truncated fibrinogen production (Fig. 37).  
Immunostaining detection and FACS 
For immunostaining, 0.1 million cells were seeded overnight in one 12-well plate. 
Immunostaining was carried out using a goat anti-human fibrinogen (MP Biomedicals, USA) as 
the primary antibody and Alexa Fluor 488 donkey anti-goat IgG (H+L) as the secondary 
antibody. BD Cytofix/Cytoperm fixation/permeabilization kit (BD, Basel, Switzerland) was used 
for the staining process. Each sample was added to four wells on the plate. To the first well, 
0.5l of primary antibody was added while 1.5l primary antibody was added into the second 
well. In the third well, no primary antibody was added. In the forth well, no secondary antibody 
was added. The last two wells were there to act as negative controls. Finally PFA 1% solution 
was added for fixation. FACS was used to characterize the cell population of each group using 
CyAnTM ADP flow cytometer (Dakocytomation, Glostrup, Denmark). Data was acquired using 
Summit® software and analysed with FlowJo® software. 
ELISA (enzyme-linked immunosorbent assay) 
Expressed truncated fibrinogen from CHOFGA5aa-IGF1 and CHOFGA5aa-MMP-IGF1 cell lines were 
analyzed by a sandwich ELISA for assembly capacity. An ELISA assay of the conditioned media 
was carried out in triplicate as described previously 10, 11. Briefly, 96-well assay plates (Milian, 
USA) were bound with IgG fraction goat anti-human fibrinogen capture antibody (MP 
Biomedicals, USA) with a dilution of 1:1000 at room temperature for 1 hour. After washing three 
times in PBST (0.05% Tween-20 in PBS, pH 7.4), the plates were blocked with 1% BSA (Sigma, 
Switzerland) in PBS for 30 minutes at room temperature. The conditional medium which was 
collected after 24 hours was incubated in plates at room temperature for 2 hours. The plates 
were detected using the goat anti-human fibrinogen peroxidise-conjugated detection antibody 
(MP Biomedicals, USA) and TMB peroxidise substrate. Color was developed and plates were 
read at 450nm. 
For human IGF1 ELISA, the Quantikine Human IGF-1 immunoassay kit (R&D, USA) was used 
according to the manufacturer’s protocol. 
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Fibrinogen-IGF1 protein production and purification  
Recombinant chimeric fibrinogen-IGF1 fusion protein expressed by CHO cells was secreted in 
the cell medium. During large-scale protein production, one liter of ITS cell medium was 
collected every seven days from the 10-layer cell factory. The same batch of CHO cells could 
produce the fusion protein for one month. EDTA-free protease inhibitor (Roche) was added to 
avoid fusion protein degradation. Recombinant fibrinogen was precipitated slowly at 4°C from 
the medium with saturated ammonium sulphate which reached a final concentration of 40%. 
After centrifugation at high speed (12000xg for 50 minutes at 4°C), the supernatant was 
discarded carefully to avoid disturbing the pellets. The pellets were then redissolved in 50ml 
HBSS containing Ca2+ and Mg2+ and applied to a thiopropyl Sepharose 4B column 5ml coupled 
with peptide AAGPRP 12, specific for fibrinogen.  
 
Fig 38. The peptide AAGPRPC structure. A cysteine was added at the carboxy (C) terminus of 
peptide GPRP (that is, GPRPC) for conjugation to the functional groups presented in the 
thiopropyl Sepharose 4B polymers via the free thiol through Michael-type addition 13. Two 
alanines acted as protection group and added at the N-terminus of the peptide GPRP. 
The AAGPRP peptide (Fig. 38) was synthesized in the lab using standard FMOC chemistry. A 
cysteine was added at the C-terminal end of the peptide for conjugation to the functional groups 
that are present in the thiopropyl Sepharose 4B polymers. In brief, 334mg of thiopropyl 
Sepharose 4B (GE Healthcare Bio-Sciences) was prepared according to the manufacturer’s 
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instructions to give a 1ml gel. 30mg of peptide, AAGPRP, was immobilized in the gel. After 
washing, the column was stored at 4°C cold room and ready for mutant fibrinogen purification. 
For purification, the binding buffer was 0.1M HEPES with 20mM CaCl2, pH7.4. The washing 
buffer was HBSS containing Ca2+ and Mg2+. The elution buffer was 1M NaBr and 50mM NaAc, 
pH5.3. During elution, pH value of the buffer was 5.3, which was too acidic for fibrinogen. So, 
several drop of 1M HEPES was added in each elution tube to adjust the pH to 7.4, which 
required 10l of 1M HEPES for each 1ml of elution buffer. 
The recombinant fibrinogen concentration was determined at A280 using the extinction coefficient 
280=1.506 for a 1mg/ml fibrinogen solution. The purity of the proteins was analyzed by 9% 
reducing SDS-polyacrylamide gel electrophoresis.  
Results and discussion 
Gene cloning and vector construction 
All PCR amplication requires the use of cDNA templates, two primers, Ampli Taq Gold DNA 
polymerase (Applied Biosystems), deoxynucleoside triphosphates (dNTP) and Mg2+. The 
amplified PCR products with predicted size of about 500bp were observed in lane 2 (Fig. 39) by 
1% agarose gel. If there were no cDNA templates or no primers in the PCR amplication solution, 
then no PCR product band was visible (lane 3 and 4).  
  
Fig 39. PCR amplication fragment of human IGF1 insert about 500bp showed on a 1% w/v 
agarose gel. A) plasmid pMYKpuroFGA5aaIGF1 (left); B) plasmid pMYKpuroFGA5aaMMPIGF1 (right); 
lane 1: Commercial 1kb DNA ladder; lane 2: PCR with both cDNA and primers; lane 3: PCR with 
cDNA and without primers; lane 4: PCR with primers and without cDNA. Lanes 3 and 4 were the 
negative controls. It was showed that only one band at lane 2 was visible.  
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After cloning, the plasmids of pMYKpuroFGA5aaIGF1 and pMYKpuroFGA5aaMMPIGF1 were transformed 
into subcloning Efficiency® DH5TM Competent cells (chemical competent cells) for clone selection. 
Using designed primers (Table 6) and PCR amplication, partial insert fragments were analyzed on 
1% Agarose gel using GeneRulerTM 1kb DNA ladder (Fermentas). Selected clones were due to 
one visible band at about 250bp, such as clones 3 and 6 of pMYKpuroFGA5aaIGF1 and clones 2 and 3 
of pMYKpuroFGA5aaMMPIGF1 (Fig. 40). According to DNA sequence results from Microsynth, clones 3 
and 6 of pMYKpuroFGA5aaIGF1 and clone 2 of pMYKpuroFGA5aaMMPIGF1 had the right DNA sequences 
expected, which would be used for mammalian cells transfection. 
  
Fig 40. Clones screening by PCR amplication using designed primers on a 1% w/v agarose gel. 
A) plasmid pMYKpuroFGA5aaIGF1 (left); B) plasmid pMYKpuroFGA5aaMMPIGF1 (right). The DNA size 
marker is a commercial GeneRulerTM 1kb ladder (lane 1). A band about 250bp was visible at 
clones 3 and 6 of plasmid pMYKpuroFGA5aaIGF1 and at clones 2 and 3 of plasmid 
pMYKpuroFGA5aaMMPIGF1.  
Table 6 Primers used for plasmids clones selection. 
Plasmid construction/primer name Oligonucleotide sequences (5’ → 3’) 
pMYKpuroFGA5aaIGF1: 
fgnhIGFliftprimer GAAACGACTGGAGGTGGACATTG 
fgnIGFrevprimer GGTAGAAGAGATGCGAGGAGGAC 
pMYKpuroFGA5aaMMPIGF1: 
fgnhIGFliftprimer GAAACGACTGGAGGTGGACATTG 
MMPIGFrevprimer GGTAGAAGAGATGCGAGGAGGAC 
500 
10,000 
1,500 
250 
bp 
A B 
1 1 
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Cell lines analysis 
Transfected CHO cells were cultured in the selection medium containing puromycin and G418 to 
eliminate cells non-transfected for two months. Fibrinogen ELISA was effectuated once per 
week to check fibrinogen expression by different truncated fibrinogen CHO cell lines. After 
selection based on several consecutive fibrinogen ELISA results, the cells that expressed most 
truncated chimeric fibrinogen were transferred and grown in 10cm plates. Using these cells, 
highest quantity of fibrinogen could be obtained at the same volume of medium. Because 
transfected CHO cell lines intend to reject the transfected plasmid, it is important to keep several 
cell clones of same cell line.  
Because during manipulation it was difficult to distribute exactly one cell per well in 96-well 
plates, it was important to analyze the cell population of each cell line to be sure that these cell 
lines originated from the same cell. The goal was to guarantee the optimal fibrinogen production 
by these cells. The monoclonal cell line was characterized by FACS. Because the truncated 
fibrinogen was expressed and secreted by the cells, the immunostaining process was more 
straightforward compared to the analysis of the whole cell lysate method. 
According to FACS results (Fig. 41), three cell lines CHOFGA5aa, CHOFGA5aaIGF1 and 
CHOFGA5aaMMPIGF1 were all monoclonal due to only one cell population peak, in the blue colour. It 
meant that the cells had the same profile of fibrinogen expression. So, these cell lines were 
stored in liquid nitrogen for further truncated fibrinogen production. 
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Fig 41. FACS characterisation of monoclonal cell line. A) CHOFGA5aa cell line; B) mixing 2 cell lines together; 
C) CHOFGA5aaIGF1 cell line; D) CHOFGA5aaMMPIGF1 cell line. The first peak (green) represents the population of 
cells non-stained, neither first nor second antibodies added. The second peak (red) represents the 
population of cells stained with second antibody only. The third peak (blue) represents the population of 
cells stained with both first and second antibodies. The cell population in the first and second peaks is used 
as negative control. Note that there are 2 peaks for 2 cell populations for cell line B. Three cell lines, A, C, 
and D, representing CHOFGA5aa, CHOFGA5aaIGF1 and CHOFGA5aaMMPIGF1 were all monoclonal due to one cell 
population peak (blue). Ab: antibody 
Characterization of recombinant fusion protein secretion  
In 10cm plates, 1 million CHOFGA5aaIGF1 and CHOFGA5aaMMPIGF1 cells were seeded separately and 
inoculated for 36 hours in ITS medium for fusion protein production. Then ELISA was performed 
to quantify the production of the fusion proteins fibrinogen-IGF1 by CHO cells. Each sample was 
made in triplicate. 
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According to the ELISA results (Table 7 and Fig. 42), the quantity of truncated fibrinogen 
expressed by the two cell lines was about the same, around 0.025g/ml. But the quantity of 
truncated IGF1 detected by antibody was very different, 0.157 ng/ml for CHOFGA5aaIGF1 cells and 
1.65 ng/ml for CHOFGA5aaMMPIGF1 cells. For the stoechiometric concentration ratio of fibrinogen to 
IGF1, we observed 15.8 for CHOFGA5aaIGF1 cell line and 152.8 for CHOFGA5aaMMPIGF1 cell line. So, 
CHOFGA5aaMMPIGF1 cells expressed the more immune-reactive IGF1 than CHOFGA5aaIGF1 cells. It 
seemed that the protein structure of Fgn-MMP-IGF1 was more flexible than that of Fgn-IGF1 
due to the MMP linker between fibrinogen and IGF1. We believe that adding the MMP linker in 
the fusion protein increased the enzymes invasion and improved antibody detection. 
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Fig 42. The concentration of protein expressed by CHOFGA5aaIGF1 and CHOFGA5aaMMPIGF1 cell lines was detected 
by antibody using a fibrinogen ELISA (left) and a hIGF1 ELISA (right). It showed that according to ELISA 
results, for both cell lines fibrinogen expression was similar and that hIGF1 expression was significantly 
different. The quantity of hIGF1 expressed by CHOFGA5aaMMPIGF1 cell line was much higher than that by 
CHOFGA5aaIGF1 cell line, 1.649ng/ml and 0.157ng/ml respectively.  
 
Table 7. Protein concentration detected by antibody  
Fibrinogen IGF1 
Cell line 
Concentration [g/ml] SD Concentration [ng/ml] SD 
CHOFGA5aaIGF1 0.0242 0.0033 0.157 0.0065 
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Truncated chimeric fibrinogen purification 
The purification of recombinant fibrinogen from conditioned serum-free media (SFM) was 
achieved by two steps in a 4°C cold room. The first step was to precipitate the recombinant 
fibrinogen from SFM via saturated ammonium sulphate. The second step was using fast protein 
liquid chromatography (FPLC) (GE Healthcare, USA). An AAGPRP affinity column was made 
using a Sepharose 4B column coupled with the peptide AAGPRP synthesized in the lab. The 
idea of using the peptide AAGPRP was from the fibrinogen coagulation cascade. When 
thrombin cleaved amino termini of fibrinogen A- and B-chains, the exposed N-terminal of A- 
chain was Gly-Pro-Arg-Val (GPRV) and that of B-chain was Gly-His-Arg-Pro (GHRP). This step 
activated fibrinogen coagulation cascade to fibrin polymerization. So, the modified Gly-Pro-Arg-
Pro (GPRP) was used to binding fibrinogen 12, 14-16. But due to GPRP similar to GPRV, which 
played an important role in the fibrinogen coagulation process, fibrinogen polymerized in the 
AAGPRP affinity column during purification. In Fig. 43, one visible elution peak was observed. 
But when the eluted samples were analyzed by SDS-PAGE on 10% gels and stained with 
SimplyBlue™ SafeStain, there was no band visible on the gel. 
To avoid fibrinogen polymerization during purification, monoclonal fibrinogen antibody IF-1 
affinity chromatography was proposed 17-19. IF-1 was purchased from Kamiya Biomedical 
Company (Thousand Oaks, California). The purification was in development in Prof. Thomas 
Barker’s lab at Georgia Tech. Recombinant fibrinogen was precipitated with saturated 
ammonium sulphate. The pellets were then redissolved in buffer containing 10mM CaCl2 and 
applied to a Sepharose 4B column coupled with monoclonal antibody IF-1, specific for 
fibrinogen. Fibrinogen was eluted with a buffer containing 5 mM EDTA; dialyzed against 20mM 
HEPES (pH 7.4), 150mM NaCl, and 1mM CaCl2 for one change and then extensively against 
20mM HEPES (pH 7.4) and 150mM NaCl; and stored at -70°C.The fibrinogen concentration 
would be determined at A280 using the extinction coefficient 280=1.506 for a 1mg/ml fibrinogen 
solution. Purity of the proteins would be analyzed by 9% reducing SDS-polyacrylamide gel 
electrophoresis. 
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Fig 43. Purification of recombinant fibrinogen by AAGPRP affinity chromatography. The first 
peak represents flow through. The second peak represents eluate. The eluted fractions were 
collected separately and shown on stained 10% reducing polyacrylamide SDS-PAGE (lanes 2, 3 
and 4). Lane 1: starting material. Molecular weight marker is a commercial prestained protein 
ladder. It showed no band on the gel, which means no purified recombinant fibrinogen obtained. 
Conclusion 
Fibrinogen (Fgn), a soluble plasma protein found in all vertebrates, is a covalent dimer 
composed of pairs of three polypeptide chains called A-, B- and -chains. Fibrinogen A chain 
can be truncated to amino acid 189 while maintaining the capacity to be assembled into a 
secreted, detectable fibrinogen. It is feasible to produce recombinant chimeric fibrinogen, which 
directly incorporates, at the genetic level, growth factors of interest into fibrin matrices. We 
believe this new generation of the fibrin delivery system represents a significant advance over 
current delivery systems. This novel approach could allow for near-complete incorporation of 
protein species into fibrin polymers resulting in high levels of control over the delivered protein 
factor. 
Human IGF1 was chosen for its simple active form (single chain) and low molecular weight 
(10kDa). The modified plasmids DNA containing FGA5aa-hIGF1 and FGA5aa-MMP-hIGF1 were 
transfected into CHO cells separately using Lipofectamine 2000 reagent, followed by 
puromycin selection. Fibrinogen ELISA was used to select the optimal truncated fusion protein 
expression clone of cell lines. The optimal stable cell lines CHOFGA5aaIGF1 and CHOFGA5aaMMPIGF1 
were characterized by ELISA with fibrinogen and human IGF1 antibody and by FACS. During 
1 2 3 4
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the characterization of the cell lines, it was found that the fusion protein structure of fgn-MMP-
IGF1 was more immune-reactive than that of fgn-IGF1 because the stoichiometric concentration 
ratio of fibrinogen to hIGF1 for the CHOFGA5aaMMPIGF1 cell line was closer to the expected value. 
The optimal cell lines were monoclonal as observed by FACS, growing from the same single 
cell. These cell lines were chosen for the production of recombinant chimeric fibrinogen hIGF1 
fusion protein. 
Recombinant fibrinogen was secreted in the production medium by CHO cells due to the 
secretion genes in the expression vector. Fibrinogen was precipitated preliminarily from the cell 
medium, and collected with 40% saturated ammonium sulphate. We then tried to purify the 
recombinant truncated fibrinogen by AAGPRP affinity chromatography according to the 
literature. Due to fibrinogen polymerization in the column during purification, we switched to an 
IF-1 affinity column. The monoclonal antibody IF-1, specific for fibrinogen, was coupled in a 
Sepharose 4B column. Purified recombinant fibrinogen was analyzed by SDS-PAGE under 
reducing conditions at 10% gel. When the gels were stained with Coomassie blue, there should 
be three bands representing mutant A-(41kDa), B-(55kDa) and -(47.5kDa) chains. Finally, 
the purified recombinant fibrinogen should be analyzed by western blot and the amino acid 
sequence would be confirmed by mass spectrometry.  
The purification process for the recombinant fibrinogen variants is still under development. When 
the recombinant fibrinogen is purified, the bioactivity analysis will be performed, such as the 
clotting assay (fibrinogen polymerization) and cell proliferation assay (for the hIGF1 component). 
This still requires additional development. 
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Chapter IV Local delivery and controlled release insulin-
like growth factor-1 for bladder muscle regeneration 
Summary 
Human insulin-like growth factor-1 (IGF1) has been under investigation by biotech companies for 
decades because of its potential therapeutic functions. But the wide application of IGF1 in 
clinical trials has been discouraged by its deleterious side effects due to the required high 
frequency of dosing and concentration used for treatment. The controlled release of IGF1 to 
mimic physiological patterns is considered a promising approach. In this study, local delivery and 
controlled release of IGF1 in fibrin-based biomaterials are investigated. A novel fusion protein 
(TG-IGF1) was designed with one transglutaminase enzyme factor XIIIa substrate for covalent 
crosslinking into fibrin gels at the N-terminus and the bioactive part of native IGF1 at the C-
terminus. Determined by one commercial IGF1 ELISA kit, the quantity of purified TG-IGF1 
obtained per liter bacteria culture was about 5ug. The sequence of the purified fusion protein 
was confirmed by MALDI-TOF mass spectrometry. The bioactivity of the fusion protein was 
analyzed in vitro compared with recombinant native IGF1. The cell proliferation profile was 
similar for both wild-type and engineered IGF1 proteins using the metabolic MTT assay. An 
assay for IGF receptor tyrosine phosphorylation showed that both wild-type and engineered 
IGF1 proteins were bioactive and activated the IGF receptor. In a three-dimensional model, 
neonatal human bladder smooth muscle cells (SMCs) were seeded in the fibrin gel incorporated 
with TG-IGF1 and recombinant native IGF1 respectively. The morphology of the seeded cells 
was analysed ultra-structurally using transmission electron microscopy (TEM) 3 days after 
inoculation. According to the morphology of cells seeded in the fibrin gel only, the cells with TG-
IGF1 displayed larger and more secretory vesicles than those with recombinant native IGF1 due 
to the rapid diffusion of the recombinant native IGF1 from the fibrin gel. Confocal imaging 
revealed that both wild-type and engineered IGF1 proteins did not stimulate neonatal SMCs to 
form elastin in the fibrin gel after 5 days. The response of the bladder SMCs in the fibrin gel to 
the IGF1 fusion and native protein was analyzed by qRT-PCR for extracellular matrix and 
adhesion molecules 24 hours after inoculation. The bladder SMCs in the fibrin gel without any 
IGF1 was used as control. No statistical difference for gene expression between those cells was 
noticed. These data demonstrate that TG-IGF1 is fully bioactive, and additionally by design has 
the beneficial ability to be entrapped within and released from fibrin gels.  
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The experiment in vivo assessed in smooth muscle repair in rat bladder model, in which a 
resection of the muscle was made. Fibrin gels incorporating TG-IGF1 or (free) recombinant 
native IGF1 were applied directly on the top of the tissue defected. The fibrin gel without any 
IGF1 was utilized as negative control. After 28 days, the rats were sacrificed, and the bladders 
were formaldehyde-fixed and permeabilized. After bladders were paraffin-bedded and sectioned, 
three histological stainings were made, Hematoxylin & Erythrosine (HE), Masson’s Trichrome 
(TM) and Prussian Blue (PB). All histological images taken were approved by pathologist Dr. 
Taminelli. The histological staining revealed that the rats treated by fibrin gels containing TG-
IGF1 displayed bladder muscle layer regeneration without fibrosis formation which was a 
superior result compared to the control groups. Due to complete fibrin gel degradation, no 
bioactive IGF1 was remained after tissue repair. Thus, its systemic side effects were limited. The 
area of muscle regenerated was quantified blindly with Dr. Hasegawa using program Fiji 
according to images taken previously. The value was normalised by the area of muscle intact in 
the same bladder section. It showed that detrusor muscle layer was regenerated about 27% 
(second experiment) up to 31% (first experiment) for TG-IGF1 compared to 23% (second 
experiment) for recombinant native IGF1. The percentage of detrusor muscle regenerated for 
two control groups was around 10%. 
Introduction 
In 1957, IGF1 was discovered by Samon and Daughaday 1, 2 as a sulphation factor. In 1972, 
IGF1 received its second name as somatomedin 3 because of the relationship between IGF1 
and growth factor (GH). In 1976, IGF1 received its current name due to its bioactive presence in 
serum and its similar structure to insulin 4. From then on, more and more functions of IGF1 have 
become known. IGF1 is secreted by many tissues and affects nearly every cell in the human 
body. IGF1 plays an important role in growth 5. IGF1 deficiency during childhood results in 
growth retardation and impaired skeletal development 6, 7. IGF1 has an amino acid sequence 
similar to insulin and can bind to the insulin receptor. So, it has insulin-like activity, such as 
increasing glucose uptake by peripheral tissues 8, 9. Use of IGF1 treatment in clinical trials has 
been shown to improve glucose metabolism, reduce the need of insulin for insulin-dependant 
diabetic patients, increase insulin sensitivity and limit related obesity 10, 11. In addition, IGF1 can 
regulate cell growth and proliferation. Cells need IGF1 to complete the cell cycle through G1 to S 
phase 12-14. IGF1 can also increase the probability of cancer cell survival through the IGF1 
receptor 15-17. Use of the IGF1 receptor inhibitors is being investigated in cancer patients 18. 
Furthermore, IGF1 can protect neurons of the peripheral nervous system (PNS) from apoptosis 
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19, 20. IGF1 could also be used in life-threatening situations, such as with burns and postsurgical 
trauma 20. Finally, IGF1 can accelerate skeletal muscle regeneration and maintain skeletal 
muscle structure and function 21-23. These are the reasons that IGF1 is one of most studied 
growth factors in the body. Its wide applications in the clinic have been investigated since 1987 
24, but due to severe side effects observed during treatment, the quantity of IGF1 used and the 
exposure duration of IGF1 to injured tissues have to be resolved.  
Currently, biomaterials are commonly used for the controlled release of IGF1, such as silk fibroin 
embedding PLGA 25 and hyaluronan (HA) 26. In this work fibrin matrices, which is FDA approved 
as a biomaterial for tissue hemostasis (Tisseel VH kit, Baxter AG), were used as scaffold. An 
advantage of fibrin as a system as we propose it for implementation used is that IGF1 can 
incorporate covalently into the fibrin matrices instead of simple entrapment, because of the 
addition of a small peptide group called TG. TG is the first eight amino acids of the 2-plasmin 
inhibitor (2PI1-8), sequence NQEQVSPL 27, 28. It is also the substrate for the Factor XIIIa, which 
is the transglutaminase enzyme for fibrinogen coagulation 29. Thrombin, calcium and Factor XIIIa 
catalyze fibrinogen polymerization to form a three dimensional matrix. Factor XIIIa can cross-link 
proteins bearing the TG sequence to fibrin during matrix polymerization. This system provides a 
direct and strong binding between IGF1 and the fibrin matrix and therefore eliminates the 
possibility of IGF1 diffusing out of the formed gel. When cells invade the fibrin matrix, plasmin 
and matrix metalloproteinases (MMPs) are produced and activated by the leading edge of the 
cells. These enzymes degrade the fibrin matrix around the invaded cells, and liberating the 
bound IGF1. The rest of the matrix including the IGF1 bound inside is left intact due to no cells 
having invaded yet, until the cells invade the entire matrix and replace it as new tissue growth 29, 
30. In this way, the fibrin matrix can “release” IGF1 during a short-term period until the injured 
tissue regenerates or is repaired. For this system, a mutant IGF1 protein containing one Factor 
XIIIa substrate 2-PI1-8 at N-terminus should be made.  
The injured tissue chosen for this work was the bladder wall. The bladder is a very elastic organ. 
Urine is filled and expelled several times per day, in volumes up to 500ml each time. The 
elasticity of the bladder wall comes from the detrusor muscle layer 31. The peripheral neurons 
are also important to its physiological function 32. Surgical or traumatic injury and disease, which 
induce bladder wall dysfunction, require muscle layer regeneration with the participation of 
smooth muscle cells (SMCs) 33, 34. IGF1 can stimulate SMC growth and proliferation through the 
integrin v3 35-37, prevent neuronal apoptosis and improve the injured neuron repair 23. IGF1 is 
also known to improve heart function, regenerate injured heart muscle (Fig. 44) 38 and 
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accelerate injured skeletal muscle and neuron repair 21, 23. However chronic IGF1 administration 
can induce pathologic cardiac hypertrophy and fibrosis 39, 40. The purpose of this study was to 
examine injured bladder muscle regeneration using IGF1 cross-linked fibrin gels delivered locally 
at the site of injury.  
 
Fig 44. Schematic drawing showing IGF1 mediated signal transduction pathways to regulate cell 
survival in myocardial tissue 11. When IGF1 engages and activates IGF1 receptor on the cell 
surface, several signalling pathways are activated and mediate cardiomyocytes DNA synthesis, 
growth, remodelling, and anti-apoptosis. Thereby protein synthesis is stimulated and myocardial 
apoptosis is decreased, which result in increasing cardiac muscle mass (Hypertrophy), 
protection against losing myocardium, and maintaining myocardial function. 
Materials and methods 
Construction of 2PI1-8-IGF1  
Human IGF1 cDNA was obtained by PCR from the plasmid pCR2. 1-hIGF1, was kindly provided 
by Prof. Aebischer, EPFL. To obtain the 2PI1-8-IGF1 cDNA, a factor XIIIa substrate sequence 
NQEQVSPL must be added at the N-terminus of the mature human IGF1 protein. For the 
truncated mutant IGF1 protein purification, the pGEX6P1 expression vector was chosen. The 
expression vector pGEX6P1 was purchased from GE Healthcare (USA), and prescission 
protease at 4°C was used to cleave the glutathione S-transferase (GST) tag. Due to inefficient 
95 
cleavage, the thrombin cleavage sequence LVPRGS was added at N-terminus of 2PI1-8-IGF1. 
To avoid purification problems, a polyhistidine-tag (His tag) sequence HHHHHH was added at 
the C-terminus of 2PI1-8-IGF1. All added sequences were in frame with IGF1 cDNA (Fig. 45). 
 
Fig 45. A schematic view of gene construction. A factor XIIIa DNA substrate sequence was 
added at 5’ of mature human IGF1 cDNA (that is 2PI1-8-IGF1) for binding to fibrin matrices. Six 
histidines DNA sequence was added at 3’ of mature human IGF1 cDNA for protein purification 
by His-affinity chromatography. Thrombin cleavage DNA sequence was added at 5’ of 2PI1-8-
IGF1 DNA for final cleavage of 2PI1-8-IGF1 from fusion protein. For insertion 2PI1-8-IGF1 DNA 
into plasmid vector, two restriction enzymes, BamHI and XhoI, were added at 5’ and 3’ terminal 
separately.  
Due to a primer length limitation, PCR amplification was separated into two steps. For the first 
step of PCR amplification, the Forward primer was 5’- AAGAACAAGTCAGTCCCCTT 
ATGGGACCGGAGACGCTCTG-3’. The reverse primer was 5’- TGGTGATGACGACCT 
TCGATAGCTGACTTGGCAGGCTTGA-3’. For the second step of PCR amplification, the 
Forward primer containing BamHI restriction site (single dark underlined) was 5’-
CGCGGATCCCTGGTTCCGCGTGGATCTAATCAAGAACAAGTCAGTCCCCTT-3’. The reverse 
primer containing XhoI restriction site (single dark underlined) was 5’-
CCGCTCGAGTCAATGGTGATGGTGGTGATGACGACCTTCGAT -3’. The thrombin cleavage 
sequence was discontinuous underlined. The 2PI1-8 sequence was double underlined. The 
6xHis tag sequence was single underlined. 
Cloning of pGEX6p1-2PI1-8-IGF1 
Using AmpliTaq DNA polymerase kit (Applied Biosystems, USA), the PCR component was 
prepared according to the formulation in Table 8. The final reaction volume was 100ul. 
Polymerase chain reaction (PCR) is a technique widely used in molecular biology. There are 
three steps in PCR (Fig. 46).  
1. Denaturation: This step is to denature the DNA template by heating, which would 
disrupt the hydrogen bonds between complementary bases of the DNA strands to 
yield single strands of DNA. 
Thrombin 2PI1-8 Human IGF1 6xHis BamHI XhoI 
96 
2. Annealing: This step is to anneal the primers to the single-stranded DNA template. 
The polymerase binds to the primer-template hybrid then begins the DNA synthesis. 
The melting temperature is determined by the primers used. 
3. Elongation: This step is to synthesize a new DNA strand complementary to the DNA 
template strand by adding nucleotides (dNTPs). The temperature depends on the 
DNA polymerase used.  
Table 8. PCR required reagents for AmpliTaq DNA polymerase kit 
Sequences added Component Volume per rx Final concentration 
2 10x QIAGEN PCR buffer 10 l 1X 
3 dNTP mix (10mM each) 2l 200 M of each dNTP 
3 MgCl2 25mM 6l  
4 Primer A (4 M stock) 5l 0.1-0.5 M 
4 Primer B (4 M stock) 5l 0.1-0.5 M 
Last Taq DNA polymerase 1 l 2.5 units/rx 
1 Distilled water Variable, 70 l - 
5 Template DNA, A chain 1 l (1.7/) ≤1 g/rx 
The PCR program used for AmpliTaq DNA polymerase kit was made according to the kit 
manufacturer’s protocol. Using a PCR machine (Fig. 47, Applied Biosystems, USA), the reaction 
was running with the following program:  
94°C   12 minutes    X1 
95°C   45 seconds   X30 
64°C   59 seconds   X30 
72°C   120 seconds   X35   <1k bp 
72°C   8 minutes   X1 
4°C   Indefinite 
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Fig 46. Schematic drawing of the PCR cycle. 
There are three steps in the reaction, denaturation 
at 94°C, annealing at about 54°C and extension at 
72°C. One cycle is shown here.  
 
Fig 47. One thermal cycler (Applied Biosystems, 
USA) used for PCR amplification in this 
manuscript. 
5% PCR product was identified by agarose gel electrophoresis on 1% gel with GelRed nucleic 
acid stain staining (Brunschwig, Switzerland).  
After identification, 95% PCR product was purified using a JetQuick PCR purification spin kit 
(Brunschwig, Switzerland) to delete small base pair molecules, such as primers. Then the 
purified PCR product and expression vector pGEX6P1 were digested by BamHI and XhoI 
restrictions enzyme in BamHI buffer at 37°C for 5 hours. Digested pGEX6p1 expression vector 
was purified on agarose gel using Jetquick gel extraction spin kit (Brunschwig, Switzerland), 
while the digested PCR product was purified by JetQuick PCR purification spin kit (Brunschwig, 
Switzerland). Then ligation was carried out between PCR fragment and digested vector at 16°C 
for 14 hours with T4 DNA ligase. The proportion used of components for the ligation was 
according to the equation below:  
insertofng
vector
insertofratiomolar
vectorofsizekb
insertofsizekbvectorofng .....
...
.....   
Then the ligation solution was transformed into subcloning Efficiency® DH5TM chemical 
competent cells (Invitrogen, USA). Furthermore, the transformation solution was spread on pre-
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warmed LB-Agar plates containing 100g/ml of Ampicillin. The plates were incubated overnight 
with parafilm around the edge at 37°C. 
Finally, the colonies were picked up randomly from LBA plates and screened by PCR. The 
Forward primer was 5’- GGGCTGGCAAGCCACGTTTGGTG-3’. The reverse primer was 5’- 
CCGGGAGCTGCATGTGTCAGAGG-3’. The PCR product was identified using agarose gel 
electrophoresis. 
TG-IGF1 protein expression, extraction and purification  
The pGEX6p1-IGF1 plasmid was transformed into BL21 competent cells (Amersham) for protein 
expression. A colony was picked randomly from the overnight Luria-Bertani ampicillin (LBA) 
plates and grown in 5ml LBA medium at 37°C with speed 220rpm for 12 hours. Then 2ml 
bacteria culture was diluted in 1000ml 2xYT ampicillin medium supplemented with 1% glycerol 
(1g per 100ml) in 1x2.0-liter Erlenmeyer flask. The bacteria culture was incubated with shaking 
230rpm at 37°C for about 5.5 hours until OD600 about 1.2. 10ml 100mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Axon lab, Switzerland) was added inside to induce protein 
expression at 30°C with speed 230rpm for 5 hours. 
After the TG-IGF1 protein was expressed in BL21 bacteria culture, the culture was centrifuged at 
4000g for 20 min at 4°C to sediment the pellets. The pellets were placed on ice and 
resuspended in 40ml ice-cold 1x Phosphate buffered saline (PBS) pH 7.4 supplemented with 
Complete Protease Inhibitor Cocktail (Roche, Switzerland). The cells were lysed by adding 0.1 
volume of a 10mg/ml lyzozyme solution in 1xPBS and followed by sonication on ice three times 
15 seconds at max speed without foaming. Then 10U/l deoxyribonuclease I (DNAse I) (Fluka, 
USA) was added to a final concentration 10U/ml. The lysate was gently mixed for 30 minutes to 
dissolve the fusion protein at 4°C. Finally, the mixture was centrifuged at 10,000xg for 30 
minutes at 4°C to remove insoluble components. The supernatant containing extracted TG-IGF1 
protein was filtered through a 0.22m pore filter into a fresh container. The solution was stored 
at 4°C before preceding the purification procedure (flow chart in Fig. 48).  
The purification procedure was separated in two steps and performed using ÄKTA FPLC 
(Amersham Pharmacia Biotech, USA). The first step was with a GSTPrepTM FF 16/10 20ml 
column (Amersham Pharmacia Biotech) for GST-TG-IGF1 fusion protein purification. The 
loading rate was 1ml/min and PBS was used as binding buffer. The elution buffer was 50mM 
Tris-HCl and reduced with 10mM glutathione at pH 8.0. 
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The purified GST-TG-IGF1 fusion protein was digested by 20U/mg thrombin protease (stock 
concentration 1U/l, Amersham) at RT for 16 hours. 
 
Fig 48. Flow chart of TG-IGF1 protein production and purification. From a LBA agar plate, one 
colony was picked up and grew in 5ml LBA medium for 12 hours. 2ml fresh bacteria culture was 
then growing in 1L LBA medium for about 5.5 hours. After adding IPTG, the bacteria cultute was 
growing for additional 5 hours. Finally the pellets were collected from centraifugation. The 
extracted cytosol solution was purified using FPLC machine. 
The second step of purification was to remove GST tag from the GST-TG-IGF1 fusion protein. 
The system was washed with 1xPBS solution; the sample was loaded into the charging column 
with a syringe. The HiTrap Benzamidine FF column (for binding thrombin) was connected to the 
GSTrap FF column (for binding GST). Then the system was switched to the “inject” position. 
PBS was used as the binding buffer. The purified TG-IGF1 protein was collected in the flow 
through. The elution buffer, 50mM Tris-HCl and 10mM reduced glutathione at pH 8.0, was used 
to recondition the column and to remove the GST tag from the column. The other elution buffer, 
0.05M Glycine-HCl pH 3.0, was to remove thrombin from the Benzamidine FF column. The 
columns were finally conditioned in PBS for storage. 
The TG-IGF1 protein concentration was determined at A280 using the extinction coefficient 
280=0.48. The size of protein expected was10.4kD (PI 6.3). The purity of the proteins was 
analyzed by 10% reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). Then using one commercial IGF1 ELISA kit, the quantity of obtained purified TG-IGF1 
was measured. 
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MTT cell proliferation assay 41 
The MTT assay is a quantitative colorimetric method to determine cell proliferation. It is an 
alternative to the thymidine incorporation test which measures cell proliferation by determining 
the amounts of incorporated tritiated thymidine into freshly synthesized DNA. The MTT assay 
measures the changes in colour following the metabolism of the reagent in the mitochondria. 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Thiazolyl Blue Tetrazolium 
Bromide) was purchased from Fluka, USA. This assay measures the activity of the mitochondria 
in cells to reduce a yellow tetrazolium component (MTT) into an insoluble purple formazan 
product (reaction in Fig. 49). So, this assay was also a measurement for cell viability as dead 
cells would not produce the color change. 
3T3 cells were seeded in 96-well plates before assay, each sample triplicate. During the assay, 
the cell medium was removed. 100l PBS and 20l MTT (5mg/ml) were add into each well. The 
cells were incubated at 37°C for 2 hours. Then the MTT medium was removed again and 100l 
isopropanol was added into each well to lyse the cells and to solubilize the colored formazan 
crystals. The plates were wrapped in aluminium foil to avoid the light and incubated at 37°C for 
another 30 minutes. Finally, the samples were read using an Enzyme-linked immunosorbent 
assay (ELISA) plate reader (Tecan, Männedorf, Switzerland, Fig. 50) at a wavelength of 570 nm. 
The amount of color produced was directly proportional to the number of viable cells. 
Fig 49. Reaction schema showing MTT assay mechanism. 
Yellow MTT was reduced to purple formazan by mitochondrial 
reductase in living cells. A solubilisation solution was added to 
dissolve the insoluble purple formazan product into a colored 
solution. The absorbance of this colored solution could be 
quantified by a spectrometer. 
 
Fig 50. Plate reader Tecan Safire2 
(Männedorf, Switzerland) used for 
absorbance measurement in this manuscript. 
It is a fully modular monochromator-based 
microplate detection system. 
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Receptor phosphorylation assay  
There exist three kinds of phosphorylation receptors, phosphoserine, phosphothreonine and 
phosphotyrosine. IGF1 receptor belongs to the tyrosine kinase family. IGF1 function on cell 
proliferation and development is carried out through its binding to the IGF1 receptor at the cell 
surface, which leads to autophosphorylation and phosphorylation of several receptor substrates. 
So, IGF1 receptor phosphorylation is very important in the regulation of the signalling pathways 
for various biological responses 42-44 (Fig. 51). It also offers a good method to test the bioactivity 
of the engineered recombinant protein TG-IGF1. 
For the IGF1 receptor phosphorylation assay, 3T3 cells were seeded on 6-well plates until the 
confluence about ≥80%. Then the cell medium was removed. The cells were washed three times 
by 1xPBS buffer. Finally 2ml fresh 1% penicillin streptomyocin (PS) DMEM/F12 medium was 
added into each well. The same quantity 60ng/ml of TG-IGF1 and recombinant native IGF1 were 
added into each well to activate IGF1 receptor for 20 minutes at 37°C 
The cells were washed 1x with cold PBS on the ice. To each well was added 100l RIPA lysis 
buffer (Sigma Aldrich) cocktail supplemented with protease inhibitor (Roche), 200x sodium 
orthovanadate, 100x Okadaic acid (Brunschwig, Switzerland), 100x phenylmethylsulphonyl 
fluoride (PMSF) (Sigma Aldrich, USA) and 20x Sodium fluoride (NaF). The cells were 
immediately scraped with a cell scraper. The total cell lysates were transferred into low-binding 
1.5ml eppendorf tubes and rotated at 4°C for 30 minutes. The solutions were boiled for 5 
minutes at 95°C after reduced 6x Lamelli buffer was added.  
The total cell lysates were loaded on 13% polyacrylamide gels and run at 100mV for 1 hour. 
Then the proteins in gels were transferred to nitrocellulose membranes at 80mV for 1 hour. After 
blocking in 5% bovine serum albumin (BSA) / Tris-Buffered Saline Tween-20 (TBST) pH 7.4 for 
1 hour at room temperature (RT), the membranes were incubated overnight at 4°C in 5% 
BSA/TBST containing 1:1000 rabbit polyclonal to IGF1 receptor antibody (phospho 
Y1165+Y1166) (Abcam, UK). The membranes were rinsed 4x5 minutes in TBST and incubated 
at room temperature for 1 hour in 5%BSA/TBST containing 1:10,000 goat anti-rabbit IgG (H+L)-
HRP conjugate (Bio-rad, USA). After the second antibody solution was removed, the 
membranes were washed 6x5 minutes in TBST. Finally, the membranes were incubated 5 
minutes with SuperSignal west pico chemiluminescence detection solutions (Pierce, USA). The 
phosphorylation bands around 100kD were visualized by timed exposures to CL-XPosure Film 
(Pierce, USA). 
102 
 
 
Fig 51 Simplified scheme showing tyrosine receptor phosphorylation pathway 42. Upon binding of 
a ligand, autophosphorylation of the receptor is followed by tyrosine phosphorylation of several 
receptor substrates. These substrates interact with other proteins to activate several 
downstream pathways. Each pathway can themselves phosphorylate and dephosphorylate the 
receptor tyrosine kinase and its substrates leading to a complex picture of phosphorylation and 
dephosphorylation events. The activation of a signaling pathway will result in various phenotypic 
effects, including changes in migration, apoptosis and proliferation. P, phosphate; PPase, 
phosphatase. 
After the membranes were stripped in western blot stripping buffer (Pierce, USA), the 
membranes were re-blocked in 5% BSA/TBST for 1 hour at room temperature. Then the 
membranes were incubated overnight at 4°C in 5% BSA/TBST containing 1:1000 rabbit 
polyclonal to IGF1 receptor antibody (Abcam, UK). The remaining steps were the same as the 
previous ones. The second antibody solution used was 5%BSA/TBST containing 1:10,000 goat 
anti-rabbit IgG (H+L)-HRP conjugate (Bio-rad, USA). This time, the bands of total IGF1 
receptors around 100kD were visualized by timed exposures to CL-XPosure Film (Pierce, USA). 
103 
Fibrin gel formation 
Human fibrinogen (Pg, vWF & Fn depleted) was purchased from Enzyme Research Laboratories 
(USA). It was dissolved in sterile Tris-Buffered Saline (TBS) pH 7.4 solution 1 hour at 37°C at 
25mg/ml. The resulting solution was sterilized by filtration through a 0.22 m syringe filter. Then 
the fibrinogen solution in 10 kD cut-off dialysis cassette (Pierce, USA) was dialysed against 1000 
volumes of TBS for 24 hours at room temperature to remove salts presented in the initially 
protein buffer. The resulting fibrinogen concentration was determined by measuring the 
absorbance at 280 nm using the extinction coefficient 1.51. The solution was stored at -80 °C. 
Fibrin gels (70l) were made by mixing the various components in an ultra low binding 96-well 
plate (Corning, USA). SMCs were trypsinized and washed 3 times with PBS and resuspended in 
serum-free media (SFM) to obtain high cell concentrations. Final concentrations of 6 mg/ml 
fibrinogen, 76 g/ml fibronectin, 5 mM Ca2+, 2 NIH units/ml of Factor XIIIa, 2 NIH units/ml of 
human thrombin, 20 % (v/v) cell solution, 100ng/ml TG-IGF1 or recombinant native IGF1 (R&D 
systems, USA) and 17 µg/ml aprotinin were obtained in the solution. During this experiment, the 
control sample was with fibrin gel alone without IGF1. Finally the gels were transferred to a 48-
well plate containing 300 µl of cell medium supplemented with 10 % fetal bovine serum (FBS) to 
mimic physiological condition. 
Isolation of human bladder smooth muscle cells 
Human bladder tissue was obtained kindly from Professor Peter Frey. The smooth muscle cells 
were isolated from bladder tissue by antibody conjugated magnetic beads. 12.5l anti-human 
epithelial antigen, clone Ber-EP4 (Dako Cytomation, Denmark) and 4l anti-human fibroblast 
antigen, Thy-1/CD90 (Dianova, Germany) were conjugated separately to 100ul dynabeads pan 
mouse IgG (Invitrogen, USA) at a final concentration 1ugAb/1x107beads. 
Fresh bladder tissue, transported in sterile Hanks Balanced Salt Solution (HBSS) supplemented 
with 5% PS, was washed twice by HBSS. Then the tissue was cut into narrow strips (~3x10mm) 
to facilitate epidermal removal. After HBSS was removed, the tissue was incubated in 0.5mg/ml 
liberase blendzyme I (Roche, Switzerland) at 37°C for 2 hours. Using 70m cell strainer, the 
pellets were separated from the remaining tissues. After centrifugation at 800rpm for 5 minutes 
at 4°C, the tissue cells were resuspended in 2ml cell medium.  
20ul epithelial beads were added per ml cell culture. The cell medium was rotated gently at 4°C 
for 15 minutes. The magnetic separator was used to collect the supernatant. In this way, the 
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epithelial cells were removed from the tissue cells. Then 20ul fibroblast beads were added per 
millilitre (ml) cell culture. Again the cell medium was rotated gently at 4°C for 15 minutes. The 
magnetic separator was used to collect the supernatant. This time, the fibroblast cells were also 
removed from the isolated tissue cells. Finally 20ul dynabeads CD31 (Invitrogen, USA) were 
added per ml cell culture. The same steps were repeated to remove endothelial cells from the 
isolated tissue cells. Thus, there were only smooth muscle cells (SMCs) in the supernatant. After 
centrifugation at 800rpm for 5 minutes at 4°C, the tissue cells were resuspended in 10 ml alpha-
MEM/F10 media supplemented with 10% fetal bovine serum, 1% penicillin streptomyocin (PS) 
and 1% fungizone, spread in one T-25 flask and incubated at 37°C under humidified 5% CO2. 
The medium was renewed every 3 or 4 days. The cells were cultured until 90% confluence and 
then sub-cultivated.  
Transmission electron microscopy (TEM) 
TEM is a powerful tool to reveal the crystallographic structure and the surface states of nano-
particles on an atomic scale. It can also be used to analyze the morphology and even 
composition of a specimen. It is also used to deduce the correlation between microstructures 
and their properties 45.  
In this work, TEM (Fig. 52) was used to analyze the SMCs cellular morphology in fibrin gels. The 
cultured cells in the fibrin matrix were fixed for 4 hours with a cold (4°C) solution of 2% 
paraformaldehyde (PFA) and 2.5% glutaraldehyde in 0.1M phosphate buffer, pH 7.4. To ensure 
good fixation, the gels were cut into small (1 mm3) blocks shortly after the fixation was begun. 
After fixation the blocks were washed thoroughly three times for 5 minutes each with 0.1M 
cacodylate buffer, pH 7.4. The blocks were subsequently fixed for 1 hour in 1% osmium tetroxide 
and 1.5% potassium ferrocyanide in 0.1M cacodylate buffer, pH 7.4 and then 40 minutes in 0.1M 
1% osmium tetroxide alone in cacodylate buffer, pH 7.4. The subsequent washing was 
performed in distilled water two times for 3 min each. Then the blocks were stained in 1% uranyl 
acetate for 40 minutes. The next step involved washing in distilled water for 5 minutes, and the 
subsequent dehydration was performed through increasing concentrations of ethanol in 50%, 
70%, 2x96% and 2x100% ethanol, three times for 3 min each. In the next step, we used 30 min 
incubation in a mixture of equal volume of 100% ethanol and Durcupan. The blocks were 
washed in durcupan ACM (Fluka, Switzerland) three times for buffer exchange. Then the blocks 
were embedded in fresh Durcupan ACM resin at least for 4 h. The resin with hardened for 24 
hours in a 65°C oven and then the blocks trimmed with glass knives. The ultra-thin sections 
were obtained at 50 nm thickness using a diamond knife (Diatome, Switzerland) and 
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ultramicrotome (Leica UCT). The sections were placed on grids (SPI, West Chester, PA, USA) 
and contrasted with lead citrate. Images were captured digitally on a CCD camera (SIS Morada, 
Munich) inside a Philips CM10 transmission electron microscope (Aachen, Germany) at a 
filament voltage of 80kV. 
 
Fig 52. The Philips CM10 TEM used in this manuscript. It is a stable instrument, used primarily 
for biological samples, also used for materials research on nanoparticles.  
Total RNA extraction 
Total RNA from SMCs was extracted with Trizol (Invitrogen, USA) and RNeasy Mini Kit (Qiagen, 
USA) according to the manufacturer’s protocol. This method was used to extract total RNA from 
small amount of cells (106-107). In brief, human SMCs were incubated in fibrin gels at 37°C with 
5% CO2 for 24 hours and then isolated from gels using high purity trypsin 5mg/ml (Calbiochem, 
Germany) in one RNAse-pyrogene free tube. After centrifugation at 1500rpm for 5 minutes, 
SMCs were resuspended in 800ul Trizol and incubated at room temperature for 10 minutes. 
Then 160ul phenol-chloroform-isoamyl alcohol mixture (Fluka, USA) was added. The tubes were 
shaken vigorously by hand for 15 seconds and incubated at room temperature for 3 minutes. 
Then the tubes were spun for 15 minutes at 4°C at 12,000xg, and the aqueous phase was 
removed. The organic phase was re-extracted two times more with 500ul phenol-chloroform-
isoamyl alcohol mixture. After centrifugation for 2 minutes at room temperature at 12,000xg, the 
aqueous phase was removed. Three fractions of aqueous phase were collected and mixed with 
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equal volume of 70% ethanol (EtOH). The solutions were loaded onto RNeasy mini columns, up 
to 700ul per time. The columns were spun for 15 second at 10,000rpm. The columns were 
washed with 350ul RW1 and spun for 15 second at 10,000rpm. Then the columns were 
incubated for 15 minutes at room temperature in 10ul DNase I stock solution and 70ul RDD 
buffer. The columns were again washed with 350ul RW1 and spun for 15 second at 
10,000rpm.Then the new collection tubes were used. The columns were washed with 500ul 
RPE and spun for 15 second at 10,000rpm. The columns were washed again with 500ul RPE 
and spun for 15 second at 10,000rpm. The flow through was discarded. Finally, total RNA was 
eluted with 30ul RNAse free H2O in one new 1.5ml RNAse-pyrogene free tube by spinning for 1 
minute at 10,000rpm. The eluted RNA was stored at -70°C. 
The concentration and purity of the RNA were estimated spectrophotometrically using a ND-
1000 spectrophotometer (Nanodrop; Wilmington, DE). The integrity of the extracted total RNA 
was assessed using the Agilent 2100 Bioanalyzer and RNA6000 Nano LabChip Kit (Agilent 
Technologies, Palo Alto, CA) prior to qRT-PCR assay. 
Gel immuno-staining  
Fibrin gels (70ul each) were taken out of the cell medium for elastin immuno-staining. After 
washing twice in PBS, the gels were fixed in 4% paraformaldehyde (PFA) at 4°C for 30 minutes. 
Washing twice again in PBS, the cell membranes were weakened with 0.1% Triton X-100 for 10 
minutes at room temperature. After washing twice in PBS, the gels were blocked in 2% FBS in 
PBS for 30 minutes at room temperature (RT). Rabbit polyclonal elastin antibody (Abcam, UK) 
was used as primary antibody at 1:50 dilution in PBS with 2% BSA. The gels were then 
incubated in primary antibody solution overnight at 4°C. 
After washing three times with fresh PBS, 30 minutes-1 hour each at RT, the gels were in Alexa 
Fluor 488 goat anti-rabbit IgG from Molecular Probes (Invitrogen, USA) at 1:100 dilution in PBS 
with 2% BSA with few drops of 0.5% Triton over night at 4°C. 
After washing three times with fresh PBS, 1 hour each at RT, the gels were incubated in the 
second antibody solution of Rhodamin Phalloidin (20ul in 0.8ml PBS with 2% BSA) from 
Molecular Probes (Invitrogen, USA) over night at 4°C for F-actin staining. 
After washing three times with fresh PBS, 30 minutes-1 hour each at RT, the gels were 
counterstaining of nuclei stain in diluted Hoechst 33342 5uM (Invitrogen, USA) (2.5ul in 2ml 1% 
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BSA/PBS) 1 hour at RT. Finally, after washing three times with fresh PBS, 30minutes-1 hour 
each at RT, the gels were stored at 4°C and ready for confocal imaging. 
Confocal fluorescence microscopy 
Fluorescence microscopy was performed using a LSM 510 META - ConfoCor 2 system (Carl 
Zeiss Jena GmbH, Jena, Germany). The Zeiss laser scanning confocal system was equipped 
with 5 lenses, including a 63 magnification oil immersion objective of numerical aperture (NA) 
1.4 and a 40 magnification oil immersion objective of numerical aperture (NA) 1.3. There were 
seven laser lines to be selected for fluorescence images. All parameters used in the image 
acquisition step had to be standardized (output laser power, pinhole diameter, detector gain, 
amplifier offset) to maintain high reproducibility. Because of overlapping of the 
excitation/emission spectrum between different fluorochromes, the fluorescence ratio images 
might be multitrack analyzed. Image analysis was performed using the LSM510 software. Each 
image was represented by 512x512 pixels.  
Quantitative real-time PCR (qRT-PCR) assay 
To get the first strand of cDNA from RNA, the reverse transcription kit used was SuperScript III 
first-strand synthesis system for RT-PCR (Invitrogen, USA). The volume of samples was 
normalized using the same quantity of total RNA. 
Real-time RT-PCR was performed using a Bio-Rad iCycle IQ multicolour detection system (Bio-
Rad, USA). PCR primers were purchased from SaBiosciences (USA) to amplify and detect 84 
genes in the field of extracellular matrix and adhesion molecules. These primers were loaded in 
96-well plate, containing 5 housekeeping genes and one genomic DNA. Real-time PCR 
amplifications were carried out in a 25ul volume containing 12.5ul iQ SYBR Green Supermix 
(Bio-Rad), 1ul first strand cDNA and 11.5ul H2O. The running program was set according to 
manufacturer’s recommendation. In Brief, the reactions were run at an initial denaturation step at 
95º C for 10 min followed by 40 cycles consisting of 95ºC for 15 sec and 60ºC for 1 minute. 
Finally the dissociation curve was run at 95°C for 1 minute, 65°C for 2 minutes and from 65°C to 
95°C at 2°C per minute. Reactions were performed in triplicate and threshold cycle values were 
averaged. The data was normalized using the ∆∆Ct method. 
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Animal experiments 
Sprague-Dawley female rats 250g (12 weeks of age) were used in this study. Two series of 
animal experiments were carried out. During the first series, twelve rats were randomly divided 
into three groups of four rats each, fibrin gel without IGF1, fibrin gel with 100ng TG-IGF1 and no 
fibrin gel. During the second series experiment, twenty rats were randomly divided into four 
groups of five rats each, fibrin gel without IGF1, fibrin gel with 100ng TG-IGF1, fibrin gel with 
100ng recombinant native IGF1 and no fibrin gel. All surgical procedures and experimental 
manipulations were in accordance with a protocol approved by the Veterinary Authorities of the 
Canton Vaud according to Swiss law (protocol number 2146). 
Induced by an inhalation reagent isoflurane (4% of inspired concentration) and oxygen, rats 
underwent one general anesthesia procedure. Receiving 50ul Morphasol-4 subcutaneous for 
analgesia due to the surgery and drops of Viscotears on eyes to prevent eyes from drying during 
the operation, rats were put on a heating carpet to maintain their body temperature during 
operation. Anaesthesia was maintained with isoflurane (1% inspired concentration) and oxygen. 
The abdomen of rats was shaved by razor and sterilized by betadine and 70% ethanol. Working 
under sterile conditions, the urinary bladder was isolated. Using a scalpel, a straight Vannas 
spring scissors (FST, USA) and a stainless steel mini Dumont #M5S (WPI, USA) under a 
microscope, three resections about 1 to 2mm diameter were made on the posterior wall of the 
bladder, where the muscle layer was removed and the mucosal lining was intact (Fig. 53). Then 
a 100ul fibrin gel was directly applied on the top to cover three resections using a low binding 
0.5ml tube (Milian). After surgery, the muscular layer of the abdomen was sutured with 
resorbable #5.0 Dafilon (B.Braun, Switzerland) and the skin was sutured with stapler proximate 
plus MD 35 R (Johnson & Johnson, Switzerland). Betadine gel was used to sterilize the sutured 
abdomen. Then the rats were kept on a heating carpet (35°C) until awake. The total duration of 
the experiment was 28 days. 
The staples were removed 10 days after surgery. The state of rats was observed every day after 
surgery until dissection.  
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Fig 53. Flow chart showing animal experimental manipulation: A) three resections made on the 
bladder wall; B) 100ul fibrin gel was made on the top of three resections; C) The abdomen 
muscle layer was sutured by absorbable #5.0 Dafilon; D) The abdomen skin was sutured by 
staples 
Animal dissection 
28 days after surgery, rats were sacrificed by carbon dioxide asphyxiation. The bladder was 
found and the urethra was tied by one suture. Then around 100ul fresh 4% paraformaldehyde 
(PFA) solution was injected via the urethra into the urinary bladder by needle for fixation (Fig. 
54). The bladder was then cut vertically at the bottom of the ventral knot and removed in a 
suitable container filled with fresh 4% PFA solution, where the fixation of the bladder was 
continued at 4°C. 
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Fig 54. Rat dissection and bladder fixation: A) The bladder was injected about 100ul 4% PFA; B) 
The bladder was cut off; C) The bladder was fixed in one container with 4% PFA  
Histological analysis 
Bladders were washed by PBS and then dehydrated in 75%, 96%, 100% ethanol and xylene 
consecutively. Finally, the bladders were immersed in paraffin overnight. Paraffin-embedded 
bladder tissues were cut at 5um thickness by microtome. The sections were stained with 
hematoxylin and eosin (erythrosine) (H&E). This stain was a simple method for general 
morphology of the tissue. The sections were stained also with Masson's Trichrome (MT). 
Trichrome staining was a collection of techniques designed to selectively demonstrate muscle, 
collagen fibers, fibrin and erythrocytes. Finally the sections were stained with Prussian Blue 
(PB). This stain was identifying hemosiderines in the site of injection. All histological images 
taken were approved by pathologist Dr. Taminelli. 
Quantification blindly of detrusor muscle regenerated 
The area of muscle regenerated was quantified blindly with Dr. Hasegawa by the program Fiji 
according to approved images taken previously. The value was normalised by the area of 
muscle intact in the same bladder section. The means and standard error were calculated for 
each experimental group.  
Results and discussion 
Construction vector of pGEX6p1-2PI1-8-IGF1 
The first and second PCR fragments of 2PI1-8-IGF1 were obtained because we could observe a 
visible band around 250bp using a 1% agarose gel. Each time, 5% PCR product was run on 1% 
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agarose gel. It was obvious that second PCR fragment band was higher and clearer than the 
first one because the size of second PCR fragment was larger and concentration was higher 
(Fig. 55).  
  
Fig 55. PCR amplification fragment on a 1% w/v agarose gel: the first step of PCR for 2PI1-8-
IGF1 DNA (left); the second step of PCR for DNA insert “BamHI-thrombin-2PI1-8-IGF1-6xHis-
XhoI” (middle); Screening of 10 colonies of pGEX6p1-2PI1-8-IGF1 using standard primers 
(right). The DNA size marker is a commercial 1kb ladder. A band about 250bp was visible for 
2PI1-8-IGF1 DNA insert (left and middle). A band about 450bp was visible for every colony. 
After screening 10 random colonies of pGEX6P1-IGF1 on a LB ampicillin plate using pGEX5’ 
and pGEX3’ primers, one visible band between 250 and 500bp was observed on a 1% agarose 
gel. The expected size of the inserted 2PI1-8-IGF1 was 459bp. So, it seemed that these 10 
colonies were all good. Randomly, two colonies, colony 1 and 5, were chosen for DNA 
sequencing by Fasteris (Geneva, Switzreland). The DNA sequencing results showed that both 
colonies contained the correct DNA sequence. Therefore, they could be used for TG-IGF1 
protein production. 
TG-IGF1 protein expression and purification 
It was discovered that recombinant IGF1 produced by E.coli 46 could maintain its bioactivity. It 
means that IGF1 protein did not require post translational modification for bioactivity. This finding 
facilitated the production of recombinant IGF1.  
E.coli BL21 is a cell strain which lacks OmpT and Lon protease production. According to the 
GST gene fusion system handbook (Amersham Biosciences), this cell strain could give high 
levels of expression of GST fusion proteins. So, in this work, this cell strain was chosen for TG-
IGF1 protein expression. 
250 
500 
bp 
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During the TG-IGF1 protein production by BL21, it was found that the most of TG-IGF1 was in 
inclusion bodies. To facilitate the purification TG-IGF1 from the inclusion bodies, another cloning 
was performed using pET-22b(+) (Novagen, Germany) as an expression vector in order to 
obtain TG-IGF1 by a one step purification (His tag affinity column) instead of two step 
purification (GST tag affinity column). Consistent with the small size of the His tag at the C-
terminus, it was demonstrated that the His tag did not influence the bioactivity of TG-IGF1. So, it 
was not necessary to enzymatically remove the His tag from TG-IGF1. During the preliminary 
experiment, it was difficult to obtain very pure TG-IGF1 by His affinity purification due to 
relatively weak affinity of His-tag compared to GST-tag. It was also found that TG-IGF1 purified 
from the inclusion bodies was easily precipitated but did not display significant bioactivity, as 
expected. Finally, TG-IGF1 was purified by GST affinity column.  
Due to a small elution peak, a small quantity of GST-IGF1 was purified from the cytoplasm of 
one liter of bacteria culture (Fig. 56). The final product TG-IGF1 was in the flow through 
fractions. Using an Amicon Ultra-15 Centrifugal filter unit with membrane 5 kDa (Milian, 
Switzerland), the flow through fractions of the second purification step were concentrated to 1ml 
solution. 
 
Fig 56. Purification of TG-IGF1 by GST affinity chromatography. The first step of GST-IGF1 
purification (left); the second step of TG-IGF1 purification (right). The first peak represents flow 
through. The second and third peak represents eluate. For the first step of GST-IGF1 purification 
(left), the eluted fractions were collected, which contained GST-IGF1. For the second step of TG-
IGF1 purification (right), the flow through fractions were collected, which contained TG-IGF1.  
The purity of TG-IGF1 was analyzed by SDS-PAGE using a 12% gel. 5ul of sample was mixed 
with 5ul reduced 1xloading buffer. After heating at 95°C for 5 minutes, 10l sample was loaded 
Thrombin Flow through 
GST-IGF1 
TG-IGF1 
GST 
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on the gel. After, the gel was stained with SimplyBlueTM SafeStain solution (Invitrogen), only one 
band at about 10kD was visible on the gel (Fig. 57, left). Therefore, the collected protein was 
very pure. To further identify this protein, the band was transferred onto a membrane to perform 
a western blot analysis. The mouse monoclonal [1F6-3H10] to IGF1 (Abcam, UK) was used as 
the first antibody at a dilution 1:5000. 10%milk in PBST was used as the blocking buffer. Only 
one band at about 10kD on the film developed (Fig. 57, right). So, this protein was TG-IGF1. The 
quantity of purified TG-IGF1 was determined by Quantikine® human IGF-I immunoassay (R&D 
systems, USA), which was about 10ug from 2 liters bacteria culture. 
 
Fig 57. Purified recombinant TG-IGF1 shown on stained 12% reducing polyacrylamide SDS-
PAGE (lane 2) and on membrane reacted with anti-IGF1 antibody, visualized by 
chemiluminescence (lane 4). Lanes 1 and 3: molecular weight marker broard range in kDa 
(prestained; Bio-rad). 
The TG-IGF1 protein purification process was repeated several times. Each time, the same 
result was obtained on SDS-PAGE and by western blot. 100ul protein, loaded on the reduced 
SDS-PAGE gel and stained by SimplyBlueTM SafeStain solution, was cut and sent to proteomics 
facility in EPFL for amino acid sequencing by MALDI-TOF mass spectrometry. After analysis, 
the resolved amino acid sequence from fragmentation and parent ion mass was first compared 
to the expected sequence to check the coverage rate and then was secondly compared to the 
sequences of all proteins in the database of the host expression cell, such as E. coli in this case. 
The sequencing results showed that there were two close bands on the gel about 10kD and that 
both of them were TG-IGF1. There was very weak sequence coverage between the protein sent 
and the E. coli proteins sequences in the database. But there was strong sequence coverage, 
up to 80%, between the protein sent and the expected sequence. Two close bands on the gel 
were due to slight difference between two 3D conformations of TG-IGF1. This is a common 
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phenomenon in protein engineering. Thus, we proved unambiguously that the TG-IGF1 was 
produced and thoroughly purified.  
MTT cell proliferation assay 
For the MTT cell proliferation assay, a standard curve was determined to find the optimal cell 
number for the MTT assay.  
Four cell densitier of Hela cells were seeded on one 96-well plate, 6x103, 1.2x104, 2.5x104 and 
5x104 cells. The samples were made in triplicate for each cell number. 12 hours after seeding, 
the cell medium was removed and MTT assay was running as usual.  
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Fig 58. Standard curve to determine optimal cell number for MTT cell proliferation assay. Axis x 
was cell concentration in 1000 cells per ml. Axis y was optical density at 570nm. It showed 
optical density increased with cell concentration. Due to test of cell proliferation with time, the 
cell number chosen was 1x104 for this assay. 
Because IGF1 stimulated cell proliferation, the cell number chosen should be the lowest value in 
the linear part of the standard curve (Fig. 58) to avoid the cell overgrowth during the MTT assay. 
So, the cell number chosen was 1x104 for the MTT assay. 
3T3 cells were trypsinized and washed three times by PBS buffer. After cell counting, 1x104 cells 
were seeded in serum free medium in 96-well plates, which were pre-coated by 1% BSA/PBS. 
Ten different IGF1 concentrations were added in each well to stimulate 3T3 cells proliferation, 0, 
1, 3, 6, 9, 12, 15, 18, 21 and 24ng/ml. The different effect of recombinant native IGF1 and TG-
IGF1 on 3T3 proliferation was also compared in this assay. Two time points were taken, each 
sample in quadruplet. After 46 hours and 77 hours of cell proliferation, the cell medium was 
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removed and an MTT assay was performed. From the Fig. 59, it showed that TG-IGF1 and 
recombinant native IGF1 stimulated 3T3 cell proliferation in the same profile. For the 46 hours 
stimulation, the cell number was in the stationary state for IGF1 concentration higher than 
12ng/ml. When cell proliferation was stimulated by IGF1 for 77 hours, the cell number was 
nearly independent on IGF1 concentration.  
From this assay, it showed that recombinant TG-IGF1 was the same in terms of bioactivity as 
the recombinant native IGF1 for cell proliferation. 
 
Fig 59. Effect of recombinant native IGF1 and TG-IGF1 on fibroblast 3T3 cell proliferation. The 
cells (10,000 per well) were seeded in 96-well plates overnight and then treated separately with 
various concentrations (0-24ng/ml) of IGF1 for 46 hours (A) and for 77 hours (B). Cell 
proliferation was estimated on the basis of optical density. The data represent the mean (±SEM) 
of 4 wells. 
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Receptor phosphorylation assay  
For the phosphorylation assay, it was difficult to retain phosphorylation, which dissapeared very 
quickly. Many factors could influence the result of this assay, such as the time used to stimulate 
3T3 cells by IGF1, time to lyse the cells and the presence of protein phosphatases in the cells. 
All the components in the cell lysis buffer were to inhibit protein phosphatase activity, including 
Okadaic acid 47. So, this assay was needed to be performed quickly and on ice. 3T3 cells were 
stimulated by IGF1 less than 20 minutes. Each sample was made in duplicate. 
From the Fig. 60, it reveals that TG-IGF1 and commercial recombinant IGF1 could bind to the 
IGF1 receptor of 3T3 cells to stimulate the formation of phosphorylated IGF1 receptor, which 
was visualized by receptor phosphorylation antibody (Fig. 60A). For the negative control without 
IGF1 stimulation, no phosphorylated receptor was visible on the film.  
For the proteins on the same membrane, there were IGF1 receptors in all samples, which were 
visualized on the film due to the IGF1 receptor antibody. Due to the 2 subunits in the IGF1 
receptor, there were 2 bands visible on the film (Fig. 60B). 
From this assay, it was revealed that recombinant TG-IGF1 displayed the same bioactivity as 
the native recombinant IGF1 for IGF1 receptor phosphorylation stimulation. 
 
Fig 60. Western blot analysis of receptor phosphorylation assay showing one band at 100kD 
corresponding to IGF1 receptor. 3T3 cell lysates were probed with a phosphospecific IGF1 
receptor antibody (A) and with a correspondent IGF1 receptor (B). Negative control was with no 
IGF1 added. TG-IGF1 was TG-IGF1 stimulated cell lysate. The positive control was recombinant 
native IGF1 stimulated cell lysate. 
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Isolation of human bladder smooth muscle cells 
To confirm the identity of the isolated neonatal human smooth muscle cells (SMCs), SMCs 
markers were used, such as the alpha smooth muscle actin antibody, smooth muscle myosin 
heavy chain 1 antibody, calponin antibody and caldesmon antibody. Alpha smooth muscle actin 
is a differentiation cell marker for SMCs 48. Smooth muscle myosin heavy chain 1 49, calponin 
and caldesmon 50 were three proteins related to SMCs contraction. The antibodies were 
purchased from Abcam (UK).  
 
Fig 61. Isolation of neonatal human bladder SMCs. After isolation process, the cells in 2D cultures 
on polystyrene tissue culture plastic ware were immunofluorescence stained with cell markers 
(green): A) alpha smooth muscle actin antibody, B) smooth muscle myosin heavy chain 1 antibody, 
C) calponin and D) caldesmon. The nuclei were counter staining with DAPI (blue). Scale bars 
represent 200m. 
The cells were washed twice with PBS and then mixed with 4% PFA for 1 hour. After washing 
three times with PBS, the cells were permeabilized with 0.1% Trixton-X for 5 minutes at RT, and 
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then washed again three times with PBS. After blocking in 2% BSA with 10% goat serum in PBS 
for 1 hour at RT, the cells were immerged overnight in the first antibody solution in blocking 
buffer. After washing four times with PBS, the cells were suspended in the second antibody 
solution for 1 hour at RT. The cells were washed again six times with PBS. Finally, the cells 
were counted after staining by Hoechst 33258 in blocking solution for 30 minutes at RT to label 
the cell nuclei.  
From the immunofluorescence staining (Fig. 61), the conclusion could be made that the isolated 
bladder cells were indeed SMCs. 
Transmission electron microscopy (TEM) 
Three types of fibrin gels (70ul each), without IGF1 (as negative control), with 50ng/ml native 
recombinant IGF1 (as positive control) and with 50ng/ml TG-IGF1, were prepared containing 
2.1x105 isolated neonatal human bladder SMCs per gel, each sample in triplicate. 
These nine gels were placed into a 48-well plate, to which 500ul alpha-MEM medium 
supplemented with 10% FBS, 1% PS, 17 µg/ml aprotinin and 1mg/ml -aminocaproic acid were 
added per well. 50ng/ml native recombinant IGF1 was also added in the cell medium for the 
positive control fibrin gel. Three days later, these gels were treated for TEM imaging. 
From the TEM imaging (Fig. 62), secretory vesicles were more numerous and bigger in the 
SMCs in the fibrin gels with TG-IGF1 than in the SMCs with the control samples. So, some 
proteins were produced by SMCs after stimulation by TG-IGF1 and were accumulated in the 
secretory vesicles until release into the extracellular environment. TG-IGF1 was released from 
the fibrin gel during gel degradation by cleavage. Thus, SMCs were stimulated by TG-IGF1 in 
the gel during three days’ incubation.  
The morphology of SMCs was similar in the positive and negative fibrin gels. The reason was 
maybe native recombinant IGF1 not cross-linked with fibrin gels, which resulted in its diffusion 
from the gel to the cell medium with the time. Even 50ng/ml native recombinant IGF1 was added 
in the cell medium, the SMCs in the positive fibrin gels were nearly in the same situation as cells 
in the negative control fibrin gels without IGF1, or maybe only slightly better. 
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Fig 62. Bright field TEM images. A) and B) represent SMCs in fibrin gel with TG-IGFI. The 
obvious secretory vesicles in SMCs were indicated by the arrows. C) and D) showed SMCs in 
fibrin gel only (negative control); no secretory vesicles were found in the cells. E) and F), SMCs 
in fibrin gel with commercial IGFI (positive control) had some small secretory vesicles (indicated 
by the arrows). Scale bars represent 5m. 
Because of these observations, we believe that the TG-IGF1 was in fact bioactive. It had some 
functions on SMCs due to obvious secretory vesicles in the cells. In contrast, gels without IGF1, 
or gels with IGF1 added to the gels by simple mixing did not reveal substantial changes in the 
cell morphology.  
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Total RNA extraction for qRT-PCR assay 
Table 9. The total RNA data summary  
Sample Concentration [ng/ul] A260/280 A260/230 RIN (over 10) 
Neonatal negative control 1 53.6 1.87 0.26 8.30 
Neonatal negative control 2 38.56 1.87 0.83 7.50 
Neonatal negative control 3 123.02 2.03 2.03 9.60 
Neonatal negative control 4 133.97 2.04 1.78 9.80 
Neonatal negative control 5 104.91 2.07 1.54 9.90 
Neonatal TG-IGF1 1 187.27 2.01 1.85 9.70 
Neonatal TG-IGF1 2 175.1 2.04 2.04 9.70 
Neonatal TG-IGF1 3 167.72 2.02 1.57 9.70 
Neonatal TG-IGF1 4 86.15 2.03 1.72 10 
Neonatal TG-IGF1 5 114.34 2.05 1.21 9.80 
Neonatal recombinant native IGF1 1 184.05 2.02 0.66 9.80 
Neonatal recombinant native IGF1 2 176.53 2.04 2.07 9.80 
Neonatal recombinant native IGF1 3 180.58 2.01 1.07 9.50 
Neonatal recombinant native IGF1 4 116.96 2.04 1.90 10 
Neonatal recombinant native IGF1 5 124.52 2.04 1.61 10 
For characterization of gene expression, three types of fibrin gels were prepared (210ul each), 
without IGF1 (as negative control), with 100ng/ml recombinant native IGF1 (as positive control) 
and with 100ng/ml TG-IGF1, containing isolated neonatal human bladder SMCs, each sample in 
quintuplicate. The gels were added to a 24-well plate, 1ml alpha-MEM medium supplemented 
with 10% FBS 1% PS and 17 µg/ml aprotinin was added per well. 100ng/ml commercial hIGF1 
was also added in the cell medium for the positive control fibrin gels. The gels were incubated 
for 24 hours at 37°C. 
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After 24 hours induction by IGF1, the total RNA were extracted from the neonatal human 
bladder SMCs cells in the fibrin gels according to the protocol. The concentration of total RNA 
extracted was measure by Nanodrop spectrophotometry (Thermo Scientific, Wilmington USA).  
For the qRT-PCR analysis, three values of total RNA extracted were important, A260/280 for 
DNA contamination, A260/230 for chemical purity and the RIN for RNA integrity number (Table 
9). It is better to obtain similar values in the same triplicate group.  
According to the obtained results, the quality of two samples, neonatal negative control 1 and 2, 
were not as high quality as the other samples. So, they were not used for qRT-PCR assay. 
Quantitative real-time PCR (qRT-PCR) assay 
The total RNA was extracted from SMCs and analyzed as mentioned above. An RT2 ProfilerTM 
PCR array plate, containing various primers for 84 genes in the field of ECM and cell adhesion, 
was purchased from SABiosciences (USA). The efficiency of the primers was estimated to be 2. 
The experiment was conducted in triplicate. The qRT-PCR array data analysis was performed 
using the ΔΔCt method. 
The relationship between the original gene expression level (L) for each gene of interest and the 
threshold cycle (Ct) is expressed as: 
CtL  2  
To normalize the gene expression level for each gene of interest (GOI) to a housekeeping gene 
(HKG), the expression levels of the two genes are divided as: 
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To determine the fold change in gene expression, the normalized gene expression of the GOI in 
the experimental sample is divided by that in the control sample: 
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  Where ΔΔCt is equal to ΔCt(expt) –ΔCt(control) 
The complete calculation for ΔΔCt method is as following: 
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There were three experimental groups, TG-IGF1, recombinant native IGF1 and no IGF1, each 
group in triplicate. Each data set was characterized by its mean and standard deviation. The 
population was assumed to be normally distributed. So, a Student’s T-test, one of the most 
frequently used tests, was applied to determine whether the means were district. This statistic 
relies on an uncertain estimate of standard deviation rather on a precisely known value. A null 
hypothesis of this test is that the variances of two distributed populations are supposed to be 
normally equal. The P value of the Student’s T-test indicates the confidence level, statistical 
significance. It represents the false discovery rate. It is more important than a fold change, which 
reveals the magnitude of differential expression but not significance.  
Table 10. All genes down-regulated with p0.05 
Sample ratio well symbol Gene description Fold change T-test P 
value 
D09 KAL1 Kallmann syndrome 1 sequence 0.53 0.0371 
G01  SPP1 Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1) 0.37 0.0468 
TG-IGF1/no 
IGF1 
G03  THBS1 Thrombospondin 1 0.76 0.0250 
TG-IGF1 
/recombinant 
native IGF1 
G03 THBS1 Thrombospondin 1 
0.82 0.0446 
A11 COL16A1 Collagen, type XVI, alpha 1 0.56 0.0124 
C08 ITGA4 Integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) 0.66 0.0169 
D03 ITGAV Integrin, alpha V (vitronectin receptor, alpha 
polypeptide, antigen CD51) 0.90 0.0493 
D09 KAL1 Kallmann syndrome 1 sequence 0.38 0.0737 
D12 LAMA3 Laminin, alpha 3 0.38 0.0151 
E10 MMP15 Matrix metallopeptidase 15 (membrane-inserted) 0.16 0.0104 
G01  SPP1 Secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 1) 0.36 0.0620 
Recombinant 
native 
IGF1/no IGF1 
G08 TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby 
fundus dystrophy, pseudoinflammatory) 0.41 0.0411 
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Normally it often chooses fold-change with P value lower than 5%. It means that 95% chance to 
have this observed fold change value represent a statistical difference. If the calculated P value 
is below the threshold chosen for statistical significance (usually 0.05 level), the null hypothesis 
which usually states that the two groups do not differ is rejected. These two groups do differ.  
According to Student’s T-test statistic, if the fold change is greater than 2 and the P value less 
than 0.05, the gene may be reported as up-regulated. If the fold change is less than 0.5 and P 
value less than 0.05, then the gene may be reported as down-regulated.  
To compare the expression level of each gene in TG-IGF1 with that in native recombinant IGF1, 
there was just one gene with a probability lower than 0.05. This gene was called THBS1 (Table 
10). But the fold change was 0.82, close to 1.0. Thus, there was no difference between the gene 
expressions by SMCs stimulated by TG-IGF1 and by native recombinant IGF1. 
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Fig 63. Comparison of relative expression by neonatal human bladder SMCs in 210ul fibrin gels 
for 84 genes related to adhesion and extracellular matrix molecules between 100ng/ml TG-IGFI 
and 100ng/ml commercial IGFI. The scatter plot depicts the relative expression level of each 
gene between TG-IGFI (y-axis) and commercial IGFI (x-axis). The red lines indicate a two-fold 
change in gene expression threshold. Two genes, ITGA7 and MMP14, have the value of fold 
change higher than 2. 
MMP14 
ITGA7 
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The gene expression results were also represented in scatter plot (Fig. 63). A scatter plot can 
suggest various kinds of correlations between variables with a certain confidence level. 
Correlations may be positive (rising), negative (falling), or null (uncorrelated). It is one of the 
basic tools of quality control.  
The scatter plot indicated that up-regulation was observed in 2 genes, Matrix metallopeptidase 
14 (MMP14) and Integrin, alpha 7 (ITGA7), which demonstrated at least a 3-fold difference in 
gene expression by neonatal human bladder SMCs in fibrin gels between TG-IGFI and 
commercial IGFI. But no gene was statistically significant due to p>0.05 (Table 11). So, we did 
not observe a difference between the TG-IGF1 and the recombinant native IGF1 on the neonatal 
bladder SMCs. 
Table 11. Fold changes in expression for genes related to adhesion and extracellular matrix 
molecules between TG-IGFI and commercial IGFI. Only genes, ITGA7 and MMP14, in Figure 7 
exhibiting a three-fold or greater change in expression are listed. But their p-value of Student’s t-
test was too high, around 0.2. So, the statistic difference was insignificant. 
Average raw Ct 
Gene 
Fold change 
TG-IGFI / 
Commercial IGFI 
t-Test 
p value Commercial 
IGFI TG-IGFI 
Matrix metallopeptidase 14 (MMP14) 4.10 0.2639 23.23 21.77 
Integrin, alpha 7 (ITGA7) 3.94 0.2184 32.47 30.77 
The gene expression results (Table 10) identified two down-regulated genes (with p<0.05 and > 
2-fold change) between TG-IGF1 stimulated bladder SMCs and no IGF1 stimulated SMCs upon 
24 hours of stimulations. According to microarray studies, both Kallmann syndrome 1 (KAL1) 
and Secreted phosphoprotein 1 (SPP1) were dramatically down-regulated in response to TG-
IGF1 in neonatal bladder SMCs. 
SPP1, also named osteopontin, is an extracellular structural protein. It is expressed in many 
types of cells, such as smooth muscle cells. It has chemotactic properties, which promote cell 
recruitment to inflammatory sites. It also functions as an adhesion protein, involved in cell 
attachment and wound healing. These integrins, v3, v5 and 51 [51, 52], bind to the RGD 
site in SPP1 and mediate cell adhesion, migration, and survival. This molecule was down-
regulated 2.7-fold in neonatal bladder SMCs cultured with TG-IGF1 (p<0.05) in reference to no 
IGF1. 
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The KAL1, also named anosmin-1, is an adhesion fibronectin-containing heparin-binding protein 
and is responsible for Kallmann’s syndrome (KS). KS is defined as a hypogonadotropic 
hypogonadisms (HH) and an olfactory deficit (anosmia) [53]. The KAL1 is involved in the 
embryonic development of the olfactory bulbs (OB). The key role of KAL1 is to facilitate 
gonadotropin neuron migration from the olfactory placode to the Gonadotropin-releasing 
hormone (GnRH) neurons of the hypothalamus. This neuronal migration defect will also result in 
GnRH deficiency and hypogonadism [54]. This molecule was down-regulated 1.9-fold in 
neonatal bladder SMCs cultured with TG-IGF1 (p<0.05) in reference to no IGF1. 
Thrombospondin 1 (THBS1) is an adhesive extracellular glycoprotein mediating cell-to-cell and 
cell-to-matrix interaction. It plays a role in angiogenesis and wound healing. It can interact with 
fibronectin, fibrinogen and integrins v3, v1 and v6 [55, 56]. This molecule was down-
regulated 1.3-fold in neonatal bladder SMCs cultured with TG-IGF1 (p<0.05) in reference to no 
IGF1. 
The gene expression results (Table 9) also identified five down-regulated genes (with p<0.08 
and > 2-fold change) between recombinant native IGF1 stimulated bladder SMCs and no IGF1 
stimulated SMCs upon 24 hours of stimulation. It means that native recombinant IGF1 down-
regulated KAL1, SPP1, LAMA3, MMP15 and TIMP3 genes expression in neonatal bladder 
SMCs. So, two genes, SPP1 and KAL1, were both down-regulated in SMCs cultured in fibrin 
gels with either TG-IGF1 or native recombinant IGF1 compared to the fibrin gels only. 
KAL1 was down-regulated 2.63-fold in neonatal bladder SMCs cultured with native recombinant 
IGF1 (p=0.07) in reference to no IGF1, while SPP1 was down-regulated 2.78-fold (p=0.06). So, 
for SMCs in fibrin gels in vitro, TG-IGF1 or native recombinant IGF1 down-regulated significantly 
SPP1 and KAL1 (n=3). 
Laminin is a base membrane protein in extracellular matrix. Each laminin is a heterotrimer, 
composed of alpha-, beta- and gamma-chains. Laminin alpha 3 (LAMA3) is the alpha 3 chain of 
laminin 5, a glycoprotein. It is involved in cell adhesion and signal transduction. This molecule 
was down-regulated 2.63-fold in neonatal bladder SMCs cultured with native recombinant IGF1 
(p<0.05) in reference to no IGF1. 
Matrix metallopeptidases (MMPs) consist of 24 zinc-dependent endopeptidases. They are 
involved in the cleavage all kinds of extracellular matrix proteins in normal physiological 
processes. They are synthesized and secreted in latent forms. MMPs need extracellular 
activation. Matrix metallopeptidase 15 (MMP15) is a membrane-type metalloproteinase (MT-
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MMP). This molecule was down-regulated 6.25-fold in neonatal bladder SMCs cultured with 
native recombinant IGF1 (p<0.05) in reference to no IGF1. 
The tissue inhibitors of metalloproteinases (TIMPs) are specific endogenous inhibitors for the 
matrix metallopeptidases (MMPs). There are 4 membranes in this family, TIMP1, TIMP2, TIMP3 
and TIMP4. TIMP3 was down-regulated 2.44-fold in neonatal bladder SMCs cultured with native 
recombinant IGF1 (p<0.05) in reference to no IGF1. 
Collagen is the main connective tissue protein in animals. Up to date there are more than 28 
types of collagen discovered. Collagen, type XVI, alpha 1 (COL16A1) is a membrane of the fibril-
associated collagens with interrupted helices (FACIT) collagen family. This molecule was down-
regulated 1.79-fold in neonatal bladder SMCs cultured with native recombinant IGF1 (p<0.05) in 
reference to no IGF1. 
Integrins are receptors mediating cell-to-cell and cell-to-matrix communication and interaction. 
They are involved in the attachment of the cells to the extracellular matrix (ECM), the signal 
transduction from the ECM to the cells and vice versa. There are 19 alpha and 8 beta subunits. 
Integrin alpha 4 (ITGA4) was down-regulated 1.52-fold in neonatal bladder SMCs cultured with 
native recombinant IGF1 (p<0.05) in reference to no IGF1, while integrin alpha V (ITGAV) was 
down-regulated 1.11-fold (p<0.05). 
 
Table 12. Real-time qPCR primer sequence 
Gene Forward Reverse 
hTropoelastin GGT GGC TTA GGA GTG TCT GC CCA GCA AAA GCT CCA CCT AC 
hLysyl oxidase CAG AGG AGA GTG GCT GAA GG CCA GGT AGC TGG GGT TTA CA 
hElastin CAT TTC CCC CGA AGC TCA G GCT TTG GCG GCT GCT TTA G 
hRPI13A AGG TAT GCT GCC CCA CAA AA TGC CGT CAA ACA CCT TGA GA 
hRPL27 TGT CCT GGC TGG ACG CTA CT CTG AGG TGC CAT CAT CAA TGT T 
At same time, gene expression of tropoelastin, lysyl oxidase and elastin were analysed using 
extracted neonatal bladder SMCs RNA. Tropoelastin is a soluble monomer of elastin. Lysyl 
oxidase is a cross-linker to polymerize tropoelastin to elastin. hRPI13A and hRPL27 are used as 
house keeping genes (Primer sequence in Table 12). All primers used were checked by 
standard curve using universal human reference RNA (Stratagene, USA). According to standard 
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curve (Fig. 64), the PCR efficiency for these primers was around 100%. So, these primers could 
be used for RT-qPCR experiment.  
The fold-change ratio results (Fig. 65) identified that TG-IGF1 and native recombinant IGF1 
down-regulated three genes expression, tropoelastin, lysyl oxidase and elastin. It showed that 
TG-IGF1 and native recombinant hIGF1 had nearly same function on neonatal bladder smooth 
muscle cells in the fibrin gels. 
 
Fig 64. Standard curves for five primers, hRPI13A, hRPL27, hElastin, hLysyl oxidase, and 
hTropoelastin, using universal human reference RNA (Stratagene, USA). Note that efficiency of 
standard curve for these 5 primers is around 100%. So, the primers are validated for further 
experiments of RT-qPCR. 
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Fig 65. Fold-change ratio result for gene expression of tropoelastin, lysyl oxidase and elastin 
responding to TG-IGF1, recombinant native IGF1 or no IGF1. Note that two genes, tropoelastin 
and lysyl oxidase, were down-regulated in same fold-change ratio by TG-IGF1 and native 
recombinant IGF1.  
Confocal imaging for elastin detection 
Nine fibrin gels (70ul each) were made for confocal imaging, three gels per group. 100ng/ml TG-
IGF1 or recombinant native IGF1 was incorporated in fibrin gels. The fibrin gels only were acted 
as the negative control. The gels were inoculated in a 48-well plate for 5 days, 300ul 10% FBS 
1% PS alpha-MEM medium with aprotinin was added per well. For the gel with 100ng/ml native 
recombinant hIGF1, 100ng/ml native recombinant hIGF1 was also added in the cell medium. 
After 5 days inoculation, the gels were immuno-stained for elastin. The samples were sectioned 
and analyzed by confocal laser scanning microscopy. 
All imaging was carried out using a Zeiss x63 Apochromat objective in three different locations 
per gel with a z stack of 20 images each. Background fluorescence was determined by imaging 
the negative control gel, fibrin gel without IGF1. Elastin was green-labelled. The cell skeletal F-
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actin was red-labelled. The cell nuclei were blue-labelled (Fig. 66). From the confocal imaging, 
no elastin was formed by neonatal bladder SMCs in the fibrin gel due to no detectable green 
colour.  
 
Fig 66. Confocal imaging of elastin (green) formation by neonatal bladder SMCs seeded in the 
fibrin gels after 5 days stimulation. A) fibrin gel without IGF1; B) fibrin gel with TG-IGF1; C) fibrin 
gel with native recombinant IGF1. The cell filamentous actin (F-actin) was staining with 
rhodamine–phalloidin (red). The nuclei were counter staining with DAPI (blue). Sale bars 
represent 200m. Note that no elastin was formed by neonatal bladder SMCs. 
TG-IGF1 retention in fibrin gel matrices 
Because TG is supposed to crosslink IGF1 in the fibrin matrices, it is important to compare TG-
IGF1 and recombinant native IGF1 retention in the fibrin gel matrices under the same condition.  
In this experiment, two kinds of 100ul fibrin gel matrices containing 50ng/ml TG-IGF1 or 
recombinant native IGF1 were prepared in a UltraLow binding plates 96 well plate (Corning, 
Lowell, USA), each kind of gel in triplicate. The gels were transferred into a 1.5ml low binding 
Eppendorf tube (Vaudaux Eppendorf, Hambourg, Germany) containing 1.2ml Tris-buffered 
saline pH 7.4 (TBS). During inoculation in TBS buffer, TG-IGF1 or recombinant native IGF1 was 
released from fibrin gels at the indicated time points was determined by a Quantikine human 
IGF-1 kit (R&D systems, USA). An IGF1 standard curve was also determined according to 
manufacture’s instruction. So, TG-IGF1 or recombinant native IGF1 retained in the fibrin gel 
could be determined. The fixed time points were 0h, 30 minutes, 1h, 2h, 6h, 12h, 18h, 24h, 35h, 
A B C 
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52h and 55h for TG-IGF1 and 0h, 30 minutes, 1h, 2h, 6h, 12h, 24h, 30h, 41h, 52h and 55h for 
recombinant native IGF1.  
As indicated in Fig. 67, it was observed that at the beginning of 30 minutes, about 4% TG-IGF1 
was burst from the fibrin gel matrices. Then after 6 hours incubation, about 8% TG-IGF1 was 
released from the fibrin gel matrices. Within the 60h incubation period, about 88% of added TG-
IGF1 remained within fibrin gel (n=3, values were means ± SEM). 
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Fig 67. Determination of TG-IGFI and commercial IGFI controlled releasing from fibrin gels in percentage 
vs incubation time in hour. 100ul fibrin gels with 50ng/ml TG-IGFI or commercial IGFI respectively were 
incubated in 1.5ml TBS at 37°C. At the indicated time points, released IGFI concentration in TBS was 
determined by ELISA with human IGFI antibody (n=3, value were mean ± SEM). 
It was also showed that at the beginning of 30 minutes, about 8% recombinant native IGF1 was 
burst from the fibrin gel matrices, double quantity more than TG-IGF1. Then after 6 hours 
inoculation, about 16% recombinant native IGF1 was released from the fibrin gel matrices, which 
was also nearly double quantity more than TG-IGF1. Within the 60h incubation period, about 
81% of added recombinant native IGF1 remained within fibrin gel (n=3, values were means ± 
SEM). So, for 100ul fibrin gel, TG-IGF1 was 7% more controlled released from gels than 
recombinant native IGF1 under the same physiologic condition. 
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Rat bladder muscle layer regeneration 
HEK-Blue LPS detection kit (Invitrogen, USA) was used to determine the endotoxin value for 
TG-IGF1. This kit is based on the ability of Toll like receptor 4 (TLR4), to recognize structurally 
different LPS from gram-negative bacteria and in particular lipid A, their toxic moiety. 
HEK-blue-4 cells, which are very sensitive to lipopolysaccharide (LPS), were seeded 30’000 
cells per well in one 48-well plate. Three days later, the cell medium was removed. 360ul HEK-
blue detection medium was added into each well. Then 40ul dilution medium containing different 
quantities of TG-IGF1 were added into each well. The samples were tested in duplicate. Then 
the plate was incubated for 18 hours at 37°C. Finally, the plate was read at 640nm. According to 
the standard curve, the endotoxin value for TG-IGF1 was 1 EU/ug. The endotoxin value for 
recombinant native IGF1 was also <1 EU/ug. Thus, the endotoxin value for TG-IGF1 was slightly 
higher than that of the native recombinant IGF1. Both were judged to be acceptable for 
implantation. 
During two series of animal experiments, no mortality was observed. During the first series, 
there were four rats in the negative control group, resection only. There were four rats in the 
fibrin gel only group. There were also four rats in the fibrin gel with 100ng TG-IGF1. The rats 
were distributed randomly to each group. The experiment was conducted for 28 days. In the 4-
week specimens, there were a few unusual formations in three bladders, one in the negative 
control group (#1), and two in fibrin gel only group (#2 and 3). The images of H&E staining of all 
specimens are in Annex 1. 
From the standard histological staining results (Fig. 68), it was noticed that the rat bladder 
regenerated its muscle layer in the fibrin gel with TG-IGF1 group, but also involved lymphocytes 
and mast cells. Lymphocytes were involved due to inflammation, which may be caused by 
endotoxin present in the TG-IGF1 and by wound. Among the 4 rats in this group, three bladders 
displayed different degrees of bladder muscle layer regeneration. During animal surgery, fibrin 
gels were made in-situ with a sterile low binding eppendorf tube on the top of three resections. 
About one minute later, the gel was cut off the wall of tube. Due to an inflated surface, one fibrin 
gel with TG-IGF1 leaked during gel polymerization in one eppendorf tube and formed glue. The 
speed of both infiltrating SMCs and gel degradation was related to the contacted gel surface. 
Thus gel degradation was slower than glue. This could be one reason that this rat bladder 
muscle layer was not regenerated due to glue formation.  
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There was no bladder muscle layer regeneration in the negative control group. The bladder 
muscle layer was slightly regenerated in the fibrin gel only group, but much less than the bladder 
regenerated in the fibrin gel with TG-IGF1 group. Due to no TG-IGF1 incorporation, there were 
few lymphocytes and mast cells involved in the muscle layer regeneration in two control groups.  
For the quantification of detrusor muscle regenerated over normal detrusor muscle, it was 
0.12±0.08 (mean±SEM, Fig. 70) for resection only group and 0.00±0.00 for fibrin gel only group. 
It was 0.31±0.18 for TG-IGFI group. So, defected detrusor muscle layer tissue was indeed 
regenerated by fibrin gel incorporated with TG-IGF1. 
During the second series, there were five rats in the negative control group, resection only. 
There were five rats in the fibrin gel only group, five rats in the fibrin gel with 100ng TG-IGF1 
group, and five rats in the fibrin gel with 100ng native recombinant IGF1 group. The rats were 
distributed randomly to each group. The experiment was conducted also for 28 days. The only 
difference of manipulation between two series experiment was the resection method. For the 
first series, the resection was made by directly cutting off the muscle layer under the 
microscope. For the second series, the resection was made by opening the muscle layer using a 
scalpel and tweezers. In the 4-week specimens, there was just one bladder in the negative 
control group displaying some abnormal tissue after H&E staining. The images of H&E staining 
of all specimens are located in Annex 2. 
From the standard histological staining results (Fig. 69), it was noticed that the rat bladder wall 
did not regenerate its muscle layer after 28 days in the resection only group. In the fibrin gel only 
group, the rat bladder muscle layer did regenerate, but very little. In the fibrin gel with native 
recombinant IGF1 group, the rat bladder muscle layer was regenerated, more than fibrin gel only 
group. In the fibrin gel with TG-IGF1 group, the rat bladder muscle layer was the most 
regenerated. This observation was confirmed by the quantitative analysis of detrusor muscle 
regenerated over normal detrusor muscle. The value was 0.08±0.07 (mean±SEM, Fig. 70) for 
resection only group and 0.11±0.09 for fibrin gel only group. Due to detrusor muscle 
regeneration, the value was much higher for IGF1 groups. It was 0.23±0.10 for native 
recombinant IGF1 group and 0.27±0.10 for TG-IGFI group. So, defected detrusor muscle layer 
tissue was indeed regenerated by fibrin gel incorporated with IGF1, especially with TG-IGF1. 
This suggests that TG-IGF1 is released in a controlled manner from the fibrin gel matrices and 
have longer effect on muscle layer regeneration than the native recombinant IGF1.  
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Fig 68. Rat bladder wall histology staining (H&E, MT and PB) for the first series experiment 
(n=4). All images were approved by pathologist Dr. Taminelli. For H&E, the muscle was stained 
deep pink red. For MT, the muscle was stained pink red. For PB, the hemosiderine were stained 
blue, representing the site of injection. Group A was resection only, nearly no detrusor muscle 
regenerated. Group B was 100ul fibrin gel only, hardly detrusor muscle regenerated. Group C 
was 100ul fibrin gel with 100ng TG-IGFI, with obviously some detrusor muscle regenerated. 
Group D was normal bladder tissue. Scale bars=500um for lane 1 and scale bars=50um from 
lane 2 to 4. 
1 2 3 4
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Fig 69. Rat bladder wall histology staining (H&E, MT and PB) for the second series experiment (n=5). All 
images were approved by pathologist Dr. Taminelli. For H&E, the muscle was stained deep pink red. For 
MT, the muscle was stained pink red. For PB, the hemosiderine were stained blue, representing the site of 
injection. Group A was resection only. Group B was 100ul fibrin gel only. For Groups A and B, there was 
nearly no detrusor muscle regenerated. Group C was 100ul fibrin gel with 100ng commercial IGFI. Group D 
was 100ul fibrin gel with 100ng TG-IGFI. For Groups C and D, there was some detrusor muscle 
regenerated. Group E was normal bladder tissue. Scale bars=500um for lane 1 and scale bars=50um from 
lane 2 to 4. 
1 2 3 4
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Groups Resection only Fibrin gel only Commercial IGFI TG-IGFI 
First experiment 0.12±0.08 0.0±0.0 NA 0.31±0.18 
Second experiment 0.08±0.07 0.11±0.09 0.23±0.10 0.27±0.10 
Fig 70. Quantitative analyze data of two series of rat bladder wall regeneration for 28 days using 
A) graphic representation of regenerated detrusor muscle in percentage and B) table 
representation of regenerated detrusor muscle in ratio. The data, blindly analyzed with Dr. 
Hasegawa using program Fiji, showed that for both experiments, fibrin gel with TG-IGFI 
regenerated more detrusor muscle defected than two control groups, resection only and fibrin 
gel only. In the second experiment, fibrin gel with TG-IGFI (27%) could regenerate slightly more 
detrusor muscle defected than the gel with commercial IGFI (23%). The measurement is 
presented as mean ± SEM. P value is not significant. 
For two series experiments, according to results from the section staining and from quantitative 
analysis of detrusor muscle area regenerated over normal detrusor muscle area, defected 
detrusor muscle was regenerated much more by fibrin gel with TG-IGFI (27%-31%) or fibrin gel 
A 
B 
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with native recombinant IGFI (23%) than by fibrin gel only (0%-11%) or resection only (8%-12%). 
So, TG-IGF1 can stimulate bladder smooth muscle regeneration.  
Conclusion 
Recombinant TG-IGF1 protein produced by E.coli was successfully purified by GST affinity 
chromatography and maintained its bioactivity. 5ug purified TG-IGF1 can be obtained per liter 
bacteria culture. Its purity was analyzed by SDS-PAGE and western blot. The amino acid 
sequence was confirmed by MALDI-TOF mass spectrometry. More than 88% of TG-IGF1 could 
be retained in the fibrin gel after 55 hours incubation. Its bioactivity was analyzed both in vitro 
and in vivo. TG-IGF1 could bind to IGF1 receptors to stimulate receptor phosphorylation and 
result in 3T3 cell proliferation using the MTT assay. In fibrin gels, TG-IGF1 could stimulate SMCs 
to synthesize proteins. This was the reason why SMCs displayed more abundant and larger 
secretory vesicles as showed in the TEM imaging compared to control samples. TG-IGF1 could 
also down-regulate two genes in SMCs in the field of ECM and adhesion molecules, the same 
as native recombinant IGF1. TG-IGF1 in fibrin gels could also accelerate rat bladder muscle 
layer regeneration (27%-31%), more than native recombinant IGF (23%) after 28 days 
treatment. It is due to TG-IGFI cross-linked and controlled releasing in fibrin gels. So, 
recombinant TG-IGF1 is more bioactive than native recombinant IGF1 in fibrin gel, which can 
better stimulate bladder smooth muscle proliferation and regeneration. 
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Chapter V Retrospective and Outlook 
Retrospective 
During this thesis I was able to learn a great deal regarding protein engineering, and how to 
bring together various research methods and techniques to create new functional fusion proteins 
towards bladder tissue repair. Towards this goal, I was able to generate both a peptide-protein 
biomacromolecule comprised of a factor XIIIa substrate and IGF1 (TG-IGF1), as well as a new 
IGF1-fibrinogen fusion protein. The goal of my research was to deliver IGF1 to an induced 
wound site using a rat bladder in vivo model. Towards this goal, I was able to produce the fusion 
protein variants and test the TG-IGF1 fusion protein both in vitro and in vivo with very favourable 
results. During this thesis, I was required to also learn about advanced cell culture techniques, 
and various other skills to characterize the in vitro and in vivo systems I used to produce this 
thesis. These include cloning, western blot, RT-qPCR, TEM, MTT cell proliferation assay, 
phosphorylation assay, recombinant protein production both by E.Coli and by mammalian CHO 
cells, mammalian cells in serum free and suspension culture, cell line isolation, recombinant 
protein purification, fibrin gel formation, cell and gel staining, animal experiment, histological 
stainings, etc. Learning these techniques will provide for a sound foundation to continue my 
scientific career, whether in industry or academia. 
The peptide TG was the first eight amino acids NQEQVSPL of 2-plasmin inhibitor (2PI1-8). It 
was the factor XIIIa substrate to mediate IGF1 cross-linking into fibrin gels during polymerization. 
The goal of adding TG sequences was to control release IGF1 from fibrin gels and then to 
strengthen IGF1 function by increasing its life span. TG-IGF1 produced by E. coli was 
successfully purified by GST affinity chromatography. Its purity was visible on SDS-PAGE using 
1% agarose gel and western blot using IGF1 antibody. Its amino acid sequence was confirmed 
by MALDI-TOF mass spectrometry.  
Then TG-IGF1 bioactivity was analyzed in vitro. TG-IGF1 showed its bioactivity same as native 
recombinant IGF1 in MTT cell proliferation assay and in IGF1 receptor phosphorylation assay 
using IGF1 receptor and phosphor-IGF1 receptor antibodies. TG-IGF1 also showed its 
advantage to the morphology of SMCs seeded on the fibrin gels. TEM images were taken when 
SMCs was inoculated for 3 days in three types of fibrin gels, fibrin gel only, fibrin gel with native 
recombinant IGF1 and fibrin gel with TG-IGF1. There were more and bigger secretory vesicles in 
SMCs when fibrin gel was incorporated with TG-IGF1. It was maybe TG-IGF1 controlled 
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released from fibrin gels so that IGF1 could act longer in SMCs than native recombinant IGF1. 
Gene expression level was also performed by RT-qPCR from SMCs inoculated in three types of 
fibrin gels for 24 hours. Gene expression level by SMCs to TG-IGF1 and to native recombinant 
IGF1 was similar among 84 genes of extracellular matrix and adhesion molecules. Two genes, 
SPP1 and KAL1, were down-regulated in SMCs cultured in fibrin gels with either TG-IGF1 or 
native recombinant IGF1 compared to the fibrin gels only. As we known that IGF1 plays one role 
in SMCs migration and angiogenesis. SPP1 mediates angiogenesis during pregnancy while 
KAL1 is involved in angiogenesis during cancer. So, for SMCs in fibrin gels in vitro, TG-IGF1 or 
native recombinant IGF1 down-regulated significantly SPP1 and KAL1 (n=3, p<0.07).  
The bioactivity of TG-IGF1 was also performed in vivo using rat bladder model. Three resections 
were made in the detrusor muscle layer. Three different kinds of fibrin gels were made in-situ on 
the top of the injury with ingrowing autologous SMCs. The bladder muscle layer was able to be 
regenerated by local delivery of TG-IGF1 in fibrin gels. From histological stainings HE, MT and 
PB, the structure of repaired tissue was similar to the native tissue and there was no fibrous 
tissue formed on the place of resection (group=3, n=4; group=4, n=5). The quantitative analyze 
data showed detrusor muscle regeneration rate of TG-IGFI, about 31% or 27%. For second 
series of experiment, due to native recombinant IGFI diffusing from gels to environment, it lost 
slightly its quantity compared to cross-linked and controlled releasing TG-IGFI in fibrin gels. So, 
fibrin gels with native recombinant IGFI regenerated defect bladder muscle layer less than TG-
IGFI, 23% instead of 27%. During dissection, injured bladders with TG-IGF1 in fibrin gels had 
one size bigger than others due to containing urine, which was a good signal for normal bladder 
physiological function. This is another indication that defected detrusor muscle layer was much 
better regenerated by TG-IGF1 than control groups. This work offered one opportunity in 
treatment for bladder dysfunction. And it would be interesting to analyze gene expression in vivo 
of angiogenesis molecules, such as SPP1 and KAL1. 
During dissection of rats, no more fibrin gels were found. All fibrin gels were degraded and no 
bioactive IGFI remained after tissue repair. On one hand, the detrusor muscle regeneration was 
not complete yet, 31% at most. So, to strengthen TG-IGFI effect on the detrusor muscle 
regeneration, more quantity of TG-IGFI could be added in the fibrin gel. On the other hand, 
systemic side effects were limited. The histological staining also revealed that the rats treated by 
fibrin gels with TG-IGFI displayed bladder muscle layer regeneration without fibrosis formation 
up to 4 weeks. It demonstrated that the design of TG-IGFI incorporated fibrin gels was useful in 
tissue engineering for wound healing and tissue regeneration.  
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Two new cell lines were made in this work, CHOFGA5aaIGF1 and CHOFGA5aaMMPIGF1. These cell lines 
were characterized by FACS using fibrinogen antibody and ELISA using both IGF1 and 
fibrinogen antibodies. Purified recombinant fusion protein fibrinogen-IGF1 would be used to 
make fibrin gels with IGF1 covalently linked. Recombinant fibrinogen protein produced by these 
CHO cells met purification problem due to low quantity of fibrinogen expressed (about 20ng/ml), 
which should be resolved in the near future. Although I was unable to purify the fibrinogen fusion 
proteins, a great deal was learned in the process, especially regarding the protein production 
and purification.  
Outlook 
Due to donor shortage, metabolic and immune problems of traditional treatment, bladder tissue 
engineering offers one alternative treatment to bladder dysfunction. It is one important part of 
tissue engineering. During the repair and regeneration process in the body, the body’s response 
to the jury is the summary of all factors and can trigger a lot of mechanisms, which can result in 
fibrosis tissue and scar formation. So, fibrosis is one challenge for tissue engineering.  
In order to restore bladder function and structure without side effect, several technologies are 
developing. First, nanoscale materials can be used as scaffold to facilitate the communication 
between cells. Secondly, tissue bioreactors can be employed to imitate bladder mechanical 
environment to enhance artificial bladder tissue formation in vitro. Thirdly, stem cells, such as 
mesenchymal stem cells, can be used and differentiated into smooth muscle cells for bladder 
wall regeneration. Fourthly, beside collagen-based matrix, more biomaterials can be provided as 
scaffold with and without cells and proteins, such as growth factors. Atala’s research group had 
successfully made one neo-bladder in vitro using synthetic scaffold PLGA/PGA with UCs and 
SMCs seeded on two sides. Finally the bladder tissue engineering is also related to the 
angiogenesis/vasculation and nerve system regeneration of injured tissue.  
In this work, although the mechanisms of detrusor muscle regeneration are not well understood, 
we attempted to restore and maintain bladder function by regenerating or repairing bladder 
using IGFI. Because TG-IGFI showed its bioactivity and its controlled releasing profile in fibrin 
gels in the diver assays and in animal experiment, more animal models can be used to testify its 
bioactivity, such as pig bladder muscle layer regeneration and rat heart muscle regeneration. 
Due to fibrin gels too soft and lack of mechanical strength, TG-aprotinin to controlled release 
TG-IGFI from fibrin gel or synthetic polymers, such as PLGA and PEG, can be incorporated with 
fibrin gels and be used as co-polymer biomaterials. 
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Although a great deal of research has been produced regarding both natural materials and 
synthetic tissue engineering, few products have produced approved therapeutics. In this sense, 
we are still in the early stage of tissue engineering. During this thesis I was able to display rat 
bladder smooth muscle cell regeneration using a relatively simple fibrin gel / TG-IGF1 fusion 
protein matrix. However, this is only the beginning. Further research must be directed at not only 
repair of an induced wound, but total bladder regeneration. Towards this goal delivery of novel 
fusion proteins, peptide, and small molecules will need to be deployed to achieve the complex 
signal cascade necessary to achieve this result. This could be accomplished by the fusion of 
synthetic nanocarriers such as hydrolytically sensitive hydrogel microspheres or polymersomes, 
and or functionalized polymeric micelles to release hydrophobic small molecules.  
To solve the problem about low fibrinogen expression by CHO cell lines, there are several 
options. First, more new cell lines showing higher fibrinogen expression should be made. 
Secondly, the expression system for CHO cell line can be changed. But CHOfgn cells grew 
difficult in suspension cell culture due to sticky fibrinogen polymerisation. The problem is 
resolving slowly. If this problem can be resolved one day, more CHO cells, expressing 
therapeutic bioactive substance, can be culture in suspension using pTet-on system. It offers 
one new way to produce recombinant protein in industry for clinical application. Thirdly, cell 
culture medium can be changed or improved, such as feeding some special ingredients 
(glucose, certain amino acids, vitamins, etc.) which is very important for this cell line. Finally, the 
culture conditions should be modified, such as temperature, pH. Sometime lower temperature, 
such as 30-33°C, can increase CHO cell productivity.  
For the purification of fusion protein fibrinogen-IGF1, new more affinity peptides to fibrinogen 
can be found using phage library technology. Then affinity chromatography column can be made 
specially to purify fusion fibrinogen proteins. After the bioactivity of fusion protein is analyzed in 
vitro, two generations of fibrin gels can be compared in animal models, such as rat bladder 
detrusor muscle layer regeneration.  
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Annex 1. Histology staining of rat bladder specimens at 4 
weeks for first series experiment 
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Annex 2. Histology staining of rat bladder specimens at 4 
weeks for second series experiment 
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